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ABSTRACT 
Cases of HIV-1 infection are growing in large numbers, and deaths as a result of AIDS 
are escalating in South Africa. Understanding cellular immune responses to HIV-1 by 
exploring general effects and changes occurring at a cellular level, including direct 
engagement of T cells with the virus during exposure or infection will provide 
information on possible correlates of viral control. This dissertation focuses on three 
characteristics of T cells during HIV infection, dual HIV/TB co-infection and exposure to 
HIV. The characteristics examined are 1) memory and activation status of CD4+ and 
CD8+ T cell subsets; 2) T cell receptor repertoire and 3) HIV-1– specific T cell 
responses.  
 
There are two hypotheses in this dissertation. Firstly, that co-infection with TB leads to 
elevated T cell activation, disruption of the T cell receptor repertoire and altered 
patterns of immunodominance in HIV-1 subtype C-specific T cell responses in infected 
adults. Secondly, that T cell priming occurs in utero in HIV uninfected babies born to 
HIV infected mothers.   
 
 
Four cohorts were examined in this dissertation. Three were recruited from a clinic 
around the Welkom area and analysed in a cross-sectional and longitudinal manner. The 
cohorts consisted of HIV-1 infected adults, individuals dually infected with HIV and 
TB and healthy controls. Whole blood samples from the HIV and HIV/TB infected 
groups were analysed at baseline (before TB chemotherapy), at 2, 8 and 24 weeks. A 
 
 
v
further cohort consisted of babies born to HIV-1 infected mothers, with some being 
followed up at three months after birth.  
 
This dissertation consisted of five different methods: 1) the use of four colour flow 
cytometry to measure the frequency of naïve T cells (CD45RA+/CD62L+), memory 
(CD45RA-CD62L-) and activated (CD38) T cell populations in individuals singly 
infected with TB and dually with HIV and TB. This investigation was aimed at 
obtaining the overall representation of T cells involved in HIV-1 and TB co-infection. 
2) the use of flow cytometry staining with monoclonal antibodies recognizing different 
T cell receptor (TCR) Vβ specificities for quantitation of the percentage of particular 
TCR families in pools of T cells. The aim was to provide an indication of TCR usage in 
different disease states. 3) the immunoscope assay was used to measure the different 
CDR3 lengths of the TCR and assess Vβ family repertoires in newborn babies. The aim 
was to show evidence of T cell maturity at birth and whether there was TCR 
engagement in utero by analysing cord blood cells. 4) the use of the IFN-γ ELISPOT to 
measure HIV-specific T cell responses in a cohort of HIV and HIV/TB co-infected 
individuals. The aim was to identify targeted immunodominant regions and to 
determine whether TB infection resulted in differing patterns of HIV-1 specific T cell 
immunity. 5) intracellular cytokine staining (ICS) was used to confirm the responses 
obtained after initial screening with the IFN-γ ELISPOT and was used to delineate 
CD4+ and CD8+ T cell responsiveness.  
 
 
 
vi
Whole blood was stained with an array of monoclonal antibodies to measure various T 
cell subsets in HIV-1 and HIV/TB co-infected adults. The CD4+ T cells in HIV-1 
infected individuals ranged between 245 - 436, those of HIV/TB co-infected patients 
were 157-840 and the TB group had CD4+ absolute counts ranging between 583-1757 
cells/mm3. CD4+ T cells were reduced as a result of HIV-1 infection and HIV/TB co-
infection, and no loss of these cells was seen as a result of single infection with TB.  
There was a loss of naïve T cells, with increased memory phenotypes in the presence of 
TB and HIV single infection, which was more pronounced in the presence of HIV and 
TB co-infection. The loss of naïve CD4+ and CD8+ T cells was associated with a high 
HIV-1 plasma RNA load in patients co-infected with HIV and TB. CD8+ T cells in HIV 
singly infected and HIV/TB co-infected individuals were highly activated when 
compared to those infected with TB only, which was likely due to the high HIV plasma 
RNA load. The standard course of six months of TB therapy in HIV/TB co-infected 
adults did not lead to recovery of absolute CD4 cells, nor did it stem the loss of naïve 
CD4+ and CD8+ T cells, which remained in a highly activated state: possibly due to 
unchanged HIV-1 RNA loads.  
 
The fine specific nature of T cell activation was investigated by examining TCR Vβ 
expansions in HIV and TB single and co-infected individuals. Whole blood was stained 
with CD3+, CD4+, CD8+, CD38+ and an array of Vβ-specific antibodies. Polyclonal 
skewing of the TCR Vβ repertoire, showing expansion of various Vβ−CD4+ and -CD8+ 
families was observed in TB and HIV-1 single and dual infection. A more restricted 
usage of the T cell repertoire was observed in both HIV and HIV/TB co-infected patients, 
where major and oligoclonal expansions of Vβ11, Vβ16, Vβ20 and Vβ22 were observed. 
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No major expansions were observed in TB single infection. Overall, significantly greater 
use of TCR Vβ families were found in the CD8+ T cell compartment rather than by 
CD4+ T cells in both HIV-1 and HIV/TB co-infected adults.  
 
A cohort of neonates born to HIV-infected mothers was used to assess TCR usage using 
immunoscope analysis to support the hypothesis that the TCR repertoire skewing in cord 
blood cells can be a marker of T cell priming in-utero. The repertoire measured in HIV 
uninfected neonates born to HIV-1 infected mothers displayed a polyclonal skewing of 
various TCR families and oligoclonal distribution of Vβ5, Vβ6a, Vβ7, Vβ18, and Vβ23 
families as compared to the Gaussian distributions seen in healthy controls. This study 
readily detected perturbations in the TCR repertoire in presumed HIV exposed babies and 
that newborns possess an intact TCR repertoire.  
  
Measurement of HIV-1-specific CD8+ T cells was made to identify which regions of the 
expressed HIV genome were immunodominant and what impact of co-infection with TB 
may have. PBMC samples were thawed and cultured in vitro using CD3+/CD4+ bi-
specific antibody to preferentially expand CD8+ T cells and measure IFN-γ producing 
cells in the ELISPOT and confirmed with the ICS. The ELISPOT results were interpreted 
in SFU/million PBMC and as percentages of T cell subsets in ICS assays.  HIV-1 subtype 
C-specific CD8+ responses were readily detected in both HIV-1 and HIV/TB co-infected 
patients, however, patterns of peptide targeting were different between the two groups. 
Gag was targeted by 85% of HIV-1 infected patients, whereas only 27% of HIV/TB co-
infected patients targeted Gag. Pol was targeted by 73% in the HIV/TB group. Gag and 
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Nef responses observed in some (n =7) of the patients were confirmed using ICS. These 
data infer that TB co-infection may change patterns of targeting and in how CD8+ T cells 
recognize HIV antigens.  
 
Collectively, this dissertation demonstrated the existence of highly activated CD8+ T 
cells, most probably driven by high HIV-1 plasma RNA loads; restricted TCR usage by 
CD8+ T cells, predominantly in individuals dually infected with HIV and TB; possible 
shifting of immunodominant HIV-specific CD8+ T cell responses as a result of co-
infection with TB. Despite successful treatment of TB with chemotherapy, these 
immunological observations remained unchanged.  
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CHAPTER 1 
INTRODUCTION AND LITERATURE 
REVIEW 
 
1.1  INTRODUCTION 
 
The human immunodeficiency virus (HIV) infection epidemic is growing in developing 
countries, such as those in Sub-Saharan Africa. Current statistics indicate that 5.5 million 
persons in South Africa are infected with HIV-1 (UNAIDS 2006, AIDS Epidemic 
Update). HIV infection initiates a slow progressive degeneration of the immune system. 
It infects cells bearing the CD4 antigen, along with co-receptors CCR5 and CXCR4 on 
their surface (Lusso, 2006; Rubbert et al., 1998), mainly macrophages and CD4+ T 
helper cells (Shacklett et al., 2003). CD4+ T helper cells play an important role in 
facilitating and enhancing the functions of other immune cells that protect the host from 
invading pathogens.  The hallmark of HIV-1 infection is the gradual decline in the 
numbers of CD4+ T cells and as a result, the immune system becomes suppressed and 
allows the development of various opportunistic infections which contribute to disease 
progression and ultimately Acquired Immunodeficiency Syndrome (AIDS). One of the 
most common of these opportunistic infections in South Africa is Mycobacterium 
tuberculosis (TB) (Wilkinson et al., 1997). Understanding the characteristics of T cells in 
people infected with HIV-1 and during TB infection may provide valuable information 
on HIV pathogenesis. 
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One of the most common forms of HIV-1 transmission in South Africa is through mother 
to child transmission (Brody et al., 2003). This can occur through several routes: foetal 
exposure to maternal body fluids during gestation, delivery, and breastfeeding (Gordon et 
al., 1992). It is generally acknowledged that the increase in susceptibility of infants and 
neonates to viral infections, including HIV-1, is related to the immaturity of their immune 
system (Krampera et al., 2000; Siegrist et al 2001) but the correlates of protective 
immunity to neonatal HIV-1 infection is poorly understood. Understanding the 
characteristics of T cells in neonates infected or exposed to HIV-1 may hopefully shed 
light on possible protective mechanisms. 
 
Understanding cellular immune responses to HIV-1 by exploring general effects and 
changes occurring at a cellular level, including direct engagement of T cells with the 
virus during exposure or infection will provide information on possible correlates of viral 
control. This dissertation focuses on three characteristics of T cells during HIV infection, 
dual HIV/TB co-infection and exposure to HIV. The characteristics examined are 1) 
memory and activation status of CD4+ and CD8+ T cell subsets; 2) T cell receptor 
repertoire and 3) HIV-1 antigen – specific T cell responses.  
 
Various cohorts of HIV-1 infected and HIV-1 exposed individuals have been included in 
this dissertation, including those individuals who are co-infected with mycobacterium 
tuberculosis (TB). Also included are HIV-1 uninfected children born to HIV-1 infected 
mothers, aiming at determining the level of antigen exposure.   
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1.2 LITERATURE REVIEW 
1.2.1 HUMAN IMMUNODEFICIENCY VIRUS 
Human immunodeficiency virus (HIV) is a retrovirus belonging to the family of 
Lentiviruses, which was initially described in 1983 (Montagneur, 2002). Infection with 
HIV shows a chronic course of disease, persistent viral replication in 
monocytes/macrophages (Zhu et al., 2002) and gut-associated lymphoid tissue 
(Guadalupe et al., 2003). HIV is the causative agent of Acquired Immunodeficiency 
Syndrome (AIDS), a disease associated with severe immunosuppression as a result of 
infection and loss of CD4+ bearing T lymphocytes (Guadalupe et al., 2003).  
 
1.2.1.1 Virus composition and structure 
HIV is a genetically complex, 100nm RNA virus consisting of three structural genes; env, 
pol, gag and six regulatory genes, tat, rev, vif, nef, vpr and vpu. A schematic diagram of 
the structure of HIV is shown in Figure.1.1 and gene arrangement is shown in Figure 1.2. 
Each viral particle contains 72 glycoprotein complexes, which are integrated into the 
lipoprotein membrane surrounding it. The external glycoprotein gp120 may be easily 
shed into the external environment within the host, and can therefore be detected in 
serum, as well as within the lymphatic tissue in HIV infected individuals. The 
transactivator gene (Tat) stimulates the transcription of HIV-1 DNA into RNA, promote 
RNA elongation, enhance the transportation of HIV RNA from the nucleus to the 
cytoplasm and it is also essential for translation. The virion protein expression (rev) is a 
gene that positively regulates the expression of virion proteins. Nef has been shown to 
cause down-regulation of CD4 and HLA class I (A and B alleles) molecules from the 
Chapter 1 
 
 
4
surface of infected cells, therefore facilitating viral escape from immune T cell attack 
(Aiken et al., 1996), as well as interfering with T cell activation and function by binding 
to proteins that are involved in intracellular signal transduction pathways. The potential 
importance of nef in disease progression has been shown where deletions of portions of 
the nef gene have been associated with slow disease progression and low viral replication 
(Collins et al., 1999). Vpr is essential for viral replication in non-dividing cells such as 
macrophages. It stimulates the HIV-LTR (long-term region) and it is also important for 
transport of the pro viral DNA to the host cell nucleus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Structure of an HIV virion particle (D.W  Sears, 2007. http://tutor.lscf.ucsb.edu) 
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Figure 1.2: Schematic diagram of the genes of HIV-1, showing the three structural genes (gag, pol, and 
env) and the regulatory gene (nef, tat, rev, vpu,vpr and vif  (Dan Stowell, 2006. 
http://www.mcld.co.uk/hiv). 
 
The vif protein enhances viral infectivity and also enhances cell to cell transmission of 
HIV-1 (Gabudza et al., 1992). Vpu is essential for the budding process, because 
mutations in vpu have been shown to dis-able release of viral particles from infected cells 
(Schubert et al., 1996). 
 
1.2.1.2 Portal of entry and replication   
 
HIV enters target cells (e.g. CD4+ T lymphocytes and monocytes/macrophages, dendritic 
cells and glial cells) by attaching its gp120 molecule (the envelope glycoprotein) to the 
CD4+ molecule on the surface of these cells (Randall, 1999; Rubbert et al., 1998; Blanco 
et al., 2002). This attachment requires interaction of gp120 with two host cell receptors, 
the CD4 molecule and a chemokine receptor, either CCR5 (R5 using) or CXCR4 (R4 
using). Gp120 primarily binds to certain epitopes of CD4 and induces conformational 
changes in gp120 that promote a more efficient interaction of the V3 loop of gp120 with 
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its respective co-receptor. Binding to the co-receptor in turn triggers a rearrangement of 
gp41 to extend the α-helical fusion domain, which then interact with the cell membrane. 
Penetration of the viral particle into the host cell is then followed by uncoating, i.e. when 
the viral core enters the cytoplasm of the target cell. Viral RNA is then converted to 
proviral DNA in the cytoplasm of the target cell. This conversion is mediated by the viral 
enzyme reverse transcriptase (RT) and it is the most important step in viral replication. 
RT inhibitors are currently widely used to inhibit viral replication (nucleoside and non-
nucleoside analogues) and are utilized for effective treatment in HIV-1 infected 
individuals. The provirus then migrates to the nucleus and integrates into the host 
chromosome with the help of the viral enzyme, integrase. The pro-viral DNA remains in 
the cell for as long as the cell survives, and is the continuous source of new viral progeny. 
The RNA transcript is formed from pro-viral DNA, and it gets processed to yield a 
complex pattern of subfragments of the initial transcript that serve as messenger RNAs 
for generation of viral proteins. Viral proteins are then assembled and packaged into a 
mature virus particle that buds from the cell as a free virion released into the extracellular 
space (Figure 1.3). 
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Figure 1.3: The life cycle of HIV virus showing viral entry and replication. 
(http://www.gladstone.ucsf.edu/gladstone/files/publicaffairs/HIVlifeCycle.gif).  
 
1.2.1.3  Mechanisms of HIV transmission 
HIV is transmitted when infected blood, semen, vaginal fluids, or breastmilk enter 
another person’s body. HIV can be transmitted by any infected person or injection of 
infected blood, or from mother to infant during pregnancy or at the time of birth. Viral 
transmission can occur in a number of ways (Douglas et al., 1992; Puren et al., 2002; 
Schmid et al 2004). 
 
1.2.1.3.1 Sexual intercourse  
The virus can enter the body during sexual intercourse through the mucosal membranes 
of the anus, vagina, penis, or mouth, as well as through cuts, sores and abrasions on the 
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skin. Oral sex is risky as well, but not as risky as vaginal and anal intercourse. Infection 
takes place when the virus crosses the mucosal surface and binds to cells that express 
CD4 and CCR5 and/or CXCR4. The risks of acquiring infection are increased by the 
presence of sexually transmitted diseases (Korenromp et al., 2005) and lowered by male 
circumcision (Auvert et al., 2001; Auvert et al., 2005). Plasma levels of virus broadly 
correspond to viral loads in the genital secretions, which are associated with the risk of 
transmission (Hart et al., 1999). Heterosexual transmission is the most common route of 
HIV-1 acquisition in South Africa (Schmid et al., 2004; Hunter et al., 1993; Abdool 
Karim et al., 1992). 
 
1.2.1.3.2 Occupational Exposure and infection 
Health care workers are at risk of being infected in the case of a needle stick injury. From 
a study conducted in Durban, South Africa, thirteen percent of hospital staff reported 
injuries with HIV positive patients (Gouden et al., 2000). Trainee registrars were the 
highest risk group (60%), with 94% percutaneous and 65% occurred during emergency 
surgery injuries (Gouden et al., 2000). Needle stick injuries and eye splashing of infected 
material can also be a source, especially in laboratories where high concentrations of 
virus is being used for research experiments. Healthcare workers mostly prone to HIV 
infection are nurses, laboratory technicians, surgeons, housekeepers, morgue technicians, 
and non-nursing attendants. Based on multicenter trials of more than 3000 healthcare 
workers, the risk of HIV infection is very high after needle stick injury or parenteral 
injury, which results in direct inoculation of infected material (Gouden et al., 2000). 
Meanwhile, the risk is very low following mucous membrane exposure (Kandla et al., 
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1997).  Other factors, which affect the risk of HIV infection in health care workers, 
include the volume of inoculum, the quantity of virus, depth of penetration, type and size 
of needle, and actual infection of blood (Gouden et al., 2000; Veeken et al., 1991) 
 
1.2.1.3.3 Blood transfusion  
Extensive testing of the blood by donor banks is performed before the blood can be 
distributed for donation. However, there is still a risk of HIV-infected donated blood 
because of donors who are in the ‘window period’ during acute infection (Sitas et al., 
1994). The increased use of Nucleic Acid Testing (NAT) (303) (Scuracchio et al., 2007) 
would minimize the use of HIV infected donor blood, as this would detect early infection 
during acutely infected potential donors. There have also been new policies put in place 
in South  Africa  to reduce the prevalence of HIV in blood donors, which included 
closing donor clinics in areas where HIV prevalence is high (Heyns et al., 2006). 
Following new policies, prevalence of HIV-1 in blood donations declined from 0.17% in 
2000 to 0.08% in 2002. The prevalence of HIV in first time donors decreased by 45% 
(Heyns et al., 2006).  
 
1.2.1.3.4 Injection drug use 
Small amounts of blood can remain in needles and syringes, which poses a high risk of 
transmission when the same tools are used without being sterilized. This happens 
predominantly among drug users. Intravenous abuse of Wellconal was reported in a study 
conducted in Johannesburg from 86 patients who were admitted to Johannesburg hospital 
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(Williams et al., 1997). Studies on treatment demand pointed to substantial use of 
heroine, although most of the users tend to smoke rather than inject (Parry et al., 2005). 
 
1.2.1.4  Mother to child transmission (MTCT) 
MTCT is referred to as vertical transmission, when the mother is infected with HIV and 
then transmits the virus to the unborn baby in-utero or to the newborn during birth and 
also through breastfeeding. Intrauterine infection and infection during delivery has been 
extensively reduced by the use of AZT or single dose Nevirapine during the last trimester 
of pregnancy or to the baby immediately after birth (Coetzee et al., 2005; Sherman et al., 
2004). One of the most common routes of perinatal transmission is via breast milk and 
the issues around whether mothers should breastfeed or not is currently controversial 
(Doherty et al., 2006, Chopra et al., 2002). Maternal viral load has a direct effect on all 
three modes of transmission (Thea et al., 2006, Rigopoulos et al., 2007), where the higher 
the viral load, the more likely is transmission (Hayes et al., 2006). Caesarean section has 
been shown to reduce perinatal transmission by more than 50% (European collaborative 
study, 2005).  
 
1.2.1.4.1  Infection at fertilization and post fertilization stages 
It has been shown that free virus or HIV infected leukocytes present in the ejaculate may 
reach the site of fertilization in the upper oviduct. The embryo may also be susceptible to 
infection as a result of the presence of virus in the female genital tract (Spinillo et al., 
2006). Virus has been isolated from the vaginal and cervical fluid and from the cells of 
the cervix (Maher et al., 2005). There is also evidence of a leucocytic infiltration of the 
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cervix and the uterus following insemination. If CD4-bearing cells are infected, the 
chances of intrauterine infection are increased.  Infection of the zygote is also likely to 
happen through the motile sperm, carrying free virus from the vaginal and cervical 
secretions, which has been shown in vitro by expression of HIV proteins from human egg 
infected at the time of fertilization (Kiessling, 1998; Whitmer et al., 1992). 
 
1.2.1.4.2   Infection at implantation  
Trophoblasts (cells forming the placental barrier) invade maternal endometrial capillaries 
within a few days of implantation (Lunghi et al., 2007). The invading trophoblasts 
encounter infected cells during this time and therefore, contact of the trophoblasts with 
maternal blood poses hazards of HIV infection since placental trophoblasts will be bathed 
in maternal blood (Vidricaire et al., 2004; Al-Harthi et al., 2002). Direct infection of 
trophoblasts may cause transmission of the virus to the foetus. Infection was found to be 
independent of gp120/CD4 interaction but requires heparin sulfate proteoglycans for 
uptake of the virus (Vidricaire et al., 2007).  
 
1.2.1.4.3  Transmission across placental villi and the chorioamnion 
Most maternal-foetal exchanges are mediated by the placenta. The placental 
syncyciotrophoblast plays a major role in these interactions since it is in direct contact 
with maternal blood (Menu et al., 1999). Some studies have suggested that 
monocytes/macrophages and epithelial cells lining the foetal capillary may function as a 
reservoir for the HIV (Maher et al., 2005). DC–SIGN may facilitate the transplacental 
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transmission of HIV, where DC-SIGN is a C-type lectin that is able to bind gp120 with 
high affinity and has been found to be expressed in the placenta (Soilleux et al., 2001).   
 
Another potential route is through the chorioamnion (Menu et al., 1999), where the 
cellular trophoblast and the maternal decidua are joined together. This happens in late 
gestation. The deciduas contain maternal blood vessels, macrophages, lymphocytes and 
thus may serve to expose the adjacent trophoblast to HIV. From here the virus or infected 
cells may cross the foetal connective tissue and amnion and enter the amniotic fluid. It 
has been demonstrated that women showing positive granulocyte elastase at delivery 
should be suspected of having had chorioamnionitis during pregnancy, which increases 
the risk of intrauterine transmission of HIV (Kaseba-Sata et al., 2006; Bhoopat et al., 
2005). 
 
1.2.1.4.4  Infection during delivery and postpartum  
There are reported risks of transmission even if the baby escapes intra-uterine HIV 
infection. HIV has been isolated from vaginal and cervical secretions from about one-half 
of infected women studied (Nunnari et al., 2005; Saracino et al., 2000), making it 
possible that the foetus could be infected. Distinguishing intrapartum and postpartum 
infection has been difficult to prove. Current methods involve performing a PCR at birth 
and from specimens obtained within 72 hours of birth to indicate in-utero infection 
(Mock et al., 1999; Fawzi et al., 2001; Sherman et al., 2005).  
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1.2.1.4.5  Infection through breastfeeding 
Breastfeeding is a potential mode of vertical transmission, especially in those countries 
where HIV prevalence is high. HIV-1 transmission via breast milk ranges from 8%-16% 
(Nduati et al., 200; Wiktor et al., 1999). There is no clear evidence of the timing of 
transmission during breastfeeding. Studies have demonstrated that the number of infected 
breast milk cells per million cells was associated with levels of cell-free viral RNA in 
breast milk (Koulinska et al., 2006; Rousseau et al., 2004). This suggests that infected 
breast milk cells may play a role in transmission of HIV via breast-feeding than cell free 
virus. 
 
1.2.2 NEONATAL T CELL IMMUNITY AT BIRTH 
Neonatal immune responses are generally considered to be immature and therefore lead 
to susceptibility of infants to both viral and bacterial pathogens. Neonates depend on 
maternal antibodies since neonatal humoral immunity is entirely underdeveloped. 
However, it has been determined that the foetal immune system can be activated to 
produce antigen specific responses as shown during parasitic infections with 
Trypanosoma cruzi (Hermann et al., 2002) and human cytomegalovirus infection 
(Marchant et al., 2003). Clonal T cell expansions have been previously identified in 
peripheral blood of HIV-1 infected children (McFarland et al., 2002), which further 
supports the existence of a matured T cell immunity during infancy. It has been 
demonstrated that human foetal CD8+ T lymphocytes can expand, differentiate, and 
acquire effector functions during a CMV infection and that this response shares similar 
characteristics to that found in adults (Marchant et al., 2003). It has therefore been 
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concluded that human CD8+ T cells can be primed in utero and could provide immunity 
to newborns against viral infections. A better understanding of the immune system in 
early life is required to develop vaccines that could protect infants from viral infections.  
 
1.2.3 THE EPIDEMIOLOGY OF HIV-1 INFECTION IN SOUTH AFRICA 
Worldwide, the number of HIV-1 infected individuals exceeds 40 million. The majority 
of these live in developing countries of Asia, South America and Sub-Saharan Africa. 
The profile of the epidemic to date at a national level, as produced by UNAIDS stated 
that the total number of people living with HIV in South Africa was estimated to be 5.5 
million. It is estimated that 240 000 children between the age of 0-14 are infected with 
HIV-1 and 320 000 AIDS deaths have been reported (UNAIDS update, 2006). 
 
There were around 530,000 new infections between the middle of 2004 and the middle of 
2005, and around 340,000 AIDS deaths over the same period (Groenewald et al., 2005). 
The HIV prevalence is still growing, and this has resulted in an estimated 520,000 
untreated South Africans who are sick with AIDS and in need of antiretroviral treatment. 
It is also estimated that 1.5 million South Africans have died of AIDS-related illnesses 
since the beginning of the epidemic (Groenewald et al., 2005). The ASSA2003 (Actuarial 
Society of South African AIDS and Demographic model) predicts that the total number 
of HIV infections in South Africa will increase slightly, from 5.2 to 5.8 million by 2010 
(Groenewald et al., 2005). It is predicted that the annual number of new HIV infections is 
likely to remain at approximately half a million over the next few years, despite the 
significant interventions that have already been introduced to limit the spread of HIV. 
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Amongst other interventions is the implementation of an Operational Plan for 
Comprehensive HIV and AIDS Care, Management and Treatment. By the end of 
December 2005, 111 827 people were estimated to be accessing free antiretroviral drugs. 
Significant progress has also been made in prevention through campaigns such as the 
Government Mass Media Campaign (Khomanani-http://www.aidsinfo.co.za/) Soul City 
(http://www.soulcity.org.za/); Love life (http://www.lovelife.org.za/) and others. The 
Government is also continuously distributing free condoms (UNAIDS update, 2006). 
According to the South African National HIV Prevalence communication Survey-2005, 
the highest rate was found to be among South African females at 33.3% (between 25-29 
years old) followed by males at 26% (between 30 and 34 years old) (Shisana et al., 
2005). There appears to be a high HIV prevalence among South African children which 
are estimated at 129,621 children aged 2-4 years and 214,102 children aged 5-9 (Shisana 
et al., 2005).  The most predominant HIV-1 subtype in South Africa is Clade-C, with 
only a few of A, B, D, G, and U (Bredell et al., 1998; Puren, 2002). These other subtypes 
represent a very small fraction of the predominant circulating subtypes.  
 
 1.2.4 INTERACTION BETWEEN HIV-1 AND MYCOBATERIUM  
   TUBERCULOSIS 
Globally, Mycobacterium tuberculosis (TB) is one of the common HIV-associated 
opportunistic infections and the leading causes of AIDS related deaths. An estimated 1.7 
million people (27/100) died from TB in 2004, including those co-infected with HIV (248 
000) (WHO report, 2005). The incidence of TB in South Africa is currently 718 
cases/100 000 annually, with the prevalence rate of 670 cases per 100 000 population. TB 
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mortality has been reported at 135 per 100 000 population per annum. 60% of these cases 
are HIV infected (WHO report, 2005), which are adults between the ages of 15-49 years. 
Approximately 10% of infected individuals develop active disease, which if left 
untreated, will kill more than 50% of its victims (Bonfioli et al., 2005). 
  
1.2.4.1 Mycobacterium tuberculosis 
Mycobacterium tuberculosis is a human-type aerobic acid fast tubercle bacillus, which is 
classified as a Gram-positive (Fisher et al., 1990). The bacterium is an intracellular, 
growing in mononuclear phagocytes e.g. macrophages (Zhang et al., 1999). It is a slow-
growing pathogen with the generation time of 12 to 18 hours. It has a hydrophobic cell 
wall with a high lipid content, which makes it impermeable to the usual gram stains. 
Once stained, the cells resist decolorization with acidified organic solvents and are 
therefore called “acid fast”. One commonly used acid-fast staining method for TB is the 
Ziehl-Neelson stain (Prasanthi et al.,  2005). The TB smear is fixed, stained with carbol 
fuchsin (pink dye), and decolorized with acid-alcohol. The smear is then counterstained 
with methylene blue or certain other dyes. Acid-fast bacilli appear pink in a contrasting 
background (see Figure.1.4). Laboratory diagnosis of tuberculosis is made by a positive 
tuberculin skin test, which can be confirmed by X rays of the chest and microscopic 
examination of the sputum or tissue samples using Ziehl Neelsen stain. This may 
however, be confirmed by laboratory culture of the bacterium (Toure et al., 2006). 
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Figure 1.4: Mycobacterium tuberculosis appearing as pink rods/bacilli (pointed by the arrow) on a Ziehl 
Neelsen stain (http://www.search.com/reference/Tuberculosis). 
 
1.2.4.2 Host response to tuberculosis 
TB infection commences with the acquisition of bacilli by the susceptible person via 
infectious droplets from an infectious case (Fennely et al., 2004). These droplet nuclei are 
transmitted from one individual to another via coughing, sneezing, talking and singing. 
Following inhalation, most of the larger droplets become lodged in the upper respiratory 
tract (the nose and throat), where infection is unlikely to develop. The smaller droplets 
pass through to the small air sacs of the lung (the alveoli) where infection begins after 7-
21 days post exposure (Johnson et al., 2006). Transmission can only occur from people 
with active TB disease (see 1.2.3.4). Individuals at risk include immunocompromised 
patients such as those with HIV/AIDS (Cahn et al., 2003), health care workers who serve 
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high-risk clients (Corbett et al., 2007; Naidoo et al., 2006), and children exposed to 
adults in high-risk categories (Soeters et al., 2005). 
In the alveoli, the mycobacteria are taken up by macrophages and dendritic cells, to the 
lung parenchyma and eventually to the lymph nodes (Johnson et al., 2006; Abdel-Dayem 
et al., 1997). At this stage lymphocytes begin to infiltrate as they are presented with 
microbial antigens. TB-antigen specific T cells induce the formation of a granuloma 
around infected macrophages primarily composed of monocyte-derived macrophages, 
CD4+ T cells and an outer ring of CD8+ T cells (Tsai et al., 2006). In the granulomatous 
lesion, macrophages are activated by T lymphocytes through production of type 1 
cytokines (IFN-γ and TNF-α) (Roach et al., 2002). IFN-γ activates macrophages which 
are now capable of destroying the microbe. It is at this stage that the individual becomes 
tuberculin-positive, which is a result of the host developing a vigorous cell-mediated 
immune response. It is also at this stage that the tubercle is formed, which does not allow 
the microbe to multiply but to persist for extended periods. Many macrophages can be 
found surrounding this tubercle, but remain in an inactive form, and used by the microbes 
to replicate. The granuloma persists for years and efficiently contains tubercle bacilli as 
long as an individual remains immunocompetent (Chan et al., 2004).  
 
1.2.4.3 Mycobacterium tuberculosis disease progression 
It is thought that progression from TB exposure and infection to TB disease occurs in 
individuals whose immune system fails to control bacilli and they begin to multiply. This 
may occur soon after infection (primary TB disease in 1-5% of cases) or many years after 
infection (post primary TB, secondary TB, reactivation of dormant bacilli in 5-9% of 
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cases). About 5% of infected persons will develop TB disease in the first two years, and 
another 5% will develop the disease later in life (McShane et al., 2005). The risk of 
reactivation increases with immune suppression, especially that caused by HIV (Milburn 
et al., 2001). Apart from HIV infection, there are other conditions that increase the risk of 
progression to TB disease, which includes silicosis, end stage renal disease, poorly 
controlled diabetes, chronic malnutrition and those who smoke tobacco (Johnson et al.,  
2006; Ariyothai et al., 2004). 
 
TB disease most commonly affects the lungs, where it is referred to as pulmonary TB. 
Extrapulmonary sites include the pleura, central nervous system (meningitis), lymphatic 
system, genitourinary system and bones and joints, and the hematogenous spread known 
as miliary tuberculosis (Farid et al., 1999; Maltezou et al., 2000). 
 
1.2.4.4  Tuberculosis treatment 
TB is currently treated by means of combination therapy, using cocktails of 3-4 drugs 
with different properties: Isoniazid, rifampicin, streptomycin which is a combination that 
has antibacterial activity; as well as isoniazid, rifampicin, ethambutol which is a 
combination used to inhibit the development of resistance. Vaccination against TB is 
routinely practiced in many countries as a prevention strategy. The Bacillus Calmette-
Guerin (BCG) vaccine is a live, attenuated strain of mycobacterium bovis which was 
introduced in 1922. However, the true efficacy of BCG is unknown. Some studies 
suggest 60-80% effective rate in children. BCG is still used in South Africa, however the 
use of BCG in the United States of America (USA) has been stopped because its 
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effectiveness in preventing infectious forms of TB is uncertain and the reactivity to 
tuberculin that occurs after vaccination interferes with management of persons who are 
possibly infected with TB. The primary strategy in the USA is to minimize the risk of 
transmission by the early identification of persons who have latent TB infection and the 
use of Isoniazid or Rifampicin for preventing progression of latent TB to active TB 
disease (CDC-MMWR, 1996).   
 
1.2.4.5 HIV/TB co-infection  
 Immunosupression, resulting from HIV infection hinders the ability of macrophages to 
clear TB infection, therefore enabling the bacilli to spread easily throughout the body. 
The risk of progression to TB disease is between 5 to 10% per year for co-infected 
patients, compared to a 7-10% risk for the rest of their life for patients with TB only. In 
areas like Sub-Saharan Africa where TB is endemic, many individuals harbor latent TB 
infection and reactivation occurs consequently due to the immunosuppressive effect of 
HIV infection.  In this regard, it has been widely noted that TB is a high grade pathogen 
that is the most common cause of death in HIV infected patients (Cahn et al., 2003). As a 
result, HIV is likely to have significant implications for the management and control of 
TB infection. 
 
HIV-1 infected patients with tuberculosis were reported to have lower CD4+ and CD8+ T 
lymphocyte counts than patients with single TB or HIV infection, respectively (Villacian 
et al., 2005; Rodrigues et al., 2006). These findings are an indication of disease 
progression in HIV infected individuals presenting with an opportunistic infection. High 
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activation of CD8+ T cells has been demonstrated in patients co-infected with HIV-1 and 
TB (Rodrigues et al., 2006). Virological and immunological impact of tuberculosis on 
HIV disease has been well documented. Among other studies, it was reported that TB 
provides a milieu of continuous cellular activation and irregularities in cytokine and 
chemokine circuits that are permissive of viral replication and expansion in vivo (Toosi, 
2003). An increase in HIV plasma RNA load was observed soon after onset of TB 
(Goletti et al., 1996) with increased viraemia in bronchoalveolar lavage fluid. In HIV-1 
infected persons with pleural tuberculosis, increased HIV-1 activity was demonstrable in 
both pleural-acellular and pleural mononuclear cells (Richter et al., 1994); increased 
HIV-1 systemic heterogeneity was found in dually infected patients. Distinct quasispecies 
were found to be more frequent in patients with both HIV-1 and TB, as opposed to HIV-1 
infected patients without TB (Richter et al., 1994). The overall conclusion from these 
findings presents a clear indication that sites for active TB infection in subjects co-
infected with HIV and TB play a critical role in HIV replication and evolution. As long 
as these sites harbor TB infection, they contribute to systemic viral activity. Additionally, 
TNF-α is produced and circulated in abundance in TB infected individuals (Toossi et al., 
2001; Bal et al., 2005, Raja et al., 2004) and has been shown that TNF-α enhances HIV 
replication in vitro (Kitaura et al., 2004).  
 
1.2.5  HIV IMMUNOPATHOGENESIS 
Infection with HIV initiates a slow progressive degeneration of the immune system, 
infecting predominantly cells bearing the CD4+ marker on their surface, mainly 
macrophages and CD4+ T helper lymphocytes (Klatzmann et al., 1984; Dalgleigh et al., 
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1985). The hallmark of HIV infection is a gradual decline in the numbers of CD4+ T 
helper cells (Clerici et al., 1997; Alimonti et al., 2003; Holm et al., 2005). Depletion of 
CD4+ T cells result in progressive suppression of the immune system which gives rise to 
introduction of various opportunistic infections that leads to AIDS. CD4+ lymphocyte 
depletion has been shown to be the result of a combination of specific virus-induced cell 
death, activation-induced loss of the memory (CCR5+CD45RO+) cell pool, occurring 
predominantly in the gut associated lymphoid tissues (Veazey et al  2000) and impaired 
renewal of the naïve (CD45RA+) cell pool  (Lawn et al.,  2001). 
 
1.2.5.1 CDC classification of HIV infection and disease stages 
The CDC classification system for HIV infected adolescents and adults, categorizes 
persons on the basis of clinical conditions and CD4+ T lymphocyte counts (CDC-
MMWR, 1992). The three CD4+ T lymphocyte categories are: 1) Greater than or equal to 
500 cells/µl, 2) 200 – 499 cells/µl, 3) less than 200 cells/µl. The clinical categories/stages 
are: Stage A) Asymptomatic HIV infection B) Symptomatic conditions including 
candidiasis, Herpes zoster, e.t.c C) AIDS defining illness including Pneumocystis carinni 
pneumonia, cytomegalovirus disease, wasting syndrome e.t.c. CD4+ T cell counts are 
higher in infants and young children than in adults. The immunological status of children 
is therefore based on age-specific CD4+ levels. The three CDC-CD4+ T lymphocyte 
immunologic categories applied for children  are: 1)   No evidence of  suppression  with 
>= 1500 cells/ml for less than 12 months; >= 1000 cells/ml for 1-5 years; and >= 500 
cells/ml for 6-12 months,  2) moderate suppression with 750-1499 cell/ml for < 12 
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months; 500-999 for 1-5 years; and 200-499 for 6-12 years. 3) Severe suppression with < 
750 for < 12 months; <500 for 1-5 years; and < 200 for 6-12 years (CDC-MMWR, 1994). 
 
1.2.5.2 Mechanisms of CD4+ T cell depletion  
There are various considered mechanisms of CD4 depletion in HIV-1 infected 
individuals. It is unclear whether one mechanism predominates or that all operate. The 
possible reasons for CD4 depletion include: 
• Direct cytopathocity: HIV virions are synthesized in an infected cell, which then 
buds out of the cell in such a way that they create punctures on the cell membrane 
resulting in cell death (Morita et al., 2004 ; Cadd et al., 1997). 
• Syncytia formation: In in-vitro studies performed using established cell lines, the 
HIV-envelope protein (gp120) expressed on the surface of infected cells could 
fuse with the CD4+ molecule of uninfected cells and form large multinucleated 
cells or syncytia. Syncytia get large, are unwieldy, and ultimately die prematurely 
(LaBonte et al., 2000). Syncytia formation may be an in vitro effect as this has not 
been observed in vivo 
• Apoptosis: CD4+ T lymphocytes have been shown to be killed by autologous 
HIV-infected cells, without syncytium formation. This cytolytic mechanism 
depends on gp120–CD4 binding, which triggers apoptotic death (Nardelli et al., 
1995; Heinekelein et al., 1995; Herbein et al., 1998).     
• Autoimmunity: HIV–specific CD8+ cytotoxic T cells (CTL) become stimulated 
by HIV antigens to kill infected CD4+ cells, through secretion of granules 
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(perforin and granzyme) that mediates the killing process (Shankar et al., 1999; 
Zarling et al, 1999; Liu et al., 2007). 
 
1.2.5.3 CD4+ and CD8+ T cell function  
CD4+ T helper cells provide critical help to B cells in the production of antibodies 
against HIV antigens, including stimulatory signals (e.g. IL-2) for B cell proliferation, 
differentiation into immunoglobulin–producing or memory B cells, and isotype switching 
from IgM to IgG (Barlett et al., 1990; Fogelman et al., 2000). Studies done in mice 
demonstrated the role of CD4 help in the development of functional CD8 memory 
(Shedlock et al., 2003). Both these immune mechanisms play an important role in the 
control of viral replication (Xiang et al., 2005) cytotoxic T cells (CTL) which 
differentiates and mediates killing of infected CD4+ T cells via production of perforin 
and granzyme (Yanai et al., 2003; Pardo et al., 2004), as well as  cytokine (e.g. TNF-
 and IFN-γ) pathways (Harty  et al., 2000) .   
 
1.2.5.4 HIV RNA load 
The plasma HIV load is a major indicator of HIV-1 prognosis associated with increased 
risk of death (Vlahov et al., 1998; Mellors et al., 1997). It is influenced by co-existence 
of other chronic viral infections (e.g. CMV, EBV and HSV), (Grando et al., 2005); 
opportunistic infections such as P. carinii pneumonia, M. avium complex disease, 
Candida esophagitis, toxoplasmosis, cryptosporidiosis, and mycobacterium tuberculosis 
(Goletti et al., 1996; Cahn et al., 2003). A representative diagram of HIV/AIDS disease 
progression is shown on Figure 1.5. The dissemination of HIV during primary infection 
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is co-incident with reduction of plasma viral load and detection of strong cellular 
immunity. It is likely that the strong CTL response contributes to the initial fall in plasma 
viral load (Koup et al., 1994; Borrow et al., 1994). The deterioration in T cell immunity 
and the increase in viraemia is accompanied by a gradual depletion of CD4+ T helper 
cells and the onset of AIDS and increased susceptibility to opportunistic infections 
(Pantaleo et al., 1993). This may take a range of times, from within months to several 
years.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5:  Representation of a typical HIV /AIDS disease progression in the absence of antiretroviral 
therapy, showing a gradual decline in CD4 count, a decline in viral load reaching setpoint and then 
increasing overtime thereafter. An increase in HIV CTL and neutralizing antibodies which declines 
gradually as the disease progresses to AIDS (www.studentreader.com, 23rd March 2007). 
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1.2.6  HIV-1 EXPOSURE AND INFECTION 
There are several routes of exposure by HIV-1 which could either lead to HIV infection 
or no infection if precautionary measures are taken. The most common exposure happens 
either in an occupational setting, through drug use, sexually, as well as mother-to-child. 
Vertical/mother-to-child transmission has however, been dramatically reduced with the 
introduction of antiretroviral treatment and other precautionary measures such as 
avoidance of breastfeeding and opting for caesarean section (Coetzee et al., 2005; 
Sherman et al., 2004, European collaborative study, 2005).   
  
There is a high possibility that infants born to HIV infected mothers may have been 
exposed to HIV proteins and particles in–utero. This has been shown through several 
studies as indicated by immune activation (Clerici et al., 2000; Kuhn et al., 2002 ), HIV–
positive PCR (Peretz et al., 2006; De Andreis et al., 1996) and the presence of HIV-
specific CD4+ and CD8+ T cell responses masured by flow cytometry (Legrand et al., 
2006; Kuhn et al., 2002).  
Impaired progenitor cell function has been observed in HIV-negative infants of HIV-
positive mothers as evidenced by lower numbers of naïve CD4+ T cells and reduced 
thymic output (Nielson et al., 2001). HIV envelope peptide specific IL-2 responses 
associated with Beta-chemokine production were detectable at birth in the majority of 
uninfected infants of HIV-positive mothers (Wasik et al., 1999). It has been reported that 
children, even during the first year of life, are able to mount functional immune responses 
as indicated by the IFN-γ ELISPOT (Feeney et al, 2005; Legrand et al., 2006). Major 
expansions of Vβ-restricted T cells have also been described in infants born to HIV-
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positive mothers, which were similar to those observed in acutely infected adults. The 
expansions have been considered to be associated with HIV-specific cytotoxic T 
lymphocyte activity (Soudeyns et al., 2000; McCloskey et al., 2002).     
 
1.2.7 T CELL RESPONSES DURING HIV INFECTION 
Cellular immunity is made up of CD3+CD4+ T helper lymphocytes, CD3+CD8+ T 
cytotoxic lymphocytes, and natural killer cells (Steward et al., 1985; Parkin et al., 2001). 
The induction of cellular immune response to HIV-1 exposure and infection depends 
upon the presentation of viral antigens on the surface of infected cells or antigen 
presenting cells to the CD4+ or CD8+ T lymphocytes (Parkin et al., 2001).  
 
Upon encounter and recognition of antigen, CD4+ T helper cells produce cytokines e.g. 
IL-2, IL-1, IL-6, IL-15, TNF-α, IFN-γ) which, amongst other functions facilitates 
proliferation and activation of CD8+ cytotoxic T lymphocytes. CD8+ T cells expand and 
differentiate into effector cells upon HIV infection (Fujiwara et al., 2005; Jordan et al., 
2006; Jassoy et al., 1993). CD8+ cytotoxic T lymphocytes have been shown to be 
predominantly involved in the partial containment of HIV replication (Benito et al., 
2004; Musey et al., 1997). This has been shown in studies of long term non-progressors, 
who sustained HIV-specific activity and were able to control viremia (Propato et al., 
2001; Greenough et al., 1999; Bailey et al 2006).  
T cells recognize HIV proteins by interaction of the T cell receptor (TCR) with small 
linear HIV peptide fragments (known as epitopes) on the surface of virally infected cells 
and antigen presenting cells which may be macrophages and/or dendritic cells (Parkin et 
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al., 2001; Knights et al., 1991; Macatonia et al., 1992). There are two ways in which 
MHC molecules loading ofantigen onto MHC molecules occur. 1) During viral 
replication and protein synthesis in the infected cell, peptide fragments bind and fold in a 
specific host cell class I MHC molecules and are transported to the cell surface for 
presentation to CD8+ T cells. 2) For presentation to CD4 T cells, proteins are degraded to 
peptide fragments in intracellular endosomal compartments or exogenous antigen may be 
taken up by endocytosis and then loaded onto class II MHC proteins for subsequent 
presentation.  The MHC class I pathway presents endogenous antigen and MHC class II 
pathway presents exogenous antigens. Figure 1.6 illustrates interaction of the TCR on 
CD4+ and CD8+ T cells and MHC class-1- and class II epitope complexes. The TCR on 
the surface of CD4+ T cells recognize HIV antigens presented through MHC class II 
complex and CD8+ T cells recognize antigens presented through MHC class I (Parkin et 
al., 2001). 
 
MHC-class I molecules consist of two polypeptide chains, an α or heavy chain which has 
three domains (α1, α2, and α3) and a smaller, non covalently associated chain, the β2-
microglobulin which has one domain (Cossarizza, 1997). The α3 domain and that of the 
β2-microglobulin have a folded structure, whereas the α1 and α2 domains pair to generate 
a long cleft, or groove that is the site at which an epitope binds to the MHC molecule. As 
discussed, antigens degraded in the cytoplasm, mainly those of endogenous origin, are 
bound to MHC class I molecules and presented to CD8+ T lymphocytes. MHC class II 
molecules are formed by two chains, α and β, which forms a structure very similar to that 
of class I. The two domains forming the peptide-binding cleft (α1 and β1) are given by 
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different chains. One important difference between MHC class I and II molecules is that 
the ends of the peptide-binding cleft are open in MHC class II and closed in MHC class I. 
As a result, the ends of an epitope bound to MHC class I are constrained, whereas the 
ends of epitopes bound to MHC class II hang over the open binding cleft. Antigens 
processed in acidified vesicles, mainly exogenous, are bound to class II molecules and 
are recognized by CD4+ T lymphocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: TCR and MHC interaction. Viral peptides are presented to the CD4+ T cell via MHC class II 
(A) and to the CD8+ cytotoxic T cell through MHC-class (B).  (users.rcn.com/.../BiologyPages/H/HLA).  
 
 
In both cases, epitopes are stably bound to MHC molecules so that the upper surface of 
the molecule is kinked in such a way that residues on the bound epitope are recognized 
A B
Chapter 1 
 
 
30
by the TCR. A complete recognition by the TCR is achieved through a composite of 
residues of the MHC molecule (α1 and α2) and the epitope. CD8+ T cells increase in 
numbers in the peripheral blood after HIV infection, mirroring the decline in CD4+ T 
cells. A large proportion of CD8+ cytotoxic T cells (CTL) are HIV-specific, recognizing 
different epitopes across the HIV proteome. Many of these cells are activated to varying 
degrees and co-express markers that reflect activation events, such as CD38 and HLA-
DR (Kestens et al., 1994; Benito et al., 2004). CD8+ cytotoxic T lymphocytes directly 
kill HIV infected cells through secretion of cytoplasmic granules (perforin and granzyme 
A and B). Perforin is a monometric pore-forming protein containing serine esterase that 
may be involved in the assembly of the lytic complex. In the presence of calcium, the 
perforin monomers bind to the target cell membrane and polymerize to form 
transmembrane channels, leading to cell death and removal from the circulation (Yanai et 
al., 2003). Granzyme enters the cell through the pores that are created by perforin. 
Granzymes are a collection of serine esterases (enzymes) which interact with intracellular 
pathways in the target cell to activate mechanisms which trigger apoptosis and DNA 
degradation (Pardo et al., 2004).  
 
Another mechanism used by CTL to kill infected cells is the Fas-FasL interaction. 
Ligation of Fas induces trimerization of the Fas molecule onto the target cell surface, 
associating with a transducing molecule which recruits and activates caspases 8 and 10, 
mediating cell killing by apoptosis (Pardo et al., 2004; Pinkoski et al., 2002). 
 
 
Chapter 1 
 
 
31
1.2.8  THE SPECIFICITY OF T CELLS IN RECOGNIZING 
ANTIGENS  
Specificity of T cells is generated during T cell formation in the thymus. Lymphocytes 
mature in the thymus and recognize cell surface presented MHC-I and MHC-II 
complexed-HIV epitopes by a specific clonotype T cell receptor (TCR). During 
intrathymic maturation, T cells undergo a series of events in a positive or negative 
manner, provoking their expansion and or deletion, respectively, and ultimately 
encounter a variety of antigens in the periphery resulting in clearance of infected cells. T 
cell maturation consists of three closely related processes (Pathak et al., 2005; Delves et 
al., 2000). 
 
1.2.8.1 Migration and proliferation: Immature T cells (haematopoetic stem cell 
precursors) arise from the bone marrow, leave the bone marrow, circulate in the blood 
and enter the thymic cortex, where a high level of proliferation occurs. Selective 
processes result in death of most of the newly formed cells so that only MHC-restricted, 
self-tolerant cells survive. Surviving cells then migrate to the medulla and are finally 
discharged into the periphery (Pathak et al., 2005; Delves et al., 2000). 
 
1.2.8.2   Differentiation: This is development of the mature phenotype of T cells. 
This involves formation of TCR complexes following formation of functional TCR genes 
by somatic rearrangement of different gene segments. Some of the accessory molecules 
acquired by T cells include CD4 and CD8 molecules. Functional differentiation occurs at 
this stage so that the potential of a thymocyte to become either a helper or a cytolytic T 
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lymphocyte is already developed before the cell enters the circulation (Pathak et al., 
2005; Delves et al., 2000). 
 
1.2.8.3 Selection: Two selection processes are applied so that T cells are modified or 
shaped for specificity in recognition of epitopes in association with the MHC molecule. 
These two processes are referred to as positive and negative selection. Positive selection is 
the process by which the T cell repertoire becomes self MHC-restricted. This ensures that 
only those cells expressing TCR capable of recognizing self MHC will be permitted to 
mature. Negative selection then eliminates potential autoreactive clones, and survival of T 
cells that do not recognize self antigens (Pathak et al., 2005; Delves et al., 2000). These 
two selection processes then result in the self-restricted, self antigen-tolerant mature T cell 
repertoire (Figure 1.7) as shown in adult mice studies. 
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Figure 1.7: Positive and negative selection of thymocytes in the thymus. Immature thymocytes from the 
bone marrow are subjected to positive or negative selection, where T cells are tuned to recognize host MHC 
first. During positive selection Double-Positive T cells (CD3+CD8+ and CD3+CD4+) that can recognize 
self MHC's are selected for proliferation. Those T cells that have high affinity for self MHC die via 
apoptosis (negative selection). If they escape this elimination, they may subsequently react against self 
antigens, and cause autoimmune disease.  The selection process and apoptosis occur in the thymic cortex 
and T cell maturity occurs in the thymic medulla. Matured T cells are then transported to the circulating 
blood  (Roitt et al., 2001).   
 
Chapter 1 
 
 
34
1.2.9 THE TCR GENE: ORGANIZATION, REARRANGEMENT  
AND  GENERATION OF DIVERSITY. 
T cell differentiation in the thymus results in cells expressing randomly generated TCR 
molecules with diverse specificities. This process happens prior to the selection process. 
T cells of the T lymphocyte lineage possess functional TCR-α and β chain genes, which 
are capable of being expressed as polypeptides. The antigen-specific TCR on 90% of the 
T cells in peripheral blood is a di-sulphide-linked, heterodimeric, transmembrane 
glycoprotein composed of α and β chain (Cossarizza, 1997). Functional α and β genes 
are formed by DNA rearrangements that generate V-(D)-J genes which are then linked to 
a C-region segment by RNA splicing, following transcription. Diversity in the TCR is 
generated by random utilization of a large number of germline V, D, J segments and 
random insertion of P- and N- nucleotides junctions between the V, D, J segments of the 
β chain and the V and J gene segments of the α chains. The most variable loops of the 
TCR namely the CDR3 regions of the α and β chains lie centrally and have the most 
contact with the presented peptide side chains.  
 
Three key structural features of CDR3 predominantly contribute to this interaction: the 
amino acid sequence of  CDR3, which is critical for physical recognition of the epitope; 
CDR3 length, which influences how deep the loop can reach into the epitope-binding 
groove of the MHC molecule and represents the first structural feature to be fixed during 
maturation of antigen specific immune responses; and the identity of the J segment used 
in TCR rearrangement, as well as the germ-line J region contributes at least four 
polymorphic residues to the C-terminal portion of CDR3. A schematic diagram of the 
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TCR gene is shown on Figure 1.8. The combined sum of all the different TCRs and 
specificities in an individual forms a repertoire. Both α and β chains play a crucial role in 
shaping the peripheral T cell repertoire responding to different antigens. At least 57 V 
gene segments are used to form beta chains, and they can be grouped into 24 families of 
Vβ1, Vβ2, Vβ3.1, Vβ4, Vβ5.1, Vβ5.2/3, Vβ6a, Vβ6β, Vβ7, Vβ8, Vβ9, Vβ11, Vβ12.1, 
Vβ13.1/3, Vβ13.6, Vβ14, Vβ15, Vβ16, Vβ17, Vβ18, Vβ20, Vβ21, Vβ22, Vβ23, based 
upon having 75% or greater sequence homology (Cossarizza 1997). 
 
 
 
 
Figure 1.8: The Vβ TCR gene. 
 
1.2.10  THE T CELL RESPONSE TO HIV AND CLONAL 
EXPANSION 
Antigens are presented to naïve CD4+ or CD8+ T cells either by presentation with class 
II or class I MHC on dendritic cells. This results in immunoactivation and priming of T 
cells bearing specific T cell receptors (e.g. Vα and Vβ), as shown on Figure 1.9. 
Dendritic cells prime T cells and then on encounter with antigen on other antigen 
presenting cells, expansion of T cells occurs. The specific TCR interacts with the specific 
MHC  plus epitope complex, and this determines which Vβ family is expanded. In the 
absence of infection, the TCR repertoire is fairly stable through time within individual 
subjects (Garderet et al., 1998; Even et al., 1995). An indication of TCR engagement 
V β CDR3 Jβ C β
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with antigen can be identified by investigation of the T cell repertoire. Perturbations in 
the repertoire have been previously observed as a result of T cell antigen encounter, i.e. 
during infection with various viruses and bacteria, including HIV-1 (Mc Farland et al., 
2002; McCoskey et al., 2002; Pantaleo et al., 1994). The diversity of the T cell repertoire 
plays a critical role in recognition of antigen. A more diverse repertoire has been shown 
to give rise to multiple HIV-1 epitope targeting (Douek et al., 2002; Gamberg et al., 
1999). Previous studies have demonstrated changes in the TCR Vβ repertoire during 
HIV-1 infection (Wilson et al., 1998; Kharbanda et al 2003). Gene expression analysis or 
spectratyping/immunoscope (Pannetier et al., 1995) and/or protein expression analysis by 
flow cytometry provides quantitation of the percentage of particular TCR Vβ families in 
a pool of T cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
            
 
Figure 1.9: Cartoon of the clonal expansion of CD8+ T cells after encounter with presented antigen by a 
dendritic cell. Priming and activation of a T cell bearing TCR-Vβ1 occurs, resulting in generation of T cell 
clones bearing the same TCR-Vβ1 (courtesy of Gray CM, 2007).  
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1.2.11  MISSING GAPS IN KNOWLEDGE 
 
The main objective of this dissertation is to examine the overall characteristics and 
functional nature of T cells in response to infection and exposure to HIV-1, as well as in 
the presence of mycobacterium tuberculosis (TB) co-infection. T cell-phenotypic changes 
have been associated with HIV-1 infection when compared to normal individuals 
(Vanham et al., 1991; Ho et al., 1993). These changes have been observed in various 
cohorts of HIV-1-infected as well as in HIV/TB co-infected cohorts, mainly indicative of 
T cell activation. It has been shown that activated T cells are higher in individuals co-
infected with HIV-1 and TB (Rodrigues  et al.,  2003; Morris et al., 2003; Hertoghe et 
al., 2000). More knowledge of the pathogenesis of HIV-1 in the presence of opportunistic 
infections needs to be explored.  
 
This dissertation examines different characteristics of T cell responses to HIV-1 and TB 
in infected, exposed and co-infected individuals; ranging from phenotypes to HIV-
specific function. Effective immune reponses to HIV-1 have been associated with both 
CD4+ and CD8+ T lymphocyte functional responses. HIV-1 proteins have been shown to 
elicit HIV-1-specific CD8+ cytotoxic T lymphocyte (CTL) responses (Novitsky et al., 
2003; Masemola et al., 2004; Ramduth et al., 2005,) as measured by secretion of IFN-γ.  
The emergence of CTL during the acute stage of infection coincides with a rapid decline 
in viraemia (Wilson et al., 2000; Koup et al., 1994). This dissertation explores: a) the 
nature of T cell reponses to HIV-1 infection in the absence and presence of co-infection 
with TB; b) the nature of T cell reponses in exposed uninfected individuals and exploring 
the neonate TCR as a model for exposure.  
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The immune system of neonates is generally known to be weaker than that of adults 
(Krampera et al., 2000; Qian et al., 1997; D’Arena et al., 1998), as demonstrated by low 
expression of Th1 cytokines. However, other studies have shown it to be mature in the 
context of cellular immunity to pathogens (Regner et al., 2004; Hermann et al., 2002). 
The interruption of HIV transmission from mother to child is important, and it involves 
research studies that focus on investigating the ability of infants to respond to HIV 
vaccines and whether any immunogenicity would be elicited by those vaccines. The 
immune response of neonates to HIV-1 has not been extensively defined, therefore 
hindering possible approaches to vaccine design. A number of vaccine trials have been 
conducted (Johnson et al., 2005; McFarland et al., 2001) which elicited poor 
immunogenicity compared to adults, or no immunogenicity at all.  
 
1.2.12 AIMS AND HYPOTHESIS 
1.2.12.1 AIM 1 
Examine changes in T cell phenotypes as a result of HIV-1 infection and co-infection 
with mycobacterium tuberculosis. This investigation is aimed at obtaining an overall 
representation of T cells involved in the defense against HIV-1 exposure and infection. 
This analysis has included the influence of TB disease on T cell immunity in HIV-1 
infection.  
 
1.2.12.2  AIM 2 
To examine the T cell receptor repertoire by measuring the frequency of TCR-T cell 
families and the diversity of the T cell populations by investigating CDR3 length 
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variations. This analysis provides a more refined nature of direct T cell engagement with 
antigen exposure in vivo using two techniques to measure TCR-usage, flow cytometry 
and CDR3 length variation to identify TCR Vβ family skewing. 
 
1.2.12.3 AIM 3 
To examine HIV-1 antigen-specific CD8+ cytotoxic T lymphocyte responses and profiles 
in HIV-1 single infection and co-infection with TB. 
This analysis provides a further refined approach of investigating antigen-specific T cell 
immunity at the peptide level in both HIV-infected and dually HIV/TB infected 
individuals. 
  
1.2.12.4  HYPOTHESIS 1 
That the immune response in HIV/TB co-infected individuals leads to elevated T cell 
activation and disruption of the TCR. 
 
1.2.12.5 HYPOTHESIS 2 
That T cell priming can occur in utero as a result of HIV-1-exposure. 
  
1.2.12.6 HYPOTHESIS 3 
That the patterns of immunodominance in HIV-1 subtype C–specific T cell responses are 
altered in the presence of TB disease. 
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CHAPTER 2 
 
T - CELL PHENOTYPIC ANALYSIS TO MEASURE 
NAÏVE AND ACTIVATED CELLS 
 
2.1  INTRODUCTION 
The pathogenesis of HIV is associated with several immunological dysfunctions, mainly 
the loss of CD4+ T helper cells as well as phenotypic changes to other T cells. CD4+ and 
CD8+ have been shown to be activated in response to various pathogens including HIV-1 
(Benito et al., 1997; Kerstens et al., 1994) and mycobacterium tuberculosis (TB) 
(Hertoghe et al., 2000; S Rodrigues Ddo S. et al., 2003; Morris et al., 2003). A major 
change that occurs during HIV infection is the reduction/depletion of naïve CD4+ and 
phenotypic alteration of naïve CD8+ T cells (Rodrigues et al., 2003; Brinchmann et al., 
2000). The phenotype and hence the functional quality of these T cells have been shown 
to change upon encounter with HIV and during the course of HIV infection (Barry et al., 
2003; Eggena et al., 2005).  
 
Activation of the immune system by HIV-1 infection enhances the maturation of naïve T 
cells into effector memory cells and central memory T cells (Hazenberg et al., 2000; 
Resino S et al., 2001). Along with depletion of CD4+ T cells, HIV infection leads to an 
increase in CD8+ T lymphocyte populations, both in percentage and absolute numbers 
(Barry et al., 2003). Upon infection, T cells express activation markers such as CD38+ 
and HLA-DR+ (Chun et al., 2004, Barry et al., 2003; Ho et al., 1993). Expression of 
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CD38+ on CD8+ T cells has been shown to be a strong predictor of HIV disease 
progression (Liu et al., 1997; Lubaki et al., 1999; Chun et al., 2004; Resino et al., 2004).  
 
Measurements of the frequency of naïve, memory and activated T cells from a total 
leucocyte  population have been widely achieved by the use of four colour flow 
cytometry (Brenchley et al., 2002; Landay et al., 1990), although this is rapidly changing 
beyond four colour (Walker et al., 2004; de Rosa, 2004). Four colour flow cytometry was 
used in this dissertation to measure the frequency of naïve T cells (CD45RA+/CD62L+), 
memory (CD45RA-/CD62L-) and activated (CD38+) T cell populations in individuals 
infected with HIV-1 and mycobacterium tuberculosis (TB), to examine changes in T cell 
phenotypes as a result of HIV-1 infection and co-infection with TB. This investigation 
was aimed at obtaining an overall representation of T cells involved in HIV  and HIV and 
TB co-infection.  
 
2.2 MATERIALS AND METHODS 
2.2.1 Study cohort 
Four groups of individuals were recruited from a gold mine in Welkom, and analyzed in a 
cross-sectional manner. The cohorts consisted of HIV-1 infected, singly TB infected 
individuals, HIV/TB co-infected individuals and healthy controls. The three infected 
cohorts with CD4 counts and HIV plasma RNA copies are shown on Table 2.1. The 
medians and interquartile ranges for both CD4+ counts and plasma RNA copies are 
shown below the table. The TB and HIV/TB co-infected groups were followed 
longitudinally over a period of 6 months while they were obtaining TB therapy and 
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samples were obtained at baseline (before treatment), 2 weeks, 6 months and 12 months. 
The TB status was determined by sputum-culture. 
Table 2.1: Cohorts of HIV infected, HIV/TB co-infected and TB infected  
 
HIV+ HIV/TB TB+
Viral load Viral load
 RNA copies /ml RNA copies /ml Patient ID CD4 (cells/µl)
IM67 270 6861 IM1 140 284612 IM3 1254
IM68 420 9460 IM5 111 29861 IM4 1606
IM70 379 10887 IM6 * 6475 IM7 559
IM71 1225 15828 IM9 * 19522 IM10 957
IM72 260 21588 IM11 833 113 IM12 1073
IM73 287 3192 IM13 437 3763 IM22 585
IM74 539 5106 IM14 1395 36096 IM23 580
IM75 391 225 IM15 * 29401 IM26 627
IM76 * 14556 IM16 583 65976 IM32 1908
IM77 * * IM19 510 24658 IM35 464
IM78 * 6093 IM21 177 35413 IM40 537
IM79 537 54822 IM29 945 6378 IM41 2624
IM80 393 * IM30 66 49172 IM45 1353
IM81 36 67574 IM33 353 82638 IM46 2681
IM82 393 1980 IM34 70 128271 IM57 *
IM83 452 19756 IM36 158 48403 IM59 2285
IM84 643 20599 IM42 873 9334
IM85 300 1980 IM47 1828 12283
IM86 717 19756 IM51 155 57230
IM87 208 26216 IM56 * 12460
IM88 350 2520 IM58 117 245634
IM89 304 121 IM60 939 67166
IM90 222 82150 IM61 189 92239
IM91 371 219917 IM62 536 5217
IM92 229 6576 IM63 847 9488
IM93 56 59463 IM65 469 41398
IM66 324 3645
CD4 Count
Cohort Median IQR
HIV+ 371 245 - 436
HIV/TB 437 157 - 840
TB+ 1073 583 - 1757
 HIV RNA LOAD 
Cohort Median IQR
HIV+ 12722 4628 - 22745
HIV/TB 29861 9411 - 61603
Patient ID CD4 (cells/µl) Patient ID CD4 (cells/µl)
 
IQR: Interquartile range 
*No results  
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The HIV-1 results were obtained by a serological assay (ELISA) at baseline- The 
GENSCREEN HIV1/2 Ab EIA was used, which is an enzyme immunoassay based on the 
principle of a two-step sandwich technique. It consists of a solid phase coated purified 
recombinant gp160 and gp25 proteins. Briefly, plasma samples were added to the wells 
on the antigen coated plate and incubated at 37oC. Peroxidase conjugate was then added, 
followed by the substrate solution. The reaction was stopped using sulphuric acid. 
Samples with ODs above the cutoff were considered to be positive. The Quantiplex HIV-
1 RNA 3.0 Assay (bDNA) was used to measure plasma viral load. The method was based 
on amplification of a signal nucleic acid probe for direct quantification of HIV-1 RNA in 
human plasma. It is a nucleic acid hybridization procedure. The RNA in plasma is 
captured to a microwell plate by a set of specific, synthetic oligonucleotide capture 
probes. A set of target probes hybridizes to both the viral RNA and the pre-amplifier 
probes. The capture probes (comprised of 17 individual capture extenders) and the target 
probes (comprised of 81 individual target extenders) bind to the different regions of the 
pol gene of the viral RNA. The amplifier probe hybridizes to the pre-amplifier forming a 
branched DNA (bDNA) complex. A chemiluminescent substrate was added and the 
emitted light was measured and calibrated by means of a standard curve for 
determination of RNA load. Viral load data for HIV and HIV/TB infected individuals are 
shown on Table 2.1.  
 
Absolute CD4+ counts were determined using percentages of CD4+ T cells obtained 
using Becton Dickinson FACSort flow cytometer-CellQuest software version 1.1, which 
were calculated from total lymphocyte counts obtained from the Coulter Onyx (Coulter) 
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blood cell counter. Whole blood was stained with APC labeled-CD3 and PerCP labeled–
CD4, as described in section 2.2.2. Percentage of CD3+CD4+ T helper cells was then 
obtained from gated lymphocytes. This percentage CD3+CD4+ was then used to 
calculate the absolute value of CD3+CD4+, as a proportion of total lymphocytes obtained 
from Coulter Onyx. Absolute CD4 counts for HIV and HIV/TB co-infected patients are 
shown on Table 2.1. 
 
2.2.2  Whole blood staining and flow cytometric analysis 
Whole blood cells were labeled with FITC (Fluorescein isothiocyanate); PE 
(Phycoerythrin); PerCP (Peridin Chlorophyll) and APC (Allophycocyanin)–conjugated 
monoclonal antibodies (Table 2.2). The table describes monoclonal antibodies used to 
identify cell types/cell populations described by various markers. Whole blood (100µl) 
and monoclonal antibodies (0.5µl to 10µl) were added to 5ml FACS polypropylene tubes 
and incubated in the dark at room temperature for 30 minutes. Red blood cells were lysed 
with 2ml BD 1x FACS lysing solution. Cells were then washed by centrifugation at 
1200rpm with 3ml of sheath fluid/haematology diluent (see Appendix 1) and fixed with 
300µl of cell fixer (see Appendix 1) for acquisition and analysis on the FACSort. 
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Table 2.2: Monoclonal antibodies (conjugated to different fluorochromes) and cell types 
measured 
 
Tube Measured cell type FITC PE PerCP APC
1 Naïve CD4+ T lymphocytes CD45RA CD62L CD4 CD3
2 Naïve CD8+ T lymphocytes CD45RA CD62L CD8 CD3
3 Acutely activated CD4+ T lymphocytes CD69 CD25 CD4 CD3
4 Acutely activated CD8+ T lymphocytes CD69 CD25 CD8 CD3
5 Chronically activated CD4+ T lymphocytes HLA-DR CD38 CD4 CD3
6 Chronically activated CD8+ T lymphocytes HLA-DR CD38 CD8 CD3
 
 
2.2.3  The gating strategy 
A total of 50,000 cells were acquired on the Becton Dickinson FACSort using the 
CellQuest software-version 1.1. List mode data was analyzed using the same software by 
gating live-lymphocytes on the FSC/SSC parameter followed by gating of specific T cell 
populations. An example of the gating strategy is shown on Figure 2.1. Lymphocytes 
were selected by region 1 (R1, Figure 2.1A), and sequentially gated by region 2 (R2) 
selecting CD3+ T cells (Figure 2.1B), and then sequentially gated by region 3 (R3) 
selecting CD8+ T cells (Figure 2.1C). Using this sequential (R1+R2+R3) gating strategy, 
the percentage of CD3+CD8+CD62L+CD45RA+ (naïve CD8+ T cells) is shown on the 
upper-right quadrant of Figure 2.1D (4.14%) and memory CD8+ T cells (34%) labelled 
as CD3+CD8+CD62L-CD45RA- is shown on the bottom left quadrant. Using a 
sequential gating strategy of R1 + R2, a percentage of activated CD8+CD38+ T cells was 
determined (Figure 2.2).  Activated CD8+ T cells are shown on the upper right quadrant 
of Figure 2.2.C, which is 65.15% of  T cells expressing the CD38 marker. 
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 Figure 2.1:  Flow cytometry dot plots showing the phenotype analysis of naïve and memory T cell 
populations. Events (50,000) were acquired on FACSort and the frequency of activated CD8+ T cells was 
measured. The gating strategy for CD8+CD45RA+CD62L+ (4.14%) and CD8+CD45RA-CD62L- (34%) T 
cells are illustrated. The percentages of both naïve CD8+ T cells and memory T cells were measured using 
a sequential gating strategy (R1+R2+R3) as shown on plot -A, B, and C.        
 
 
 
 
 
 
 
 
B DC
A
R1
R2 R3
34%
4.14%
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Figure 2.2:  Flow cytometry plots showing gating strategy to measure activated T cells. The gating strategy 
for CD3+CD8+CD38+ (65.5%) is illustrated. The percentage of activated CD8+ T cells was measured 
using a sequential gating strategy (R1+R2) as shown on plot -A, B, and C.  
 
 2.3 RESULTS 
2.3.1 Comparison of CD4 + T lymphocyte counts between TB infected, HIV-1 
infected and HIV/TB co-infected individuals 
To understand the clinical picture of these groups, CD4 absolute counts were compared. 
Both HIV-1 infected and HIV/TB co-infected groups had lower CD4+ T cell counts 
when compared to healthy controls (p = 0.004 and p = 0.029 respectively) as shown in 
Figure 2.3. No differences were observed between the normal and the TB infected group 
(p = 1.000) as well as between the HIV-1 infected group and the HIV/TB co-infected 
group. Both HIV-1 infected and HIV/TB co-infected groups had lower CD4+ T cell 
counts when compared to the TB infected group (p = 0.0001). Statistical data (P values) 
is shown in Figure 2.3. The significant difference by group was calculated using 
Bonferroni, (Statacorp, College station, Texas), which is a pairwise test that measures 
R1
R2
65.15%
A B C
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differences between groups. Similar results were obtained when percent CD4 counts were 
compared between the four groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Differences in absolute CD4 counts between healthy controls and the three cohort groups. 
Statistical P values are shown in the table below the graph.  
 
2.3.2 Comparison of CD8+ T lymphocyte counts between HIV-1 infected, TB 
infected and HIV/TB co-infected individuals 
Both HIV-1 infected and HIV/TB co-infected groups had significantly higher CD8+ T 
cell counts when compared to the normal controls (p = 0.027 and p = 0.034 
consecutively) as shown in Figure 2.4. No differences were observed between the normal 
and the TB infected group (p = 1.000) as well as between the HIV-1 infected group and 
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the HIV/TB co-infected group. Both HIV-1 infected and HIV/TB co-infected groups had 
higher CD8+ T cell counts when compared to the TB infected group (p = 0.016 and 0.022 
respectively). Statistical data is shown in Figure 2.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Differences in absolute CD8 counts between healthy controls and the three cohort groups. 
Statistical P values are shown in the table below the graph. 
 
The CD4:CD8 ratios were the lowest in the HIV-1 (0.02 – 0.86) and the HIV/TB co-
infected groups (0.01 – 0.97) compared to the healthy controls donors (0.94 - 2.02) and 
the TB infected group (0.48 – 2.95) (Table 2.3). 
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Table 2.3: The CD4:CD8 ratios from the three study cohorts and the normal controls 
CD4/CD8 ratio Normal TB+ HIV+ HIV/TB+
Median 1.68 1.60 0.25 0.24
Range 0.94 - 2.02 0.48 - 2.95 0.02 - 0.86 0.01- 0.97
 
These data show that CD4 counts are suppressed in HIV infected individuals, with or 
without TB and that TB infection alone did not significantly impair either the CD4+ or 
CD8+ compartment. 
 
2.3.3 Comparisons of HIV-1 RNA load between HIV and HIV/TB co-infected  
individuals 
HIV-1 RNA load was compared between 24 HIV-1 infected and 27 of the HIV/TB co-
infected individuals. Although there was no statistically significant differences observed 
between the two groups (p = 0.075), the HIV/TB patients had a higher trend of viraemia 
than the individuals with HIV-1 only (Figure 2.5). These data may suggest that the 
elevated levels of viraemia in co-infected patients may result in different pathologies 
between the two groups. 
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Figure 2.5: Comparison of HIV-1 plasma RNA load between 24 HIV/TB and 27 HIV-1 infected 
individuals. 
 
2.3.4   Phenotypic analysis of naïve and memory T cell populations in the TB, 
  HIV-1 and HIV/TB co-infected individuals 
The first T cell subsets to be determined were the frequencies of naïve and memory T 
cells. Flow cytometry data for this phenotypic analysis was expressed as percentages of 
total T lymphocytes as shown in the gating strategy example in Figure 2.1A-C. The mean 
percentages of naïve and memory T cells between healthy individuals (n = 7), TB 
infected (n = 16), HIV-1 infected (n = 26) and HIV/TB (n = 27) co-infected individuals 
were compared.   
 
2.3.4.1  CD4+ T cells  
Differences in the mean frequencies of CD3+CD4+CD62L+CD45RA+ T cells were 
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frequency of naïve CD4+ T cells to that of TB, HIV-1 and HIV/TB co-infected 
individuals (Figure 2.6). There was a statistically higher frequency of memory CD4+ T 
cells (CD3+CD4+CD62L-CD45RA-) in the three disease cohorts when compared to 
healthy donors and conversely lower frequencies of naïve CD4+ T cells. It was 
interesting to note, that although the gross CD4 count in TB infected individuals (without 
HIV infection) did not differ from healthy controls (see Figure 2.3), there were as few 
naïve CD4+ T cells in the CD4 compartment as in those infected with HIV-1 (Figure 
2.6). The lower proportion of naïve CD4+ T cells probably reflects the transition from 
naïve to memory T helper cells. 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Differences in naïve CD4+ T cells (CD3+CD4+CD62L+CD45RA+) and memory CD4+ T 
cells (CD3+CD4+CD62L-CD45RA-) between healthy controls and the three cohort groups. Statistical P 
values are shown in the tables. Statistical P values were determined by using ANOVA and Bonferroni 
pairwise analysis for these three cohorts consecutively when compared with the healthy controls. 
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2.3.4.2  CD8+ T cells  
The control group had the highest frequency of naïve CD8+ T cells when compared with 
all the groups (p = 0.0001). The plot and statistical tables are shown on Figure 2.7. Lower 
frequencies of naïve CD8+ T cells were observed in the HIV+ (p = 0.012) and the 
HIV/TB co-infected group (p = 0.001) when compared with the TB infected group. 
Higher frequencies of memory CD8+ T cells were observed in the HIV+ (p = 0.0001) 
and the HIV/TB group (p = 0.0001) as compared to the normal donors. The CD8+ 
memory pool in the TB+ group was significantly lower than that observed in the HIV/TB 
co-infected group (p = 0.004). The frequencies of both memory CD4+ T cell and memory 
CD8+ T cell populations in all three infected groups were higher than the naïve T cells 
populations (Figure 2.6 and 2.7), and the over-representation of circulating memory T 
cells, coupled with a preferential loss of the naïve T cell population, is likely due to 
persistent antigen and maturation of naïve to memory T cells upon interaction with both 
HIV-1 and TB antigens.  
 
 
 
 
 
 
 
 
Figure 2.7: Differences in naïve CD8+ T cells (CD3+CD8+CD62L+CD45RA+) and memory CD8+ T 
cells (CD3+CD8+CD62L-CD45RA - between healthy controls three infected groups.  Statistical P values 
are shown in the tables.  
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2.3.5  Phenotypic analysis of activated CD8+ T cell populations in the TB, 
HIV-1 and HIV/TB+ co-infected individuals  
The increased frequencies of memory CD8+ T cells, demonstrated in the infected cohort 
groups, were also accompanied by increased T cell activation. The level of activation was 
achieved by measuring the percentages of CD3+CD8+ T cells expressing CD38. The 
phenotypic patterns of activated CD8+ T cells between the 7 healthy controls, 16 TB 
infected, 26 HIV-1 infected and 27 HIV/TB co-infected individuals were compared 
(Figure 2.8) 
 
A larger proportion of CD3+CD8+ T cells expressing CD38+ were observed in the 
HIV/TB group when compared with healthy controls and TB infected individuals (p = 
0.0001) followed by the HIV-1 infected group which showed higher levels when 
compared to TB and healthy control groups (p = 0.0001); as shown in Figure 2.8, no 
significant differences were observed between the normal controls and the TB group (p = 
1.0000). The presentation of the opportunistic infection (TB) in the co-infected 
individuals was associated with higher frequencies of T cells expressing CD38 and is 
perhaps in agreement with accelerated progression to AIDS (Kerstens et al., 1994). The 
increased activation status observed in the HIV/TB co-infected group is associated with 
the high levels of CD8+ memory T lymphocytes as described in section 2.3.4, as well as 
the high absolute CD8+ T cell counts. HLA-DR was expressed at very low percentages in 
the CD8+ T cells of all cohort groups and no significant differences were observed. No 
differences were observed in the frequency of acutely activated T cells: 
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CD3+CD8+CD69+ and CD3+CD8+CD25+ T cells between the four cohort groups - (p = 
1.000).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: T cell phenotype results showing the percentage (mean +SD) of activated CD8+ T cells 
(CD3+CD8+38+). The percentages of CD8+ T cell activation was compared amongst the normal controls 
and the three infected cohort groups. Statistical P values are shown in the table. 
 
 
2.3.6 Associations between naïve/memory T cells and HIV plasma RNA 
copies in individuals singly infected with HIV-1  
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infected individuals. There was an inverse trend between naïve CD4+ T cells (R = -0.354, 
p = 0.0877) and viral load, although not reaching significance (Figure 2.9A). A similar 
association was observed between naïve CD8+ and viral load (R = -0.475, p = 0.0192, 
Figure 2.9B). These data may suggest that a high burden of viraemia enhances the 
maturation of naïve T cells to memory. Although not significant, the trends towards 
positive correlations were observed between memory CD4+ (R= 0.171, p = 0.419) and 
CD8+ T cells (R = 0.328, p = 0.116) and HIV-1 RNA load (Figure 2.9C and D), 
suggesting that levels of viraemia may drive maturation of T cells from naïve to memory.  
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: The association between naïve CD4+ (A), naïve CD8 (B), memory CD4+ (C) and memory 
CD8+ (D) in patients infected with HIV-1, using Spearman Rank Order Correlation tests.  
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2.3.7 Associations between naïve /memory T cells and HIV plasma RNA 
   copies in individuals dually infected with HIV-1 and TB. 
 
The relationship between viral load and the percentage of naïve CD4+ and CD8+ T cells 
was determined from a total of 27 HIV/TB co-infected individuals. A statistically 
significant negative association was observed between naïve CD4+ T cells and viral load 
(R = -0.476 and p = 0.0124, Figure 2.10A), with a similar association observed between 
naïve CD8+ T cells and viral load in the same group (R = -0.503 and p = 0.031, Figure 
2.10B). No significant association was observed between memory CD4+ T cells (Figure 
2.10C) or memory CD8+ T cells (Figure 2.10D) and viral load in this group of 
individuals.  
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: The association between naïve CD4+ (A), naïve CD8 (B), memory CD4+ (C) and memory 
CD8+ (D) in patient dually infected with HIV-1 and TB.   
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2.3.8 The association between activated T cells and HIV-1 plasma RNA load 
Activation of the immune system in HIV infection can be measured by investigating the 
proportions of CD8+ T cells co-expressing CD38, which has been associated with disease 
progression, coinciding with high levels of viraemia (Barry et al., 2003). This dissertation 
examined the association between HIV-1 plasma RNA copies and the level of T cell 
activation, where it is hypothesized that immune activation positively associates with 
viraemia. Associations were made in 27 HIV/TB co-infected and 24 HIV infected 
individuals. A significant positive association was indeed observed between activated 
CD8+ T cells and HIV–plasma viral load (R = 0.411, p = 0.0455) in HIV-1 infected 
individuals (Figure 2.11A). Although not reaching significance there was a similar 
association seen in the HIV/TB co-infected group (R = 0.338, p = 0.0836) shown on 
Figure 2.11B.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: The relationship between activated CD8+ T cells and HIV-1 RNA load for 24 HIV-1 infected 
individuals (A) and 27 HIV/TB co-infected individuals (B) using Spearman Rank Order Correlation tests.  
 
 
H
IV
 R
N
A
 lo
ad
, l
og
10
co
pi
es
/m
l
r = 0.411
P = 0.045
20 40 60 80 100
1
2
3
4
5
6
20 40 60 80 100
1
2
3
4
5
6
% CD3+CD8+CD38+
A
20 40 60 80 100
1
2
3
4
5
6
20 40 60 80 100
1
2
3
4
5
6 B
r = 0.411
p  .0455
r = 0.338
p = 0.0836
HIV+ HIV/TB
Chapter 2 
 59
These data supports the notion that HIV replication drives T cell activation, as measured 
by the CD38 marker. 
 
2.3.9 The effect of TB treatment on CD4+ counts and HIV-1 RNA load in 
HIV/TB co- infected individuals 
 
Successful treatment of TB in HIV/TB co-infected individuals may represent an effective 
strategy in elimination of some of the immunopathology associated with dual HIV and 
TB infection. With this in mind, one of the aims of this dissertation was to explore 
whether anti-TB therapy could alleviate or reverse markers of immune activation and 
restore levels of naïve T cells.  
 
The effect of TB therapy on CD4+ T lymphocyte count and HIV-1 viraemia were 
evaluated from 10 HIV/TB infected individuals, which were selected because of 
availability of longitudinal samples, although some of the patients were lost to follow up. 
Blood samples were collected at baseline, 2 weeks, 8 weeks and 6 months of TB therapy. 
There was no change in CD4 counts or viraemia over time of treatment (Figure 2.12) 
 
 
 
 
 
 
 
 
 
Chapter 2 
 60
 
 
 
 
 
 
 
 
 
 
Figure 2.12: The effect of TB treatment on CD4+ T lymphocyte count (A) and HIV-1 RNA load (B) in 
HIV/TB infected patients over six months of anti-TB treatment.  
 
2.3.10   The effect of TB treatment on T cell phenotypes in TB singly infected  
individuals  
Naïve CD4+ T cells increased significantly by 2 weeks of anti-TB therapy (p = 0.000), 
and then declined to pre-treatment levels at 8 weeks and were maintained at the same 
level for 6 months (Figure 2.13A). As shown on Figure 2.13B, levels of memory CD4+ T 
cells were significantly reduced at 6 months (p = 0.008). Anti-TB treatment in this cohort 
group did not improve restoration of naïve CD4+ T cells; however, the memory T cell 
pool was significantly reduced. Naïve CD8+ T cells increased significantly at 8 weeks (p 
= 0.019) and declined to baseline levels at 6 months (Figure 2.13C). There were no 
differences in levels of memory CD8+ T cells (Figure 2.13D). Interpretation of these data 
suggests that anti-TB treatment had variable effects and there was probably too much 
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 (CD3+CD8+CD38+) were shown to be at the same level as those of healthy controls in 
this study group, and this did not change during anti-TB treatment (Figure 2.13E). As 
these results showed no meaningful or long term effect of anti-TB treatment on the 
phenotypes of T cells in TB infected individuals, these data infer that reduced naïve 
CD4+ T cells in this study group may not be associated with TB infection per se. One of 
the limitations of this study was the absence of longitudinal follow-up of healthy control 
donors, to establish the variation of these phenotypes without disease or pathology.             
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: The effect of TB treatment on naïve CD4+ (A) memory CD4+ (B), naïve CD8+ (C) memory 
CD8+ (D) and activated CD8+ T cells (E) in TB single infected individuals. 
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2.3.11 The effect of TB treatment on T cell phenotypes in HIV/TB co-infected 
  individuals 
This dissertation demonstrated elevated levels of CD38+-expressing CD8+ T cells in dual 
infection. A decrease in T cell activation as a result of TB therapy has been previously 
demonstrated in individuals with HIV/TB co-infection, and most of these studies 
described changes in the levels of cytokines (IFN-γ, IL-6 and TNF-α) and expression of 
HLA-DR as a marker of activation (Lawn et al., 1999, Wallis et al., 1993). This 
dissertation describes the effect of anti-TB therapy on phenotypic changes including 
CD3+CD4+ and CD3+CD8+ T cells expressing CD45RA+CD62+ (naïve), CD45RA-
CD62L-(memory), and CD38+ (activated) phenotypes.  
 
Frequencies of naïve CD4+ T cells in this study group were significantly reduced 
although when adjusting for CD4+ T cell count, the frequencies of naïve CD4+ T cells 
were sustained throughout the duration of anti-TB treatment (p > 0.05)(Figure 2.14A). 
The elevated frequencies of memory CD4+ T cells were also sustained throughout anti-
TB therapy (p > 0.05) (Figure 2.14B), suggesting that presumed removal of TB bacillus 
load made no impact on the naïve to memory imbalance. Adjusting for CD8+ T cell 
counts at each time point of anti-TB treatment in individuals co-infected with HIV-1 and 
TB, there was a marginal significant increase in naïve CD8+ T cells at 6 months (p 
=0.049) (Figure 2.14C), coinciding with a decrease in memory CD8+ T cells ( p = 0.000) 
(Figure 2.14D). Elevated frequencies of CD8+ T cells expressing CD38+ were observed 
in HIV-1 infected and HIV/TB co-infected individuals, whereas those individuals 
infected with only TB had the same frequency of CD38–expressing CD8+ T cells as 
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healthy controls. No significant difference in CD8+ T cell activation occurred at all time 
points during TB therapy in this cohort group (Figure 14E), suggesting that TB infection 
probably had a minor role to play in T cell activation observed in HIV/TB dual infection. 
 
 
 
 
 
 
 
 
 
 
Figure 2.14: The effect of TB treatment on naïve CD4+ (A) memory CD4+ (B), naive CD8+ (C), memory 
CD8+ (D) and activated CD8+ T cells (E) in HIV/TB co-infected patients. 
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been previously reported to result in apoptosis and therefore loss of CD4+ T cells (Hirsch 
et al., 2001), no loss of CD4+ T cells was observed as a result of TB infection in the 
cohort studied. CD4+ absolute cell counts in patients infected with TB in this study were 
similar to those observed in healthy controls. 
 
The loss of CD4+ T cells in HIV-1 infected patients was not significantly affected by co-
infection with TB, suggesting that loss of these cells is predominantly due to HIV-1. This 
was further confirmed by approximately similar values of the CD4:CD8 ratio observed in 
patients who were singly infected with HIV-1 and those co-infected with HIV-1 and TB 
which were both lower than the ones observed from single infection with both HIV-1 and 
TB. The CD4:CD8 ratio is used as a marker of HIV/AIDS disease progression (Taylor et 
al., 1989) where lower ratios reflect the more advanced stage of HIV-1 infection. 
 
The results from this chapter have demonstrated that the loss of CD4+ T cells is caused 
by HIV-1, and was probably not due to TB infection in these cohorts. Since anti-TB 
treatment did not restore this T cell population, it may be necessary to consider the use of 
both antiretroviral therapies concurrently with anti-TB treatment to increase survival in 
individuals co-infected with both pathogens. Previous studies have shown no significant 
reduction in HIV-1 plasma viraemia during anti-TB treatment (Lawn et al.,1999; Toossi 
et al., 2001) however, contrasting report showed a decrease in viral load after 3 months of 
treatment and which was maintained at 6 months (Morris et al., 2003). The findings in 
this dissertation demonstrate maintenance of high viraemia in HIV-1 infected individuals 
who are co-infected with TB, despite anti-TB treatment. A significant loss of 
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CD3+CD4+CD45RA+CD62L+ (naïve CD4+) T cells in all three infected groups, 
concurrent with an increase in the memory phenotype was demonstrated in this 
dissertation, which was maintained throughout a six months period of anti-TB therapy in 
HIV/TB co-infected individuals. This reduction of naïve CD4+ T cells was concurrent 
with a reduction in absolute CD4+ T lymphocyte counts and an increase in HIV-1 plasma 
load, which were not affected by anti-TB therapy. Maturation of naïve CD4+ T cells  to 
memory phenotype may pose a detrimental effect since it has been reported that memory 
CD4+ T cells are more susceptible to HIV-1 infection (Veazey et al., 2000), consequently 
leading to an increased loss of the CD4+ T lymphocyte pool. HIV-1 infection has also 
been associated with impaired renewal of naïve CD4+ T cell pool (Lawn et al., 2001), 
which may also be a factor in the reduction of these T cells. The influence of high HIV-1 
RNA copies in the loss of naïve CD4+ T cells is also demonstrated. These results 
demonstrate that loss of naïve CD4+ T cells occurs, largely in the presence of co-
infection with HIV-1 and TB, which is driven by high HIV-1 plasma load. Anti-TB 
treatment did not improve the loss of this T cell population. 
 
Similarly, HIV/TB co-infected individuals had the highest levels of memory CD8+ T 
cells, and the lowest levels of naive CD8+ T cells, which may imply that the high HIV-1 
RNA load as well as co-existence of TB may be the two factors driving maturation of 
naïve CD8+ T lymphocytes to memory phenotype. It was further demonstrated that naïve 
CD8+ were elevated and memory CD8+ T cells were reduced at 6 months during anti-TB 
therapy, which was not observed with CD4+ T cells, suggesting that removal of TB 
antigens with treatment allowed the restoration of CD8+ T cells probably because they 
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are not directly infected by HIV-1. This study did not identify any reduction of absolute 
CD8+ T lymphocytes in HIV/TB co-infected individuals, but contrasting reports 
demonstrated loss of absolute CD8+ T cells in individuals co-infected with HIV and TB, 
whereas these cells were found in large numbers during the natural progression of HIV-1 
infection (Rodrigues et al., 2005). These results demonstrate that despite severe loss of 
CD4+ T cells in advanced HIV-1 disease, anti-TB therapy could restore a pool of naïve 
CD8+ T lymphocytes which could possibly play a role in the potential control of HIV-1 
disease progression. 
 
Elevated frequencies of CD38-expressing T cells are a strong marker of HIV-1 disease 
progression to AIDS (Liu et al., 1997). CD38 reflected high levels of activation which 
appeared in large numbers in patients who were singly infected with HIV-1 as well as 
those co-infected with TB in this study.  There was no difference between activation 
levels in single HIV-1 infection and HIV/TB co-infection suggesting that activation of 
CD8+ T lymphocytes was predominantly elicited by HIV-1 rather than TB. In this 
respect, anti-TB therapy had no impact on the level of CD8+ T lymphocyte activation, 
suggesting that activation of CD8+ T lymphocytes is driven by high HIV-1 RNA load, 
despite anti-TB therapy. The influence of HIV-1 plasma RNA copies may be implicated 
in the persistence of T cell activation since there was a significant association between 
viral load and the level of activation which did not change during TB therapy. Sustained 
high levels of activation and HIV-1 plasma RNA load could therefore be related to 
advancing disease.  
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In summary, alterations in T cell phenotypes in this chapter appeared to be more 
influenced by HIV-1 than TB infection, as anti-TB treatment and removal of bacterial 
burden did not significantly alter T cell activation or uniformly affect the pool of 
circulating naïve and memory T cell populations.  
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CHAPTER 3 
 
T-CELL RECEPTOR USAGE IN HIV-1 INFECTED 
ADULTS CO-INFECTED WITH 
MYCOBACTERIUM TUBERCULOSIS 
 
3.1  INTRODUCTION 
T cell priming and activation occurs when antigens are presented to naïve CD4+ or CD8+ T 
cells by dendritic cells. The T cell receptor allows this process to occur through binding to the 
MHC and the restricted epitope (see chapter 1, section 1.2.7). This process results in expansion 
of T cells bearing specific T cell receptors and in the absence of infection or persistent 
infection, the TCR repertoire is fairly stable throughout time within an individual (Garderet et 
al., 1998; Even et al., 1995). An indication of TCR engagement with antigen can be 
investigated by measuring the T cell repertoire. Perturbations in the repertoire have been 
previously observed as a result of T cell antigen encounter during infection with various 
bacterial and viral infections, including HIV-1 (Mc Farland et al., 2002; McCoskey et al., 
2002; Pantaleo et al., 1994). The diversity of the T cell repertoire plays a critical role in 
recognition of antigen and the more diverse repertoire has been shown to give rise to multiple 
HIV-1 epitope targeting (Douek, 2002; Gamberg et al., 1999).  
Previous studies have demonstrated changes in the TCR Vβ repertoire during HIV-1 infection 
(Wilson et al., 1998; Kharbanda et al., 2003). Gene expression analysis or 
spectratyping/immunoscope (Pannetier et al., 1995) and/or protein expression analysis by flow 
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cytometry (Wilson et al., 1998) are among the most frequently used assays for analysis of the 
TCR repertoire in HIV-1 infected individuals. 
 
Flow cytometry staining with monoclonal antibodies recognizing different TCR Vβ 
specificities provides quantitation of the percentage of particular TCR Vβ families in a pool of 
T cells, and can give an indication of T cell receptor (TCR) usage in response to antigens. 
Flow cytometry was applied in this dissertation to determine TCR usage in individuals 
infected with HIV-1 and the impact of TB co-infcetion. Approximately 80% of the T cell 
repertoire can be assessed using monoclonal antibodies specific for the variable beta TCR and 
so provides a measure for surface expression of different TCR families on T cells. Thus, this 
approach, using flow cytometry, allows simultaneous measurements of Vβ-expressing CD4+ 
and CD8+ T cells.  
 
3.2  MATERIALS AND METHODS 
3.2.1   Study cohort  
TCR repertoire changes were investigated in three patient cohorts: 26 HIV-1 infected, 27 HIV-
1 and TB co-infected, 16 TB infected patients and 7 healthy controls. The TB and HIV/TB co-
infected groups were followed longitudinally while on anti-TB therapy for a period of 6 
months and samples were obtained at baseline (pre-treatment), 2 weeks, 8 weeks and 6 months 
(as described in section 2.2.1). 
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3.2.2  Whole blood staining and flow cytometric analysis  
Whole blood (100µl) and different volumes of monoclonal antibodies (Table 3.1) for 
CD3+CD4/8+CD38+Vβ+ T cells ranging from 0.5 to 10µl were added to 5ml FACS 
polypropylene tubes and incubated in the dark at room temperature for 30 minutes. Red blood 
cells were lysed with 2ml BD 1x FACS Lysing solution. Cells were then washed by 
centrifugation at 1200rpm with 3ml of wash solution (see description on Appendix 1A) and 
fixed with 300µl of cell fixer (see description on appendix 1A). A total of 50,000 cells were 
acquired on a Becton Dickinson FACSort using CellQuest software-version 1.1. List mode 
data was analysed using the same software by gating live-lymphocytes on the FSC/SSC 
parameter followed by gating of specific T cell populations. The gating strategy is shown on 
Figure 3.1. Gating of CD3+CD8+ T cells (R1) and CD4+ T cells (CD3+CD8-) as R2 finally 
resulted in measurements of 1.99% of CD8-CD38+ (CD4+) T cells –expressing Vβ5.1 and 
2.73% of CD8+CD38+)-expressing Vβ5.1. As it was shown in Chapter 2, CD38 surface 
expression was used to assess which Vβ TCR were used by activated T cells. Panels for 
analysis of Vβ1, Vβ2, Vβ6.7, Vβ9, Vβ18 were excluded for analysis of activated T cells for 
all cohort groups due to unavailability of relevant monoclonal antibodies/fluorochrome 
combinations. 
 
3.2.3  Interpretation of the TCR results 
T cell receptor usage was classified using arbitrary definitions of minor and major T cell 
expansions, using the ratio of Vβ TCR expression in infected cohorts divided by those found 
in healthy controls. Minor expansions were defined as those Vβ-expressing T cells with 
greater than two–fold but less than ten-fold higher than frequencies observed in healthy 
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controls. Major expansions were those that were ten-fold and higher than frequencies found in 
healthy controls. Thus, major expansions were considered those where Vβ TCR+ T cells had a 
ratio of ≥10.  Oligoclonal expansion of T cells, reflecting a restricted use of the T cell 
repertoire and polyclonal expansion of T cells, reflecting diverse Vβ TCR usage, were defined 
as multiple minor and major expansions respectively. Representative examples of polyclonal 
and oligoclonal expansions are shown on Figure 3.2. 
Table 3.1: List of Monoclonal antibodies used 
Tube APC PerCP PE FITC 
1 CD3 CD8 Vβ1 CD45RA*
2 CD3 CD8 Vβ2 CD45RA*
3 CD3 CD8 CD38 Vβ3.1 
4 CD3 CD8 CD38 Vβ5.1 
5 CD3 CD8 CD38 Vb5.2 
6 CD3 CD8 CD38 Vβ5.2/3 
7 CD3 CD8 CD38 Vβ6.7 
8 CD3 CD8 CD38 Vβ7 
9 CD3 CD8 CD38 Vβ8 
10 CD3 CD8 Vβ9 CD45RA*
11 CD3 CD8 CD38 Vβ11 
12 CD3 CD8 CD38 Vβ 12.1 
13 CD3 CD8 CD38 Vβ13.1/3 
14 CD3 CD8 CD38 Vβ13.6 
15 CD3 CD8 CD38 Vβ14 
16 CD3 CD8 CD38 Vβ16 
17 CD3 CD8 CD38 Vβ17 
18 CD3 CD8 Vβ18 CD45RA*
19 CD3 CD8 CD38 Vβ20 
20 CD3 CD8 CD38 Vβ21.3 
21 CD3 CD8 CD38 Vβ22 
22 CD3 CD8 Vβ23 CD45RA*
 
*CD45RA  was used in some four colour staining due to lack of availability of the relevant antibody 
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Figure 3.1: The gating strategy for Vbeta analysis by flow cytometry. Events (50,000) were acquired on the flow 
cytometer and the frequency of activated CD3+CD8-(CD4) and CD3+CD8+ T cells expressing Vbeta TCR were 
measured as illustrated, using a sequential gating strategy (R1+R2) as shown in this figure.        
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Figure 3.2: Representative examples of oligoclonal (major) and polyclonal (minor) expansions of activated 
CD8+ T cells for two HIV/TB co-infected individuals. (A) Major expansion of CD8+ T cells expressing Vβ23 
(shown by red circles) (B) polyclonal minor expansions of cells expressing Vβ5.2, Vβ7, Vβ22 and Vβ23 (shown 
by red circles).  
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3.3 RESULTS 
3.3.1     T cell receptor usage in HIV/TB dual infected individuals 
It has been demonstrated in previous chapters of this dissertation that CD8+ T cells are 
persistently activated during HIV-1 and TB co-infection, and predominantly due to HIV. In 
this chapter, the fine specific nature of T cell activation was investigated by examining TCR 
Vβ expansions in HIV and TB single and co-infected individuals. It was hypothesized that 
different Vβ TCR families are expanded in single and dually infected patients. The total T 
cells expressing 22 Vβ −ΤCR from 27 HIV/TB co-infected individuals were measured by flow 
cytometry as described in section 3.2.2. The ratio of Vβ expressing cells in HIV/TB dual 
infected patients versus healthy controls was calculated as described in section 3.2.3, and the 
results are shown in Tables 3.2 and 3.3 for CD4+ and CD8+ T cell subsets, respectively. The 
data shows for activated CD4+ T cells that there was polyclonal skewing (minor expansions) 
of activated CD4+ T cells in 14 of the 27 co-infected patients (52%), where there was major 
expansion of Vβ16 TCR using cells in two patients as shown on Figure 3.3. For CD8+ T cells, 
there was polyclonal skewing (minor expansions) of activated CD8+ T cells (Table 3.3) in 22 
of the 27 individuals analysed (82%), with oligoclonal expansions of Vβ11 and Vβ20 
observed in three individuals (Figure 3.4). Using Fisher’s Exact test, there was a significant 
difference (p=0.0418) in the frequency of polyclonal skewing, with a greater number of TCR 
being used by CD8+ than CD4+ T cells in dually infected individuals. In summary, multiple T 
cell receptors were used by CD8+ T cells rather than CD4+ T cells in individuals co-infected 
with HIV-1 and TB. 
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Table 3.2: Ratios of frequencies of Vβ-expressing CD4+ T cells  
 
TCR IM1 IM5 IM6 IM9 IM11 IM13 IM14 IM15 IM16 IM19 IM21 IM29 IM30 IM33 IM34 IM36 IM42 IM47 IM51 IM56 IM58 IM60 IM61 IM62 IM63 IM65 IM66
Vb3.1 1.3 0.3 1.1 0.4 0.9 0.3 2.3 1.4 2.0 0.8 2.4 0.2 0.4 0.3 0.2 0.3 0.5 0.2 0.5 1.5 0.4 0.1 0.2 0.7 0.6 0.2 1.2
Vb5.1 2.2 0.8 2.3 0.8 1.2 0.9 0.9 1.7 2.5 0.5 5.5 1.9 0.6 0.7 0.6 0.7 1.3 0.5 0.7 0.9 0.5 0.9 1.2 1.0 0.9 0.3 0.1
Vb5.2 0.0 2.0 1.0 1.1 1.0 1.9 2.6 2.1 1.6 0.8 1.9 0.8 0.5 1.0 0.0 0.4 1.0 0.7 0.5 0.5 0.7 1.1 0.7 0.7 0.3 0.0 7.2
Vb5.2/3 2.0 1.3 0.5 0.8 1.1 1.1 1.1 5.0 2.7 2.4 1.2 0.7 0.6 1.1 0.1 0.8 1.1 2.7 0.5 0.7 0.6 1.3 0.5 0.5 0.7 0.5 0.6
Vb7 2.7 1.0 0.5 0.9 1.2 1.1 0.6 0.7 0.7 0.9 0.8 0.5 0.6 0.6 0.0 0.9 0.3 0.6 0.3 0.7 0.8 0.8 1.0 0.6 0.9 0.4 1.0
Vb8 0.6 0.8 0.8 0.5 0.6 0.9 0.7 3.7 0.2 1.2 0.2 0.4 0.3 0.9 1.2 0.4 0.5 0.4 0.2 0.7 0.8 0.9 0.5 0.3 0.3 0.5 0.3
Vb11 2.0 1.2 1.0 0.4 0.2 1.1 0.3 1.5 1.4 0.4 3.5 0.2 0.0 0.3 0.0 0.9 0.4 0.3 0.4 0.3 0.4 0.7 0.1 0.7 0.3 0.0 0.5
Vb12.1 2.5 2.5 2.0 1.4 0.4 0.9 0.5 1.4 4.0 4.7 0.8 1.8 2.4 1.2 2.9 0.8 0.0 0.6 0.8 1.0 3.4 3.5 0.7 1.4 0.4 1.9 0.9
Vb13.1/3 0.9 1.1 1.2 0.7 0.7 1.0 0.4 1.0 1.1 1.4 0.8 0.3 0.2 0.7 0.0 0.7 0.8 0.8 0.9 0.8 0.9 1.1 0.6 1.1 0.8 0.2 0.2
Vb13.6 2.1 0.8 1.6 1.4 0.7 1.0 0.4 1.5 1.4 1.0 1.4 0.4 0.4 0.8 0.0 0.8 1.3 0.4 1.3 0.8 1.0 1.0 0.4 1.0 0.5 0.4 0.6
Vb14 1.2 0.8 1.2 1.3 0.1 0.9 0.1 0.8 0.9 0.5 1.9 0.6 0.0 0.2 3.4 0.4 0.3 0.1 0.5 0.6 0.0 0.4 0.5 1.4 0.0 0.5 0.5
Vb16 3.7 2.2 1.5 1.0 0.5 1.9 0.8 2.4 27.8 1.1 26.5 0.5 0.2 1.5 0.5 1.3 2.0 0.8 1.3 0.5 0.2 1.6 0.8 0.7 0.8 0.5 7.6
Vb17 1.4 0.8 0.3 0.8 0.7 0.8 0.4 1.2 0.9 0.4 2.4 0.4 0.2 0.8 0.5 0.7 0.9 0.5 1.0 0.9 0.5 1.0 0.8 0.8 0.6 0.6 0.1
Vb20 2.4 0.8 1.4 1.6 1.3 1.2 0.8 1.7 2.1 0.7 3.0 1.7 0.2 0.9 1.3 0.6 1.2 0.5 1.1 1.3 0.5 1.6 1.9 2.0 0.6 0.6 1.1
Vb21 2.6 0.7 0.9 1.4 0.8 0.9 0.7 1.6 2.3 1.0 2.3 2.5 0.4 0.9 0.0 1.1 1.1 0.4 0.5 0.7 0.6 1.1 0.6 0.9 0.8 0.4 0.0
Vb22 2.2 0.9 1.0 1.1 1.5 1.2 0.7 2.0 2.2 0.9 2.3 0.7 0.1 0.9 0.4 1.0 1.1 0.4 1.1 1.1 1.0 1.3 0.8 1.2 1.2 0.2 1.3  
TCR usage as shown by ratios of Vβ-expressing CD4+ T cell populations between HIV/TB co-infected individuals and healthy controls. The blue shaded 
squares are minor expansions and the yellow shaded ones are major expansions       
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Table 3.3: Ratios of frequencies of Vβ-expressing CD8+ T cells.  
TCR IM1 IM5 IM6 IM9 IM11 IM13 IM14 IM15 IM16 IM19 IM21 IM29 IM30 IM33 IM34 IM36 IM42 IM47 IM51 IM56 IM58 IM60 IM61 IM62 IM63 IM65 IM66
Vβ3.1 0.6 0.4 1.5 0.3 1.0 0.3 1.6 2.0 3.3 1.0 3.5 0.3 0.4 1.9 0.2 0.2 0.7 0.4 1.1 1.1 3.5 0.1 0.1 0.8 4.0 0.5 0.9
Vβ5.1 2.4 3.8 3.7 2.0 0.9 2.7 1.8 3.6 1.8 0.6 0.9 0.7 1.7 1.0 2.3 1.7 0.4 2.3 1.2 2.3 1.3 0.5 1.0 1.3 0.9 1.1 0.7
Vβ5.2 0.0 1.5 0.4 0.3 2.7 4.7 4.3 1.0 1.1 0.2 1.7 0.6 0.2 1.1 0.6 1.2 0.4 4.3 2.6 0.6 2.8 0.3 3.0 2.4 0.8 0.2 3.3
Vβ5.2/3 3.2 2.8 3.9 1.8 1.5 3.3 1.0 3.8 1.8 0.8 1.2 1.1 0.4 0.8 1.2 1.5 0.4 2.9 3.0 0.9 4.6 2.5 1.7 1.9 0.7 1.4 1.0
Vβ7 2.8 2.1 0.7 4.8 2.5 1.5 1.5 2.4 0.5 1.4 1.4 3.0 0.4 0.7 2.8 1.2 0.0 1.5 1.0 1.5 2.8 2.8 3.1 1.1 1.1 0.5 1.8
Vβ8 1.2 0.7 1.8 0.8 0.5 0.8 0.8 2.2 0.1 1.2 3.1 1.0 0.2 1.5 1.2 7.7 0.2 0.9 1.3 0.9 0.5 2.2 1.1 1.5 1.2 1.9 0.0
Vβ11 22.7 0.4 19.4 0.3 0.4 0.9 0.8 0.3 0.8 0.5 3.8 0.2 0.0 0.7 1.2 0.4 0.1 15.0 0.5 0.2 0.5 0.5 0.7 0.6 1.9 0.2 1.5
Vβ12.1 1.3 1.4 0.6 0.3 0.4 0.1 0.3 0.3 0.2 0.1 0.2 0.6 1.1 0.1 0.1 0.2 0.2 0.2 1.4 0.1 0.1 3.0 0.3 0.7 0.2 2.0 1.1
Vβ13.1/3 1.5 0.8 1.9 0.7 0.4 1.3 0.4 1.1 0.6 2.7 0.5 0.1 0.2 1.1 2.2 0.3 0.0 0.4 0.8 1.1 0.7 2.1 1.9 1.1 0.5 0.3 0.5
Vβ13.6 0.5 0.1 1.2 0.7 0.2 0.7 0.4 1.2 0.3 2.2 0.3 0.4 0.2 0.5 0.7 0.2 0.1 0.3 0.3 0.4 1.1 0.3 1.5 0.3 0.2 0.3 0.4
Vβ14 0.2 0.3 1.1 1.2 0.2 1.1 0.1 0.3 0.4 0.2 0.6 0.4 0.0 0.2 2.1 1.0 0.3 0.0 0.1 0.2 0.2 0.2 1.4 1.2 0.1 0.2 0.2
Vβ16 1.9 0.2 0.2 0.9 0.1 0.3 0.2 0.5 1.1 3.2 0.1 0.1 0.0 0.2 0.3 0.4 3.4 0.3 0.1 0.2 1.0 0.4 0.9 0.1 0.1 0.1 0.8
Vβ17 2.2 0.6 2.1 0.6 0.4 1.1 1.0 0.8 0.4 0.4 1.4 0.3 0.3 1.8 2.2 0.6 1.6 1.4 0.7 2.6 0.5 0.9 0.9 3.4 0.6 0.4 0.1
Vβ20 13.2 1.2 2.3 1.2 1.0 3.2 1.0 0.4 1.6 0.4 1.9 1.8 0.3 0.6 3.1 0.8 0.3 1.6 0.8 1.8 0.2 0.3 2.8 0.9 0.4 0.5 1.4
Vβ21 3.1 0.4 1.0 1.3 1.8 3.3 2.4 5.4 1.1 0.8 1.6 2.3 0.4 2.5 3.5 0.9 0.5 1.3 0.4 4.4 0.7 4.4 1.5 3.3 0.6 0.9 0.0
Vβ22 0.8 1.9 4.0 0.9 1.3 2.5 0.9 3.2 3.8 0.7 3.1 0.6 0.1 1.3 1.2 3.7 0.6 1.4 1.0 1.6 1.2 1.1 2.5 0.4 0.8 0.2 1.8
 
TCR usage as shown by ratios of Vβ-expressing CD8+ T cell populations between HIV/TB co-infected individuals and healthy controls. The blue shaded 
squares are minor expansions and the yellow shaded ones are major expansions. 
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Figure 3.3:  TCR usage of CD4+ T cells in 27 HIV/TB dually infected individuals. Major oligoclonal 
expansion of CD4+ T cells expressing Vβ16 in two HIV/TB infected individuals (IM16 and M21) is observed, 
as well as minor expansions in fourteen individuals. The horizontal blue line at the ratio of 2 indicates the cutoff 
for minor expansions and the red line at 10.0 indicates the cutoff for major expansions.   
  
 
 
 
 
 
 
 
 
Figure 3.4: TCR usage of CD8+ T cells in 27 HIV/TB dually infected individuals. Major oligoclonal expansion 
of CD8+ T cells expressing Vβ11and Vβ20 in three HIV/TB infected individuals (IM1, IM6 and IM47), as well 
as minor expansions in twenty-two individuals. The horizontal blue line at the ratio of 2 indicates the cutoff for 
minor expansions and the red line at 10.0 indicates the cutoff for major expansions.  
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3.3.2     T cell receptor usage in HIV-1 single infected individuals 
Minor expansions of activated CD4+ T cells were observed in sixteen of the 26 
individuals (62%), as shown in Table 3.4. None of the patients showed oligoclonal 
expansion of activated CD4+ T cells (Figure 3.5). As shown in Table 3.5, minor 
expansions of activated CD8+ T cells were observed in 20 of the 26 individuals (77%). 
There was oligoclonal skewing of CD8+ T cells expressing Vβ11 and Vβ22 in 3 patients 
(Figure 3.6). In summary, as observed in HIV/TB infected individuals, usage of multiple 
TCRs (polyclonal skewing) by CD8+ T cells rather than CD4+ T cells was observed in 
HIV-single infection, although this was not significant (p=0.37).        
 
 
 
 
 
 
 
 
 
Figure 3.5: TCR usage of CD4+ T cells in 26 HIV-1 singly infected individuals. Expansions of CD4+ T 
cells-expressing Vβ3.1, Vβ5.1, Vβ5.2, Vβ5.2/3, Vβ8, Vβ11, Vβ12.1, Vβ14, Vβ14, Vβ21 and Vβ22 were 
observed in sixteen individuals. The horizontal blue line at the ratio of 2 indicates the cutoff for minor 
expansions and the red line at 10.0 indicates the cutoff for major expansions. The horizontal line at the ratio 
of 2.0 indicates the cutoff for minor expansions.  
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Table 3.4: Ratios of frequencies of Vβ-expressing CD4+ T cells.  
TCR 67 68 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93
Vb3.1 0.1 1.4 2.5 2.0 0.4 0.1 0.7 0.1 0.3 0.0 0.1 0.1 0.4 1.3 0.4 0.1 0.3 0.2 0.8 0.1 0.2 0.4 1.0 1.1 0.9 0.2
Vb5.1 0.6 0.5 0.5 0.9 0.6 0.4 0.8 0.4 0.7 0.5 0.3 0.4 0.9 0.6 0.7 0.6 1.2 0.8 1.0 1.4 0.6 1.1 1.2 0.0 0.9 3.2
Vb5.2 0.6 1.5 0.5 0.9 0.4 1.1 0.0 0.2 8.1 0.9 0.3 1.0 1.3 2.3 0.5 0.5 1.3 0.7 2.4 1.6 0.6 2.0 2.3 9.4 1.6 3.2
Vb5.2/3 0.4 0.7 0.4 0.9 0.6 0.6 3.3 2.0 0.7 0.9 0.3 1.3 0.6 0.7 0.7 0.5 0.9 0.4 1.5 2.5 2.0 1.5 0.9 4.4 1.0 1.4
Vb7 0.5 0.8 0.2 1.1 0.9 0.7 0.3 0.3 1.8 0.4 0.3 0.6 1.3 0.4 0.3 0.4 1.6 0.8 1.3 2.7 0.1 1.4 1.1 1.7 1.7 1.5
Vb8 0.5 0.4 0.4 0.8 0.4 0.4 1.2 0.4 0.7 0.4 0.4 0.2 1.2 0.8 1.0 0.9 1.1 0.7 1.2 0.8 0.4 1.2 1.0 2.6 2.7 0.7
Vb11 0.8 0.5 0.4 0.7 0.8 0.5 0.6 0.3 0.2 0.5 0.3 0.0 1.7 1.0 0.3 2.0 0.9 0.5 1.5 3.2 0.7 2.1 0.8 3.1 1.0 5.5
Vb12.1 0.6 1.0 0.9 1.3 1.2 0.8 1.4 0.4 2.9 1.0 0.5 0.6 1.1 0.8 0.7 0.3 0.9 0.7 1.4 3.9 0.3 1.4 0.6 1.8 0.5 0.6
Vb13.1/3 0.3 0.3 0.3 0.5 0.4 0.3 0.3 0.3 0.9 0.3 0.4 0.3 0.5 0.4 0.4 0.5 0.8 0.6 0.6 1.1 0.8 0.7 0.5 1.3 0.4 0.3
Vb13.6 0.5 0.7 0.7 1.0 0.8 0.7 0.8 0.5 0.8 0.4 0.4 0.7 0.6 0.3 0.4 0.7 0.8 0.8 1.7 2.5 0.7 1.8 0.7 1.7 0.8 2.1
Vb14 2.2 0.4 0.4 0.4 0.9 0.4 0.4 0.2 0.3 0.1 0.3 0.3 1.7 1.2 1.3 0.6 0.7 0.5 2.7 2.1 0.9 1.3 6.9 1.8 1.7 2.7
Vb16 4.2 0.5 0.7 2.0 0.6 0.8 0.7 0.6 0.8 0.7 0.8 0.0 0.2 1.5 0.7 1.1 1.1 1.3 5.9 5.7 2.3 2.7 2.2 3.2 4.5 6.9
Vb17 0.4 0.6 1.4 0.9 0.0 0.7 0.7 0.3 0.7 0.5 0.7 0.7 0.7 0.6 0.8 0.8 0.8 0.1 1.1 1.2 0.4 1.0 1.8 1.0 0.6 1.1
Vb20 0.6 1.1 0.5 1.5 1.0 0.6 1.1 0.6 0.9 0.1 0.5 0.7 1.0 0.8 0.7 1.0 0.8 0.5 2.7 2.2 1.2 2.6 1.5 1.7 0.6 1.5
Vb21 0.8 0.9 0.3 0.5 0.6 0.7 0.9 0.6 0.6 0.4 0.9 0.4 2.2 0.5 0.3 0.7 0.7 0.6 2.2 2.4 0.8 1.5 1.4 2.1 0.9 2.0
Vb22 0.8 1.1 0.6 1.1 1.1 0.5 0.6 0.7 1.6 0.4 0.6 0.7 1.5 0.6 1.1 0.8 1.8 1.5 1.7 3.2 0.8 1.5 4.0 3.0 1.4 1.8  
 
TCR usage as shown by ratios of Vβ-expressing CD4+ T cell populations between 26 HIV infected individuals and healthy controls. The blue shaded 
squares are minor expansions.  
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Table 3.5: Ratios of frequencies of Vβ-expressing CD8+ T cells.  
TCR IM67 IM68 IM70 IM71 IM72 IM73 IM74 IM75 IM76 IM77 IM78 IM79 IM80 IM81 IM82 IM83 IM84 IM85 IM86 IM87 IM88 IM89 IM90 IM91 IM92 IM93
Vb3.1 0.0 1.5 0.8 1.1 0.3 0.0 1.3 0.0 0.3 0.1 0.0 0.2 0.2 1.2 0.2 0.0 0.2 0.0 0.3 0.0 0.2 0.2 1.6 0.6 1.1 0.1
Vb5.1 1.7 2.0 0.7 1.1 1.2 0.5 3.5 1.5 0.6 2.6 1.3 3.7 1.6 1.2 1.4 1.4 1.8 1.1 0.6 2.0 0.6 1.2 2.3 3.5 1.6 2.1
Vb5.2 0.3 1.2 0.7 0.5 0.6 0.1 1.7 1.9 1.1 0.4 0.8 0.4 1.0 3.3 0.1 0.4 0.3 1.4 4.3 0.6 0.4 0.9 7.4 0.4 1.0
Vb5.2/3 0.8 0.8 5.5 1.1 1.1 0.4 1.8 1.0 1.8 1.9 1.2 2.2 2.0 1.0 1.4 0.7 2.1 1.4 0.5 1.3 1.6 1.0 1.1 3.0 1.1 2.5
Vb7 1.5 1.3 0.1 1.1 4.3 0.6 0.4 0.6 9.2 1.0 0.2 1.3 1.9 0.5 1.4 1.5 1.2 0.9 2.2 2.2 0.0 0.9 1.2 6.6 0.9 6.4
Vb8 0.7 0.8 0.5 0.5 3.8 0.1 0.9 1.0 1.0 0.7 0.2 0.3 0.9 0.7 0.7 0.2 0.3 0.1 0.2 0.6 0.3 0.6 1.3 1.2 1.4 1.7
Vb11 1.3 0.7 0.3 0.3 0.4 0.3 1.1 0.2 0.2 0.6 0.1 0.1 1.2 1.6 0.6 3.4 2.4 1.7 0.7 3.3 0.7 2.1 11.7 2.1 0.6 2.2
Vb12.1 0.4 0.3 0.6 0.8 0.6 0.2 0.8 0.1 0.9 4.3 0.0 0.1 0.1 0.3 0.3 0.0 0.1 0.1 0.1 0.7 0.0 0.3 0.4 0.4 0.2 0.1
Vb13.1/3 0.4 0.3 0.1 0.2 0.4 0.1 0.0 0.1 0.8 0.1 0.2 0.7 0.3 0.4 0.3 0.4 0.8 0.3 0.1 0.8 0.1 0.4 0.2 0.3 0.2 0.1
Vb13.6 0.4 1.0 0.1 0.3 1.1 0.1 0.7 0.1 1.0 0.1 0.1 1.8 0.8 0.6 0.3 0.3 0.4 0.9 0.7 2.2 0.4 0.6 0.5 0.4 0.4 0.4
Vb14 0.7 0.3 4.3 0.1 0.1 0.0 0.6 0.1 0.2 0.2 0.1 0.1 1.9 3.5 1.5 0.2 0.3 0.8 1.0 1.6 1.7 1.1 8.1 2.0 0.8 1.7
Vb16 0.1 0.2 0.3 0.1 0.2 0.3 2.1 0.2 0.5 0.3 0.3 2.2 0.7 0.3 0.2 0.1 0.1 0.4 0.1 0.9 0.7 0.4 0.2 1.3 0.7 0.3
Vb17 1.2 0.8 1.3 0.5 0.0 0.1 3.5 0.9 0.9 0.8 0.2 1.4 0.8 1.4 1.5 0.2 0.5 0.9 1.8 0.8 0.5 0.6 1.6 0.9 0.9 1.4
Vb20 3.6 1.0 1.0 1.4 0.5 0.4 3.9 1.3 0.4 0.2 0.4 0.1 1.6 1.0 0.9 0.6 1.3 1.0 0.4 1.3 0.7 1.2 5.6 1.1 0.7 1.2
Vb21 1.3 1.0 0.6 0.4 1.6 1.0 1.8 0.5 0.3 0.7 2.0 1.0 1.2 1.7 1.1 0.8 0.9 2.2 0.5 1.5 0.7 1.1 3.0 2.1 0.6 1.4
Vb22 1.8 0.6 0.6 0.9 0.7 0.1 0.5 0.3 2.5 1.0 1.4 0.7 2.8 1.6 2.2 0.5 2.5 3.1 1.0 7.9 1.8 10.1 2.7 2.8 1.5 16.5  
TCR usage as shown by ratios of Vβ-expressing CD8+ T cell populations between 26 HIV infected individuals and healthy controls. The blue shaded squares 
are minor expansions and the yellow shaded ones are major expansions. 
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Figure 3.6: TCR usage of CD8+ T cells in 26 HIV-1 singly infected individuals. Major expansions of 
CD4+ T cells expressing Vβ11 and Vβ22 in two HIV/TB infected individuals (IM90 and IM91) were 
observed, as well as minor expansions in fourteen individuals. The horizontal blue line at the ratio of 2 
indicates the cutoff for minor expansions and the red line at 10.0 indicates the cutoff for major expansions.   
 
3.3.3     T cell receptor usage in TB singly infected individuals 
Minor expansions of Vβ3.1, Vβ5.2, Vβ7, Vβ11, Vβ13.1/3 and Vβ22-expressing CD4+ T 
cells were observed in 6 of the 16 TB infected individuals (Table 3.6 and Figure 3.7). As 
shown in Table 3.7, minor expansions of Vβ3.1, Vβ5.1, Vβ5.2, Vβ5.2/3, Vβ7, Vβ8, 
Vβ11, Vβ13.1/3, Vβ16, Vβ17, Vβ20, Vβ21 and Vβ22 were observed in activated CD8+ 
T cells in 15 of the 16 individuals (94%), with no oligoclonal expansions (Figure 3.8). 
The frequencies of individuals showing polyclonal skewing in the CD8+ T cell 
compartment was significantly (p=0.0021) different from skewing found in the CD4+ T 
cell population. 
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Table 3.6: Ratios of frequencies of Vβ-expressing CD4+ T cells.  
TCR IM3 IM4 IM7 IM10 IM12 IM22 IM23 IM26 IM32 IM35 IM40 IM41 IM45 IM46 IM57 IM59
Vb3.1 0.2 0.1 0.2 0.2 0.7 0.4 0.7 2.5 0.3 0.3 0.4 0.1 0.3 0.2 0.7 0.1
Vb5.1 0.5 0.8 0.6 0.9 0.8 0.7 0.6 0.5 1.0 1.0 0.9 0.9 0.7 0.7 0.6 0.6
Vb5.2 0.0 0.4 0.6 1.8 0.7 0.8 4.9 1.4 0.4 0.3 0.6 0.4 0.4 0.5 0.6 0.6
Vb5.2/3 0.3 0.5 0.2 1.3 0.8 0.9 1.2 1.7 0.2 0.5 0.6 0.6 0.4 0.5 0.7 0.5
Vb7 0.5 1.1 0.5 1.4 0.8 0.6 0.4 2.3 0.4 0.3 0.6 1.2 0.8 0.3 0.5 0.2
Vb8 0.2 0.2 0.3 0.7 0.8 0.7 0.8 0.7 0.6 0.2 0.3 0.2 0.3 0.4 0.9 0.4
Vb11 0.4 0.5 0.4 0.7 0.9 0.3 0.3 0.2 0.5 0.3 0.6 0.4 0.3 2.1 0.5 0.6
Vb12.1 0.5 1.2 0.7 0.6 1.1 0.5 1.7 0.8 0.4 0.7 0.8 0.8 1.0 1.6 0.5 0.6
Vb13.1/3 0.5 1.2 0.6 0.8 0.9 3.3 1.1 0.8 0.6 0.5 0.7 1.0 0.8 0.7 0.4 3.8
Vb13.6 0.6 1.0 0.5 0.6 0.6 0.5 0.8 1.0 0.7 0.7 0.9 0.9 0.8 0.7 0.6 0.5
Vb14 0.4 0.3 0.2 0.4 0.9 0.4 0.4 0.5 0.6 0.3 0.3 0.3 0.3 0.3 0.4 0.4
Vb16 0.8 0.6 0.5 1.3 0.7 0.9 0.8 0.9 1.3 1.0 0.9 1.0 0.9 0.6 0.8 0.9
Vb17 0.6 0.8 0.4 1.0 0.8 0.6 0.7 1.1 0.9 0.5 0.6 0.8 0.9 0.7 0.7 0.6
Vb20 0.5 1.1 0.5 1.3 1.0 0.7 1.3 0.1 0.6 0.3 0.8 0.9 1.3 0.5 0.7 0.7
Vb21 0.7 1.1 0.6 0.8 0.9 0.6 1.0 1.5 0.7 0.5 1.8 0.7 0.7 0.8 0.7 0.4
Vb22 1.2 2.4 1.1 1.1 1.1 1.1 1.2 1.3 0.8 1.4 1.4 1.5 1.5 1.1 0.7 0.6  
TCR usage as shown by ratios of Vβ-expressing CD8+ T cell populations between 16 TB infected 
individuals and healthy controls. The blue shaded squares are minor expansions. 
 
 
 
 
 
 
 
 
 
Figure 3.7: TCR usage of CD4+ T cells in 16 TB singly infected individuals. Expansions of CD4+ T cells-
expressing Vβ3.1, Vβ5.2, Vβ7, Vβ11, Vβ13.1/3 and Vβ22 were observed in sixteen individuals. The 
horizontal line at the ratio of 2 indicates the cutoff for minor expansions and the red line at 10.0 indicates 
the cutoff for major expansions.  
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Table 3.7: Ratios of frequencies of Vβ-expressing CD8+ T cells.  
TCR IM3 IM4 IM7 IM10 IM12 IM22 IM23 IM26 IM32 IM35 IM40 IM41 IM45 IM46 IM57 IM59
Vb3.1 0.6 0.3 2.0 0.1 1.8 1.4 0.5 0.6 0.1 0.2 0.6 0.0 0.2 0.2 1.0 0.2
Vb5.1 1.6 1.8 1.2 0.4 1.4 0.4 0.3 2.0 0.8 0.7 2.0 1.1 0.6 0.9 0.9 2.3
Vb5.2 0.0 1.3 2.7 0.4 0.5 0.5 2.3 0.9 0.8 0.5 0.0 1.1 0.3 2.0 0.7 1.1
Vb5.2/3 1.0 0.9 1.8 3.2 0.4 1.7 0.4 0.7 2.1 1.3 1.0 0.8 1.6 0.6 2.5 0.8
Vb7 4.4 0.5 0.8 0.7 0.5 0.6 0.2 1.0 0.2 0.8 1.8 1.9 1.7 0.1 0.3 0.5
Vb8 1.2 2.6 1.9 0.4 0.9 0.3 0.6 0.7 0.5 0.7 1.4 0.9 1.1 1.0 0.9 1.2
Vb11 0.6 1.5 0.9 0.9 1.6 0.2 0.5 0.5 0.3 0.2 1.7 0.5 0.1 8.5 1.1 1.4
Vb12.1 0.2 0.3 0.2 0.2 0.1 0.7 0.2 1.4 0.2 0.0 1.8 0.0 0.0 0.0 0.2 0.4
Vb13.1/3 0.6 1.1 1.8 5.3 0.7 0.6 0.5 0.7 0.2 0.5 1.2 0.9 2.0 0.4 0.3 2.3
Vb13.6 0.4 0.5 0.6 0.1 0.3 0.1 0.1 0.4 0.1 0.7 0.9 0.3 0.2 0.2 0.2 0.3
Vb14 0.1 0.5 0.5 0.5 0.1 0.1 0.1 0.2 0.2 0.6 0.9 0.3 0.2 0.1 0.3 1.0
Vb16 0.2 0.2 0.2 0.2 0.3 0.3 0.1 0.2 3.2 2.0 0.3 0.7 1.9 0.2 0.3 0.2
Vb17 0.5 1.0 0.6 2.0 0.6 0.8 0.8 0.8 1.3 2.1 1.9 4.5 0.9 0.4 0.5 1.2
Vb20 0.5 2.7 7.5 0.5 1.2 0.4 1.4 0.6 0.7 1.6 1.5 0.9 1.1 0.6 0.9 0.9
Vb21 0.8 1.8 1.0 0.5 1.5 0.6 1.6 0.7 0.5 0.8 3.7 0.7 2.6 0.7 0.5 0.6
Vb22 1.1 3.8 1.7 0.6 2.2 0.5 1.6 1.3 0.4 2.7 1.9 0.9 0.5 1.3 0.6 0.9  
TCR usage as shown by ratios of Vβ-expressing CD8+ T cell populations between 16 TB infected 
individuals and healthy controls. The blue shaded squares are minor expansions.  
 
 
 
 
 
 
 
 
 
 
Figure 3.8: TCR usage of CD8+ T cells in 16 TB singly infected individuals. Minor expansions of CD8+ T 
cells-expressing Vb3.1, Vβ5.1, Vβ5.2, Vβ5.2/3, Vβ7, Vβ8, Vβ11, Vβ13.1/3, Vβ16, Vβ17, Vβ21 and Vβ22 
were observed in sixteen individuals. The horizontal line at the ratio of 2 indicates the cutoff for minor 
expansions and the line at 10.0 indicates the cutoff for major expansions.  
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3.4   DISCUSSION 
Viral and bacterial antigens evoke T cell immunity which results in activation, 
proliferation and expansion of T cells bearing specific TCR (Fujiwara et al., 2005; Jordan 
et al., 2006; Jassoy et al., 1993). Findings in this dissertation have demonstrated elevated 
absolute CD8+ T cell counts and enhanced activation of CD8+ T cells in HIV-1 and 
HIV/TB co-infected patients, which were associated with expansions of CD8+ T cells 
expressing various Vβ T cell receptors as seen in this chapter. It has also been shown that 
multiple TCR, as measured by polyclonal skewing, were significantly used by CD8+ T 
cells rather than CD4+ T cells in two groups: HIV/TB co-infected and HIV-1 single 
infected. No significant skewing in either CD4+ or CD8+ TCR usage was observed in TB 
single infection. These data would suggest that a) either CD8+ T cells play an active role 
in the immune response to HIV with or without TB co-infection or b) that expanded 
CD4+ T cells reside elsewhere rather than in the peripheral circulation. It has been 
previously reported in HIV infection that expanded circulating CD8+Vβ+ T cells 
mediates HIV-specific cytotoxicity (Pantaleo et al., 1994). 
 
Previous reports have determined the existence of skewing/perturbations of the T cell 
repertoire in HIV infected children and adults using flow cytometry (McFarland et al., 
2002;, Halapi et al., 1996; Piltch et al., 2000; Soudeyns et al., 2002; Dalgleish et al., 
2002), and considerable oligoclonality of CD8+ T cells have been shown to occur and 
that they persist frequently due to antigen stimulation by persistent viruses (Wilson et al., 
1998). In agreement with these findings, oligoclonal expansions of Vβ11, Vβ20, and 
Vβ22 were observed in HIV-1 infected individuals as well as in dual infection with HIV 
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and TB. Although a more quantitative approach to this analysis was applied, limited TCR 
usage observed in HIV-1 single infection in this study may indicate a more focused 
recognition of HIV-1 epitopes. A more refined analysis of limited TCR repertoire in 
HIV-1 infection has been shown (Kalams et al., 1994), where these authors observed that 
a high degree of HIV-1 specific CTL activity may be due to oligoclonal expansion of 
specific effector cells and that this limited TCR diversity against immunodominant 
epitopes may limit recognition of mutated viral variants in regions interacting with the 
TCR and therefore allow productive viral infection.    
 
Although there were significant minor expansions of various TCR usage on CD8+ T cells 
within groups, there was no evidence of a common pattern of TCR usage between 
individuals in the same cohort group in this study. This may not be surprising as multiple 
epitopes would be restricted by the various HLA types present in these cohorts, although 
these possibilities were not measured. However, oligoclonal expansion of Vβ11 TCR 
families was observed in 3 HIV/TB infected patients and Vβ22 TCR families in 2 HIV-1 
infected individuals..  
 
Analysis of the T cell repertoire has been performed extensively in HIV-1 infected 
individuals, but there is little data on the same type of analysis in patients singly or dually 
infected with TB. This dissertation has determined that CD8+ TCR Vβ+ T cell 
perturbations in the presence of single and dual infection with TB and HIV-1 are 
significantly more frequent than CD4+ TCR Vβ+ usage and that TB likely result in 
expanded peripheral blood circulating CD8+ T cell clones.
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CHAPTER 4 
THE T CELL RECEPTOR (TCR) REPERTOIRE IN 
HIV-1 UNINFECTED NEONATES BORN TO HIV-1 
INFECTED MOTHERS 
 
4.1 INTRODUCTION   
In the previous chapter this dissertation explored TCR usage by CD8+ T cells using flow 
cytometry in adults infected with HIV and TB. This chapter investigates the TCR 
repertoire in another cohort of HIV-1 exposed uninfected infants to assess TCR usage 
without infection. Paediatric HIV-1 infection is largely acquired via transmission from 
the HIV-1 infected mother and there is a high probability that infants born to HIV 
infected mothers have been exposed to HIV and antigens in-utero. This has been shown 
through several studies as indicated by immune activation (Kuhn et al., 2002; Clerici et 
al. 2000), HIV–positive PCR (Vazquez et al., 2006; De Andreis et al., 1996) and the 
presence of HIV-specific CD4+ and CD8+ T cell responses (Legrand et al., 2006; Kuhn 
et al., 2001).  
 
It has been reported that children, even during the first year of life, are able to mount 
functional immune responses as indicated by flow cytometry (ICS) and the IFN-γ 
ELISPOT assay (Feeney et al., 2005; Legrand et al., 2006; Kuhn et al., 2001). Previous 
studies have demonstrated transient TCRVβ –expansions of CD8+ T cells in HIV-1 
infected children and infants (Halapi et al., 1996; Silvestri et al., 1996) and at lower 
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levels in uninfected children born to HIV-1 infected mothers (Soudeyns et al., 2000). 
Apart from measuring the TCR using a repertoire of monoclonal antibodies, the 
repertoire can also be analyzed based on CDR3 length variations within Vβ gene 
families, a method referred to as the TCR immunoscope (Pannetier et al., 1995, Pilch et 
al., 2000). The immunoscope technique was used in this dissertation to a) assess the 
maturity of the TCR repertoire in newborn infants and b) show evidence of TCR 
engagement in-utero by analysing cord blood mononuclear cells (CBMC) isolated at birth 
from babies born to HIV-1 infected mothers. It was hypothesized that TCR repertoire 
skewing is a marker of T cell priming in-utero as a result of exposure to HIV-1-specific 
antigens from the mother.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Study cohort 
The cohort used in this dissertation was recruited from Coronation Women and 
Children’s Hospital in Johannesburg. Peripheral blood and cord blood samples were 
obtained from 20 HIV-1 infected mothers. The mother and cord/baby samples were 
analyzed as pairs. The mothers received a single dose of Nevirapine at birth. Twenty-five 
HIV-1 uninfected babies and 10 uninfected mothers were included in this cohort as 
negative controls. The HIV status of the mothers was determined by ELISA. For the 
babies, heel prick blood samples were deposited onto Whatman filter paper as dried 
blood spots and used for the detection of HIV-1 by polymerase chain reaction (PCR).  In 
order to establish existence of other common congenital infections, ELISA assays were 
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performed for detection of Syphilis, Toxoplasma, Rubella and Cytomegalovirus on both 
mothers and babies.  
4.2.2 Immunoscope experimental procedure 
RNA was extracted from cryopreserved cord blood mononuclear cells (CBMC) (see 
4.2.3). cDNA was synthesized (see 4.2.4) and amplified by PCR (see 4.2.5) using primers 
for each of the 23 Vβ families (list is shown in Appendix 3).  Amplification was enabled 
by labelling the 3’ end of the TCR gene with a Cβ (constant region) primer and the 5’ end 
was labelled with a specific Vβ primer (Inqaba Biotechnical Industries, Hatfield, South 
Africa). A schematic diagram of a TCR gene with three different regions is shown on 
Figure 1.8 (chapter 1), which is amplified and analysed to obtain fragments of various Vβ 
genes. The PCR products were processed in a run-off PCR reaction using a fluorochrome 
labelled (blue 6-FAM) primer, purified using DyeEx resin columns and acquired on the 
ABI sequencer. Fragment sizes and peak heights were then analysed using Applied 
Biosystems Genemapper software. Figure 4.1 shows the experimental design of the 
immunoscope procedure. 
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Figure 4.1: The immunoscope experimental design 
 
4.2.3  RNA extraction 
Cord and peripheral blood was collected in ACD-anticoagulated tubes and mononuclear 
cells were isolated using the standard Ficoll Hypaque method (AEC Amersham) and 
stored in liquid nitrogen. When required, cells were quick-thawed in a waterbath at 37oC 
and using a sterile 1ml pipette, the cells were transferred to a sterile 5ml snap-cap tube. 
An aliquot of 20µl of the cell suspension was removed and counted using trypan blue 
exclusion using the haemocytometer. The cells were then centrifuged at 1400 rpm for 10 
CBMC
RNA Extraction 
cDNA
PCR - 23 Vβ genes
PCR –runoff reaction with 6-FAM primer
Sequencing (fragment sizing)
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minutes. The supernatant was decanted and the cells were suspended in 1ml of Trizol 
(Invitrogen Life Technologies) lysis reagent which lysed the cells and enabled mRNA to 
be isolated. The RNA suspension was then transferred into 1.5 microfuge tubes. RNA 
was either extracted directly or Trizol suspensions were stored at –80oC for batch 
isolation. Chloroform isoamyl alcohol (200µl)(Sigma-Aldrich) was added to the RNA 
suspension, incubated for 15 minutes at room temperature after vigorous shaking for 10 
seconds and centrifuged at 12000 rpm for 15 minutes. Isopropanol (500µl) was added, 
followed by gentle vortexing and incubated for 10 minutes at room temperature. The 
tubes were centrifuged at 12000 rpm for 10 minutes in the cold room (4oC). Ethanol 
(1ml) was added and the tubes were centrifuged at 15000 rpm for 3 minutes. The RNA 
pellet was suspended in 20µl of sterile diethylpyrocarbonate (DEPC)-treated water and 
incubated at 56oC for 10 minutes. RNA (1µl) was diluted 1/100 in DEPC water and 
optical density (OD) readings were performed on a spectrophotometer (WPA Lightwave, 
Labotec) and the RNA concentrations were calculated to make a final concentration of 
1µg/µl using the following formula:  
 
RNA concentration = A260 x dilution (100) x 40 x volume  
 
The RNA was then stored at –80oC until ready to synthesize cDNA. The purity of RNA 
was visualized by loading a fraction of RNA on a 1% agarose gel, and examined for 
sharp 28S and 18S bands (Preparation of RNA gel is shown in Appendix 2). 
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4.2.4  cDNA synthesis     
RNA (10µl) at an optimal concentration of 1µg/µl was added to 0.6 ml microfuge tubes 
(Eppendorf) after thawing on ice. 10mM dNTP (2µl 10mM) (Roche Diagnostics, South 
Africa) and Oligo-dT (2µl) was added and incubated at 70oC for 10minutes and placed on 
ice for > 1 minute and centrifuged for 5-10 seconds. RT buffer (4µl) (Roche), RNAse 
inhibitor (1µl) and AMV-RT (1µl) were added and incubated for 1 hour at 42oC. The 
mixture was then placed on ice for > 1 minute and spun for 5-10 seconds. cDNA samples 
were subsequently stored at –20oC until they were used in the PCR. 
 
4.2.5 Polymerase Chain Reaction ( PCR) 
A set of primers (5µl, 2.5mM) corresponding to each Vβ family were added to each of 24 
tubes per sample. Details of the PCR mix used are given in Appendix 4 and 20µl was 
distributed, along with each primer, into each of the tubes plus a positive cell control 
(Jurkat cell line known to express VB8, supplied by Highveld Biological, South Africa) 
and a positive cDNA control (GAP-DH, Roche). The tubes were then placed on a 
thermocycler (GeneAmp PCR System 9700, Applied Biosystems) and the mixture was 
subjected to 40 cycles of denaturation for 25 seconds at 94oC, annealing for 45 seconds at 
60oC and elongation for 45 seconds at 72oC with a extended final elongation step of 5 
minutes at 72oC. Products were visualized on a 2% agarose gel (Sigma-Aldrich) in 10X 
TBE using Ethidium Bromide (Sigma-Aldrich) staining before using 2µl of the amplified 
product for a run-off reaction with the 6 Fam labeled HuβC2  primer. Preparations of 
10X TBE, agarose gel and gel loading buffer are shown on Appendix 5. The gel was then 
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run at 230 volts using the power pack and photographed on a UVP-White/UV 
transilluminator (Vacutec, South Africa). Figure 4.2 shows a photograph of a gel for 23 
Vβ products, including the Jurkat cell line as a positive control. Final DNA products 
appear as single white bands. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: DNA gel showing the molecular weight (MW) control marker, 23 Vβ genes and a Jurkat cell 
line as a positive control. cDNA for each of  the 23 Vβ T cell receptor genes was amplified and the PCR 
products were run on 2% agarose gel. The bands appearing on top are showing PCR products for Vβ1, 
Vβ2, Vβ3, Vβ4, Vβ5, Vβ6a,Vβ6B, Vβ7, Vβ8, Vβ9, Vβ10, Vβ11,Vβ12,Vβ13a,Vβ14,Vβ15,Vβ16 to Vβ17 
as shown by the arrow. The bottom row consists of PCR products for Vβ18, Vβ20, Vβ21, Vβ22, Vβ23 and 
the Jurkat cell line. 
MW marker
Vβ1 Vβ17
JurkatVβ18
MW marker
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4.2.6 Polymerase chain run-off reaction for immunoscope analysis  
A  PCR run-off reaction was performed using 24 PCR products. Reactions were prepared 
in 0.6µl microfuge tubes. The PCR mixture details are shown in Appendix 6. Each PCR 
product (2µl) and 8µl of PCR mixture were added into each tube and placed on the 
Applied Biosystems thermocycler and subjected to 94oC for 2 minutes, 5 cycles of 94 oC 
for 25 seconds; 60 oC for 45 seconds; 72 oC for 45 seconds and to a cycle of 72 oC for 3 
minutes, followed by holding at 4 oC. Samples were stored at 4oC until they were purified 
for fragment analysis. 
 
4.2.7    Purification of run-off PCR products 
Products were purified using Performa DTR 96 well standard plate resin columns 
(Southern Cross Biotechnology, SA). The resins are gel filtration plates consisting of 
0.8µl volume columns in a standardized array, packed with gel matrix optimized to 
effectively remove dye terminator dNTPs, salts and other low molecular weight materials 
from the sequencing reactions. Reactions were performed in 0.2µl microfuge tubes on 
strips (Roche Diagnostics). Product volumes were increased by addition of 10µl of sterile 
water to 20µl in each of the 24 Vβ product tubes. The top and bottom adhesive tapes 
from the Performa plates were removed. The plates were covered with a lid, stacked on 
top of an empty plate and centrifuged at 850xg for 3 minutes. The eluate was discarded 
and the complete volume of each product was transferred to the purification plate using a 
multichannel pipette. The plates were stacked on top of a sterile 96 well receiver plate 
and centrifuged at 850xg for 3 minutes. The eluates (products) in the receiving plates 
were retained for sequencing. The remaining product was stored at –20oC.  
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4.2.8   Preparation of product and sequencing acquisition 
Dye–Ex formamide (1ml) (Applied Biosystems) was mixed with 5µl of ROX 400 
Standard (Applied Biosytems). This mixture (5µl) and 5µl of purified product was added 
to the 96 well sequencer plate (Applied Biosystems). The mixture was heated up at 90oC 
for 2 minutes and allowed to cool on ice. The samples were acquired on a 3100 ABI 
Genetic analyzer (Applied Biosytems) using a 3100 Data Acquisition Software with the 
running module described on Appendix 7, using a 50cm array length and POP6. The 
instrument equipped with a laser provides the peak fluorescence intensity (height), peak 
size and peak area. The data was automatically stored in the relevant folder for analysis.   
 
4.2.9 Gene fragment analysis using Genemapper software  
Data was analyzed using Genemapper software (Applied Biosystems). Standard peaks 
appeared red and the sample peaks appeared blue as per fluorescent dye used. The sample 
peak sizes, lengths and areas were determined by comparison with the ROX 400 
standard. A representative snapshot of peaks and data table is shown on Figure 4.3. The 
expected highest peak size were determined by measurements of the size of the 
Vβ primer length to residue 95 of the gene (i.e. the beginning of the CDR3-which lies 
between residue 95 and 106), plus the Cβ2 constant gene distance to residue 106 (73), 
plus the CDR3 length of 30 nucleotides (10 amino acids). The highest peak was expected 
to be 10 amino acids (aa) in length and subsequent peaks to be 3aa apart with the CDR3 
length of 9aa and other peaks following in descending order of variable CDR-3 lengths 
indicated by various fragments. Figure 4.3 shows a representative example of the 
immunoscope graphs for Vβ2 with sample peaks (blue) measured against the standard 
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(red). The peak sizes, heights and areas are shown in the table below the graph and the 
size of the expected highest peak is 299. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: A representative  immunoscope analysis graph of Vβ2-TCR showing the peaks for the standard 
(red) and the peaks for the sample (blue). The table is showing the peak lengths, areas and sizes. Each peak 
represents a Vβ2-T cell clone with a specific CDR3 length. The highest peak has a CDR3 length of 10aa.   
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4.2.10 Interpretation of the immunoscope results 
To quantitate Vβ-CDR3 length variability, and hence a measure of TCR skewing, the 
following formulas were used for Polyclonal Gaussian (PG), Polyclonal Skewed (PS) 
and Oligoclonal Skewed (OS) distributions (representative examples): 
 
% PG = number of PG Vβ families x 100 
Total Vβ analyzed (23) 
 
and  
 
% PS = number of PS Vβ families x 100 
Total Vβ analyzed (23) 
 
and  
 
% OS = number of OS Vβ families x 100 
Total Vβ analyzed (23) 
 
“No skewing” of the T cell repertoire is measured as a Polyclonal Gaussian (PG) 
distribution, which is observed in naïve T cells prior to antigen engagement; a 
Polyclonal Skewed (PS) distribution which is observed after a T cell response resulting 
in multiple antigen-specific T cell clones; Oligoclonal Skewed (OS) distribution which is 
observed when there has been a clonal expansion of a T cell recognizing antigen using a 
specific TCR. Examples of these peak interpretations and CDR3 distributions are shown 
on Figure 4.4, where each of the PG, PS and OS are shown:   
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Figure 4.4: Immunoscope analysis showing polyclonal Gaussian (A), polyclonal skewed (B) and 
oligoclonal skewed (C) distribution observed in peripheral blood mononuclear cells.  
 
4.3     RESULTS 
To ensure that optimal peaks were detected, several optimization experiments were 
completed prior to applying the technique to the cohort samples. 
 
4.3.1 Optimization of the PCR run-off reaction 
In order to obtain optimal conditions for the run off-PCR reaction, various conditions and 
reagent titrations were performed. The Cβ2 primer in the PCR reaction mixture was used 
at three different volumes which were identified as Mix 1 (0.12µl), Mix 2 (0.24µl) and 
Mix 3 (0.48µl). Volumes of reagent used for different PCR reaction mixtures are shown 
on table 4.1. In addition to these, each PCR mixture was combined with 2µl (Condition 
1), 4µl (Condition 2) and 6µl (Condition 3) of the PCR product for amplification used at 
8µl, 6µl and 4µl consecutively. Conditions 1, 2 and 3 were applied as indicated in Figure 
4.5, where condition 1 consists of 2µl of PCR product combined with PCR mixture 1, 2 
A B C
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and 3; condition 2 consists of 4µl of PCR product combined with mix 1A, 2A and 3A and 
condition 3 consists of 6µl of PCR product mixed with PCR mixtures mix 1B, 2B and 
3B. Three representative Vβ-TCRs were analysed under these conditions and the graphs 
are shown on Figure 4.5 (Vβ1,Vβ3 and Vβ 5). Graphs A, B and C are showing data for 
various conditions and the immunoscope peak heights/signals from mix 1, mix 2 and mix 
3 were the highest, when 4µl of the PCR product was used (Condition1). The Cβ2 primer 
was finally used in all reaction mixtures at 0.12µl (MIX 1) and the final volume of PCR 
product used was 4µl (condition 2). 
 
Table 4.1: PCR reaction mixtures used for optimization of the PCR-run off reation 
Reagent Mix 1 Mix 2 Mix 3 
Buffer 1.1µl 1.1µl 1.1µl 
dNTPs 1.1µl 1.1µl 1.1µl 
MgCl2 1.32µl 1.32µl 1.32µl 
Cβ2 primer 0.12µl 0.24µl 0.48µl 
H2O 5.12µl 5.0µl 4.76µl 
Taq polymerase 0.04µl 0.04µl 0.04µl 
 
Volume of mix = 8.8µl  
 
 
 
 
 
Chapter 4 
 
99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Optimization results for titration of the 6-Fam labeled Cβ2 primer and different product 
volumes used in a PCR run-off reaction. The CB2 primer was titrated and used in three different 
concentrations in the PCR reaction mixtures. The Cβ2 primer in the PCR reaction mixture was used at three 
different volumes which were identified as Mix 1 (0.12µl), Mix 2 (0.24µl) and Mix 3 (0.48µl). In addition 
to these, each PCR mixture was combined with 2µl (Condition 1), 4µl (Condition 2) and 6µl (Condition 3) 
of the PCR product at 8µl, 6µl and 4µl of consecutively.  Condition 1 consists of 2µl of PCR product 
combined with PCR mixture 1, 2 and 3; condition 2 consists of 4µl of PCR product combined with mix 1A, 
2A and 3A and condition 3 consists of 6µl of PCR product mixed with PCR mixtures mix 1B, 2B and 3B. 
the final reaction mixture used in all PCR reaction mixtures is highlighted in ‘Red’. 
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 4.3.2      Vβ TCR usage in cord blood samples of neonates born to HIV-1 infected  
                  mothers– A measure of exposure to HIV-1 in-utero.     
Having optimized the method, the immunoscope technique was used to obtain a measure 
of the diversity of the T cell repertoire in a scenario of possible antigen exposure. The 
CDR3 length distributions were analyzed by assessing the proportions of polyclonal 
Gaussian (PG), polyclonal skewed (PS) and oligoclonal skewed (OS) profiles from the 20 
HIV-1 babies born to HIV-1 infected mothers; 25 healthy control babies; 12 HIV-1 
infected mothers, and 10 HIV healthy control mothers.  
 
A representative Vβ TCR distribution from a healthy control baby showed a polyclonal 
Gaussian distribution for each family (Figure 4.6). A further representative Vβ 
distribution from an HIV-1 exposed (HIV uninfected) baby showed evidence for a 
polyclonal skewed distribution of almost every Vβ family (Figure 4.7). Each panel 
represents the results of the amplified PCR products from individual TCR Vβ families 
(Vβ1- Vβ23) and the 24th panel represents the Vβ8 PCR–amplified product of the Jurkat 
cell line (cDNA control). Overall, the Vβ TCR distribution profile observed in healthy 
control babies were 46% polyclonal Gaussian and 54% polyclonal skewed, with zero 
oligoclonal skewing (see table in Appendix 8). The polyclonal skewing observed in 
healthy control babies may be expected due to in utero exposure of multiple antigens 
derived from the mother. However, these data may differ from what was reported 
previously in other studies, where no clonal dominance was observed in healthy cord 
blood (147) (Than et al., 1999).  Conversely to that found in the healthy controls, the 
TCR distribution measured in babies born to HIV infected mothers (and presumed 
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exposed in utero) showed 1% polyclonal Gaussian distribution, 72% polyclonal skewed 
and 27% oligoclonal skewed (see Appendix 9), as shown in Figure 4.8. The TCR 
repertoire of babies born to HIV-1 infected mothers was highly skewed as shown by a 
statistically higher proportion of oligoclonal skewing (p <0.05) and a lower proportions 
of polyclonal Gaussian (p<0.001) when compared to healthy control babies (Figure 4.8). 
There was no difference between the distribution of polyclonal skewed TCR between 
healthy and “exposed” babies and the high degree of oligoclonality in the latter group 
suggests engagement of the TCR and clonal expansion. It is tempting to suggest that this 
may be due to engagement with antigens derived from HIV in these babies. The 
oligoclonal expansion of T cells in babies born to HIV-1 infected mothers were mainly 
Vβ18, Vb23, Vβ5, Vβ6a, Vβ7, Vb 6b and Vβ23-families (Figure 4.9), which had five to 
seven out of of twenty babies showing  oligoclonal skewing of the repertoire. 
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Vβ1 Vβ2 Vβ3 Vβ4 
Vβ5 
Vβ8 
Vβ13A 
Vβ16 
Vβ21 
Vβ6A Vβ6B Vβ7 
Vβ9 Vβ11 Vβ12 
Vβ13B Vβ14 Vβ15 
Vβ17 Vβ18 Vβ20 
Vβ22 Vβ23 JURKAT/Vβ8 
 
Figure 4.6: Immunoscope profile of a normal control baby, appearing as 100% Gaussian distribution. Each 
TCR result is shown as a density histogram with the CDR3 sizes shown on the x-axis and the peak 
fluorescence intensity shown on the y-axis. 23 Vβ families were analysed, including the Jurkat cell line as a 
positive control. 
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Figure 4.7: Immunoscope profile of a baby born to an HIV-1 infected mother, appearing as polyclonal 
skewed and oligoclonal skewed (e.g. Vβ9, Vb13B, Vβ17, Vβ21) distributions.  Each TCR result is shown 
as a density histogram with CDR3 sizes shown on the x-axis and the peak fluorescence intensity shown on 
the y-axis. 23 Vβ families were analysed, including the Jurkat cell line as a positive control. 
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Figure 4.8: The T cell receptor profiles for 20 HIV-negative babies born to HIV-1 infected mothers 
(identified as E) compared with those of 25 healthy control babies (identified as H). Proportions of 
polyclonal Gaussian (PG), polyclonal skewed (PS) and oligoclonal skewed (OS) TCR are shown on the Y-
axis as percentage of skewing within the total repertoire. Statistical p values were obtained using Mann-
Whitney Rank Sum test. 
 
 
 
 
 
 
 
 
Figure 4.9: The frequency of oligoclonal skewing from 20 babies born to HIV-1-infected mothers. 
Proportions of babies with oligoclonal skewing of the repertoire are shown on top of the bars.    
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 In order to discount the possibilities that the TCR patterns observed from cord blood 
T cells isolated from babies born to HIV-1 infected mothers were due to 
contaminating T cells from the mother, the TCR patterns in 11 mothers paired with 
their babies were compared. The TCR profiles of HIV-1 infected mothers and paired 
babies are shown in Table 4.2, where it can be seen that oligoclonal skewing of T 
cells was higher in the mothers compared to their corresponding babies. Conversely, 
high polyclonal skewing was observed in babies, but not mothers. These data suggest 
that because the Vβ family profiles were different between mother and baby, it is 
unlikely that there was contamination of maternal cells in the baby cord blood T cell 
population.  
 
Table 4.2: The TCR profiles for 12 HIV uninfected babies born to HIV-1 infected 
mothers compared with their paired mothers    
Patient ID 
Oligoclonal Skewed  
(%) 
Polyclonal Skewed 
(%) 
Polyclonal Gaussian 
(%) 
M1 88 12 0 
B1 0 95 5 
M2 88 12 0 
B2 0 100 0 
M3 75 25 0 
B3 80 20 0 
M4 36 64 0 
B4 10 90 0 
M5 79 21 0 
B5 10 90 0 
M6 33 67 0 
B6 4 91 4 
M7 62 38 0 
B7 75 25 0 
M8 5 95 0 
B8 24 76 0 
M9 71 29 0 
B9 0 100 0 
M10 94 6 0 
B10 83 17 0 
M11 100 0 0 
B11 94 6 0 
M12 86 14 0 
B12 0 100 0 
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4.3.3 Vβ TCR usage at 3 months in babies born to HIV-1 infected mothers 
It was possible to perform a 3-month follow-up in four babies by obtaining a peripheral 
blood sample. Three babies (B1, B2 and B3) had 70-90% polyclonal skewed TCR 
distribution at birth, which was maintained at 3 months after birth (Figure 4.11). 
However, baby B4 had 94% oligoclonal distribution at birth, which was altered to a 
polyclonal skew distribution at 3 months. This would suggest that babies born with 
polyclonal populations of T cells remain polyclonal and that perhaps heavily perturbed 
oligoclonal populations become more diverse in potential recognition of antigens after 
birth. 
   
 
 
 
 
 
 
 
 
 
 
Figure 4.10: TCR profiles of four HIV-1-uninfected babies born to HIV-1 infected mothers, followed at 3 
months after birth. The babies are identified by lab numbers e.g. B1 cord blood (CB) and CTL B1-3 months 
The immunoscope assay was performed from cord blood and from peripheral blood mononuclear cells at 3 
months after birth (3mo). 
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4.4 ELISA results for other congenital infections – A measure of in-utero exposure 
to antigens 
In order to determine some of the source of TCR skewing observed in the babies and that 
skewing may have been due to exposure to other infections, besides HIV, ELISA assays 
were performed for antibodies to syphilis (RPR), toxoplasma (IgG and IgM), rubella 
(IgM) and cytomegalovirus (IgG and IgM) in plasma from 17 babies born to HIV-1 
positive mothers and their corresponding mothers, as well as in 19 healthy control babies 
and their mothers. Measurement of IgM was used to detect the presence of acute 
infection in both mothers and babies, whereas IgG was used for detection of existing 
immunity to previous infections in the mother, and the existence of IgG in cord blood 
was unlikely to be meaningful as this cannot be distinguished from maternal derived 
immunity. Acute infection in both baby and mother was thus confirmed by the detection 
of IgM in cord blood and maternal plasma respectively. Detection of IgM in the mother at 
birth would also result in the possibility that the baby may have been exposed to the 
pathogen in utero. 
 
Three babies born to HIV-1 infected mothers tested positive for syphilis. Seven babies 
tested positive for toxoplasma IgG and two babies were seropositive for rubella IgM. The 
two babies with evidence of the presence of rubella IgM showed more than 90% 
polyclonal skewing with no evidence of oligoclonal expansion (Table 4.3). Seven of the 
nine babies that showed evidence of oligoclonal-T cell expansion (B6, B7, B8, 4153B, 
B14, B4, B17) were not IgM seropositive for any of the pathogens tested. All babies, 
including healthy control babies and mothers were seropositive for CMV IgG (Table 4.4), 
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which coincided with polyclonal skewing of the T cell repertoire, suggesting that the 
babies may have been exposed to CMV antigens at a certain stage in utero. A prior study 
by Marchant showed that maternal CMV infection induced oligoclonal expansion of T 
cells in foetal life. It is tempting to suggest that maternal CMV and HIV-I infection was 
able to induce polyclonal and oligoclonalskewing of the TCR in HIV uninfected babies. 
 
Table 4.3: ELISA results and TCR profiles of HIV-uninfected babies born to HIV-1 -
infected mothers (B) and their paired mothers (M) 
ELISA TCR Profiles
SAMPLE ID Syphilis (RPR) TOXO(IgG) TOXO(Igm) RUBELLA(IgM) CMV(IgG) CMV(IgM) O PS PG
M2852 neg neg neg neg pos neg
B2852 neg neg neg pos pos neg 0 96 4
M4000 neg neg neg neg pos neg 88 12 0
B4000 neg neg neg neg pos neg 0 95 5
M4004 neg pos neg neg pos neg 75 5 0
B4004 neg pos neg neg pos neg 80 20 0
M4089 neg neg neg neg pos neg
B4089 neg neg neg neg pos neg 10 90 0
M4096 neg neg neg neg pos neg
B4096 neg neg neg neg pos neg 0 100 0
M4138 neg neg neg neg pos neg 79 21 0
B4138 neg neg neg neg pos neg 10 90 0
M4140 pos neg neg pos pos neg
B4140 pos neg neg pos pos neg 0 100 0
M4153 neg neg neg neg pos neg 33 67 0
B4153 neg neg neg neg pos neg 4 91 4
M4211 neg neg neg neg pos neg 30 70 0
B4211 neg pos neg neg pos neg
M4214 neg pos neg neg pos neg
B4214 neg pos neg neg pos neg 0 100 0
M4215 pos neg neg neg pos neg 5 95 0
B4215 pos pos neg neg pos neg 24 76 0
M4219 neg pos neg neg pos neg 71 29 0
B4219 neg pos neg neg pos neg 0 100 0
M4223 neg pos neg neg pos neg 94 6 0
B4223 neg pos neg neg pos neg 83 17 0
M4227 neg neg neg neg pos neg 100 0 0
B4227 neg neg neg neg pos neg 94 6 0
M4230 pos neg neg neg pos neg
B4230 pos neg neg neg pos neg 14 86 0
M4232 neg neg neg neg pos pos 86 14 0
B4232 neg neg neg neg pos neg 0 100 0
M4256 neg neg neg neg pos neg
B4256 neg pos neg neg pos neg 67 33 0  
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Table 4.4: ELISA results and TCR profiles of healthy negative control babies (B) and 
their paired mothers (M). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ELISA TCR Profiles
SAMPLE ID RPR TOXO(IgG) TOXO(Igm)RUBELLA(IgM) CMV(IgG) CMV(IgM) O PS PG
M20 neg neg neg neg pos neg
B20 neg neg neg neg pos neg 0 74 26
M21 neg neg neg neg pos neg 8 92 0
B21 neg neg neg neg pos neg 0 50 50
M22 neg neg neg neg pos neg
B22 neg neg neg neg pos neg 0 63 37
M23 neg neg neg neg pos neg
B23 neg neg neg neg pos neg 0 10 90
M24 neg neg neg neg pos neg 0 100 0
B24 neg neg neg neg pos neg
M25 neg pos neg neg pos neg
B25 neg pos neg neg pos neg 0 64 36
M26 neg neg neg neg pos neg
B26 neg neg neg neg pos neg 0 50 50
M27 neg neg neg neg pos neg 0 100 0
B27 neg neg neg pos pos neg 0 94 6
M28 neg neg neg neg pos neg 0 100 0
B28 neg neg neg neg pos neg 0 68 32
M29 neg neg neg neg pos neg 18 82 0
B29 neg neg neg neg pos neg 0 100 0
M30 neg neg neg neg pos neg
B30 neg neg neg neg pos neg 0 75 25
M31 neg neg neg neg pos neg
B31 neg neg neg neg pos neg 0 7 93
M32 neg neg neg neg pos neg
B32 neg neg neg neg pos neg 0 77 23
M33 neg neg neg neg pos neg
B33 neg neg neg neg pos pos 0 45 55
M34 neg neg neg neg pos neg
B34 neg neg neg neg pos neg 0 70 30
M35 neg neg neg neg pos neg
B35 neg neg neg neg pos neg 0 84 16
M36 neg neg neg neg pos neg
B36 neg neg neg neg pos neg 0 75 25
M37 neg pos neg neg pos neg 0 93 0
B37 neg pos neg neg pos neg
M38 neg neg neg neg pos neg
B38 neg neg neg neg pos neg 0 14 86
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4.5  DISCUSSION 
Distribution of the TCR repertoire in healthy cord blood has previously been shown to 
have a Gaussian distribution. (Than et al., 1999, Sarzotti et al., 2003), and the repertoire 
in normal cord samples were shown to be diverse, with consistent representation of all 23 
Vβ families with no evidence of clonal dominance. In this dissertation, an equal mix of 
Gaussian and Polyclonal skewed TCR families was shown in cord bloods from healthy 
babies born from HIV uninfected mothers. Polyclonal skewing was measured when there 
was a slight shift in TCR peak position and is sensitive to any form of TCR engagement 
with antigen. It is thus expected that healthy babies may have been exposed to an array of 
maternal antigens giving rise to polyclonal skewing. Converse to this, oligoclonal 
skewing was observed in cord blood TCR from HIV-1 uninfected babies born to HIV-1 
infected mothers, suggesting that clonal expansion may be linked to exposure to HIV-1 
antigens from the mother in-utero. This was further supported from the results looking at 
syphilis (RPR), toxoplasma, rubella and cytomegalovirus immunity in mother and baby 
pairs. 
 
Studies performed in HIV-1 infected children have demonstrated evidence of clonal 
dominance in HIV infected children (Than et al., 1999; McFarland et al., 2002). 
Although we identified TCR expansions in total CBMC, clonal expansions have been 
reported to be common in CD8+ T cells in HIV-1 infected individuals, as shown by 
others (Wedderburn et al., 2001), and also described in the TCR analysis of adults 
conducted elsewhere in this dissertation (Chapter 3). A limitation of this study was that 
the functional implication of these clonal expansions in exposed uninfected babies was 
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not determined. Although other neonatal infections, or antigen exposure, could have 
given rise to the TCR skewing observed using  spectratyping, it is tempting to speculate 
that this was linked to HIV infection of the mother. Indeed, similar expansions in HIV-1 
infected children and adults have been associated with HIV-specific cytotoxic T 
lymphocyte activity. (Feeney et al., 2005, Legrand et al., 2006).   
 
To discount the possibility of TCR skewing observed in exposed uninfected neonates due 
to other possible antigen exposure or congenital infections, IgG and IgM plasma 
antibodies for four possible pathogens [syphilis (RPR), rubella, toxoplasma and 
cytomegalovirus) were screened by ELISA. Detection of CMV IgG observed in all 
babies coincided with polyclonal expansion of T cells in all babies, including healthy 
control babies, whereas, oligoclonal expansion of T cells was observed only in babies 
born to HIV-1 infected mothers. Hence, oligoclonal expansion of T cells in these babies 
is shown to be associated with HIV infection rather than other antigens. Overall, the TCR 
data collected at enrollment and three months later from exposed–uninfected neonates 
showed persistent TCR expansions. The finding that an oligoclonal skewed population 
observed in one baby, which then normalized at three months after birth showed that the 
oligoclonality detected at birth was a biological characteristic and not a technical issue. 
 
 These findings are in agreement with previously reported data showing perturbations of 
the TCR Vβ repertoire in uninfected children younger than 2 months, whereas in older 
children less expanded TCR populations were observed (Silvestri et al., 1996). In 
summary, oligoclonal skewing of the T cell repertoire in HIV-1 uninfected babies born to 
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HIV-1 infected mothers in this study infers that there was exposure to HIV-1 antigens in-
utero.  
 
The oligoclonal dominance of T cells in one neonate was transient, and possibly 
influenced by the presence of antigen. These findings also suggest that it is only in the 
absence of persistent antigen exposure that the diversity of the TCR repertoire in 
neonates broadens, at least as observed in babies born to HIV-1 infected mothers. Future 
studies are necessary to determine whether there is a link between TCR skewing in HIV 
uninfected babies with HIV antigen specificity. This association was not made in this 
dissertation and represents a limitation of the study in terms of attempting to understand 
whether T cell expansion in newborns is associated with protective immunity or a marker 
of exposure to antigen. Further studies are required to determine whether TCR clonal 
populations generated in HIV-1 exposed cord blood and 3 months follow up are HIV-1 
specific. Other studies have demonstrated that 25% of exposed but uninfected infants 
show CTL activity against HIV-1 targets, but this activity is only detectable between 4 to 
12 months of life (Halapi et al., 1996; Sandberg et al., 2003).Overall, this chapter has 
shown that it is possible to detect perturbations in the TCR repertoire in likely exposed 
and HIV uninfected babies. This study has also shown that healthy newborn babies are 
born with an intact TCR repertoire. It remains to be seen whether perturbations of the 
TCR due to exposure to antigens in utero provides immune competence or induces a 
weakness in potential T cell responses upon encounter with antigens at some point after 
birth.
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CHAPTER 5 
MEASUREMENT OF HIV-1 - SPECIFIC T CELL 
ACTIVITY 
 
 
5.1  INTRODUCTION 
 
In this dissertation, several characteristics of T cells have been investigated in different 
cohorts of HIV infected and HIV exposed, but uninfected individuals. In this chapter, the 
fine specific nature of CD8+ T cells has been measured by investigating HIV-specificity 
using the IFNγ ELISPOT assay and intracellular cytokine staining. 
 
The role of antigen-specific T cells, especially that of CD8+ cytotoxic T cells (CTL) in 
the control of HIV-1 has been well documented (Schmidz et al., 1995; Klein et al., 1995; 
Walker et al., 1996; Xia et al., 1999). It has been suggested that ultimate control of HIV-
1 infection and disease will probably rely on an effective CTL-based vaccine. Proof of 
this concept has been shown in pre-clinical experiments when immune responses in 
rhesus macaques were elicited using DNA vaccines and then challenged with SHIV  
(Amara et al., 2001; Barouch et al., 2001; Egan et al., 2000). The immune responses in 
these vaccinated macaques were able to control viraemia to nearly undetectable levels 
and prevent immunodeficiency and clinical disease, as opposed to control monkeys, 
which exhibited high viraemia and significant disease progression. These studies 
emphasize the requirement for more studies to examine correlates of immune control 
against HIV in humans. The complexities of finding a CTL-based vaccine that will work 
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in humans has been recently thwarted by the failed clinical trial of an adenovirus type 5 
vector-based immunogen containing the HIV-1 gag gene. After enrolling 3000 volunteers 
into the STEP trial, it was shown that the vaccine arm had no efficacy and possibly may 
have exacerbated HIV transmission (http://www.hvtn.org/media/pr/step1207.html). 
Whether this was a failure of the concept of CTL-based vaccines or a failure of the 
vaccine product remains to be seen. Nevertheless, understanding CD8+ T cell immunity 
in natural HIV infection remains a valuable foundation for understanding what may be 
required from a vaccine that stimulates T cell immunity. 
   
CD8+ T cells arise in the peripheral blood after HIV infection resulting in a large 
proportion of CD8+ cytotoxic T cells (CTL) that are HIV-specific, recognizing different 
epitopes across the HIV-expressed genome (Edwards et al., 2002; Addo et al., 2003; 
Peretz et al., 2005). Many of these cells are activated to varying degrees and co-express 
markers that reflect activation events, such as CD38 and HLA-DR as described in chapter 
2 of this dissertation. This activation response has been associated with increased levels 
of cytokines, including gamma interferon (IFN-γ) in the peripheral blood (Fan et al., 
1993; Jassoy et al., 1993; Jassoy et al., 1992), CSF and germinal centers of the lymph 
node (Hosmalin et al., 2006). 
 
HIV-specific T cells from peripheral blood can be identified and enumerated by detection 
of antigen induced interferon gamma (IFN-γ) secreted at a single cell level using various 
methods. 1)  The intracellular cytokine staining method (ICS) which allows detection of 
multiple peptides and whole proteins which can be added to stimulate the cells and then 
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analyzed by flow cytometry. Multiple T cell types, allowing analysis of the T cell lineage 
can be measured simultaneously using ICS. 2) Along with the ICS assay, the ELISPOT 
assay allows the quantitative measurement of the frequency of cytokine secreting cells at 
the single cell level directly ex vivo without in vitro expansion or manipulation of cell 
populations. This assay is sensitive and allows for enumeration of low frequencies of T 
lymphocytes. 3) The use of tetramers and flow cytometry analysis, which requires the 
HLA type of the analyzed sample to be known and individual MHC-class I preparation 
contains only a single peptide epitope.  These assays can also be used in measurements of 
other cytokines that are secreted in response to HIV antigens, for example IL-2 and 
TNFalpha. 
 
HIV-1 –specific T cell activity in this dissertation was measured on cryopreserved 
PBMC, by using a combination of the ELISPOT assay and intracellular cytokine staining 
(ICS). This chapter focuses on HIV-1-specific T cell recognition of HIV in a cohort of 
HIV/TB co-infected individuals. The aim was to determine whether mycobacterium 
tuberculosis had any effect on HIV-1-specific T cell immunity.  
 
5.2 MATERIALS AND METHODS 
5.2.1  Study cohort 
Two groups of individuals consisting of HIV-1 infected and HIV/TB co-infected were 
studied in a cross-sectional and longitudinal manner. The ELISPOT assay was performed 
on 14 HIV-1 and 11 HIV/TB co-infected individuals for cross-sectional analysis and 10 
HIV/TB individuals were analysed for longitudinal analysis (see Appendix 8 for cohort 
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details). The 10 individuals were followed from baseline to 12 months following a six-
monthly course of TB treatment as described in chapter 2. 
 
5.2.2  Thawing of cryopreserved PBMC 
PBMC were removed from the liquid nitrogen tank and rapidly thawed by suspending the 
vial in the waterbath and warmed at 37oC. Using a 1ml pipette, the cells were added drop 
wise into 50ml tubes with 10ml RPMI containing 10% FCS, 0.5% gentamycin (R10) and 
50 units/ml benzonase. The cells were centrifuged at 1200rpm for 10 minutes. The 
supernatant was decanted and the cells were suspended in 15 ml R10. The cells were 
centrifuged again  at 1200rpm for another 10 minutes and resuspended in 1-5ml  warm 
RPMI + 20% FCS (R20). 20µl of the cell suspension was removed, mixed with 180ml 
ViaCount solution and counted on the Guava cell counter. An additional volume of R20 
was added to the cells to make a concentration of 2 x106 cells/ml. The cells were 
incubated for 12-18 hours (overnight) at 37oC, 5% CO2 with the caps loosened. The cells 
are washed once with warmed R10 and resuspended in 1-5ml R10 for viable and total 
cell counts. The cells are then ready for the ELISPOT and ICS assays. 
 
5.2.3  The IFN-γ  ELISPOT 
Measurement of IFN-γ was performed from cryopreserved PBMC, which were either 
thawed, rested in the incubator overnight and stimulated with HIV-1 subtype C 
superpools ex vivo,  (these cells were then referred to as “fresh”) or cultured with 
CD3+CD4+ bispecific monoclonal antibody (BSMAB, kind gift from Dr Guido Ferrari, 
Duke University) to specifically expand CD8+ T cells. When added to PBMC in the 
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presence of IL-2, CD3,4B BSMAB there is a selective elimination of CD4+ T cells by 
promoting complement-mediated lysis of CD4+ T cells (Wong et al., 1987). Briefy, 2 x 
106 PBMC suspended in RPMI + 10% foetal calf serum and 0.5 % gentamycin were 
placed into individual wells of a 24 well plate + 25U/ml IL-2 + 0.1 µg/ml CD3+CD4+ 
BSMAB. After every 2 days, the medium was partially exchanged with fresh medium 
containing IL-2 and cultures were continued for five days. These cells were then referred 
to as “expanded”. The ex vivo IFN-γ ELISPOT was performed on freshly thawed PBMC 
from 10 HIV/TB individuals and on expanded CD8+ T cells from 14 HIV-1 infected and 
11 HIV/TB co-infected individuals. 
 
The ELISPOT assay was performed on polyvinylidene difluoride membrane -96 well 
plates (MAIP S45, Millipore, Johannesburg, SA), which were coated overnight at 4oC 
with 50µl of 2µg/ml anti-IFNγ- monoclonal antibody (1-D1K, Mabtech, Stockholm, 
Sweden). Nine peptide superpools that spanned the complete HIV-1 subtype C whole 
genome were used and details pertaining to peptide length, sequence strain (or 
concensus) is shown in Table 5.1. Peptides were synthesized using 9-
fluorenylmethoxycarbonyl-based solid phase chemistry (Natural and Medical Sciences 
Institute, University of Tübingen, Tübingen, Germany). All peptides were checked for 
the correct molecular weight by Elektrospray QTOF-mass spectrometry. Peptide purities 
ranged from 70-80%. Gag, Vpu, Vpr and Tat were synthesized from the consensus 
sequence of HIV-1 subtype C (a generous gift from Marcus Altfeld, Massachusetts 
General Hospital) and  Pol, Nef, Env, Vif and Rev were synthesized from viral sequence 
strains that were closest to the consensus subtype C sequence and used as a basis for HIV 
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vaccine manufacture (Williamson et al., 2003).  Nef peptides were synthesized as 15-
mers overlapping by 11 amino acids (aa), and the remaining peptides varied from 15-18-
mers overlapping at 10 residues. Peptides were dissolved in 100% dimethyl sulfoxide at 
an initial concentration of 10mg/ml and were pooled at 40µg/ml/peptide stock in 
phosphate-buffered saline (PBS) in which the final concentration of dimethyl sulfoxide 
was always less than 0.5%. 
  
Table 5.1: Synthetic peptides used in the ELISPOT  
Protein Number of peptides/superpool Length of peptide Strain
Gag 14 15-18 Concensus
Pol 24 15-18 Du 151 
Nef 10 15 Du 151 
Env 24 15-18 Du 179
Vif 12 15-18 Du 151 
Rev 14 15-18 Du 151 
Vpu 9 15-18 Concensus
Vpr 11 15-18 Concensus
Tat 12 15-18 Concensus  
 
The plate layout is shown in Table 5.2, showing the nine peptide superpools, two wells of  
media and cells only serving as negative controls and two wells of PHA as a positive 
control.  The wells were then washed 3 times with PBS-Phosphate Buffered Saline (in-
house made) and blocked with 100µl of RPMI-10% FCS for at least 2 hours. Peptide 
(50µl, used at a final concentration of 2µg/ml) was added to the wells, followed by 50µl 
of 0.5 -2 x 105 PBMC. The plate was incubated for 16-18 hours in a 37oC, 5% CO2 
incubator. Any positive reaction resulted in a release of IFN-γ, which was captured by the 
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anti-IFN-γ monoclonal antibody coating the surface of the membrane. To identify the 
positive reactions, wells were washed three times with PBS followed by three washes 
with PBS supplemented with 0.05% Tween 20 (Sigma Aldrich, SA) + 1% FCS. A 
secondary detection antibody (50 µl biotinylated IFN-γ (clone 7-B6-1; Mabtech, 2µg/ml)  
was then added and incubated at room temperature for 3 hours. After washing the plate 
six times with PBS-Tween 20, 50µl of streptavidin–bound horseradish peroxidase 
(2µg/ml -Pharmingen, Cupertino) was added and incubated for 1 hour. Developed spots 
were visualized by addition of 100µl of Novared substrate (Vector, Burlingame, 
California, USA) according to the manufacturer’s instructions and incubated at room 
temperature in the dark. As soon as the spots were visible on the membrane (as shown in 
Figure 5.1), the wells were rinsed with tap water and air-dried. When dry, developed 
spots were counted on the ELISPOT reader (CTL, ImmunoSpot, Cleveland, Ohio). The 
frequency of cells responding to each of the peptide pools was normalized as 
spots/million PBMC. A positive cutoff was defined as above 100 SFU/106 PBMC. 
 
Table 5.2: Plate layout of the ELISPOT assay using HIV-1 subtype C peptide 
superpools  
 
1 2 3 4 5 6 7 8 9 10 11 12 
Gag Pol Nef Env Vif Vif Tat Rev Vpu Vpr Media Media
Cells  Cells Blank Blank Blank Blank Blank Blank Blank Blank  PHA  PHA 
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Figure 5.1: The ELISPOT membrane showing HIV-1 antigen responding /IFN-γ+ cells appearing as spots 
on A1, A2, A3, A4 e.t.c. and PHA (positive control), which is shown on well B11 and B12. The plate 
layout is shown on table 5.2.  
 
5.2.4 Intracellular cytokine staining (ICS)  
The ICS assay was used to confirm the HIV-1 subtype C specific responses obtained by 
the ELISPOT assay and to identify the phenotype of responding cells e.g. (CD4+ and 
CD8+ T cells). The main advantage of this method is that more than one cytokine as well 
as the lineage of T cell subsets can be measured simultaneously. The method involves 
three steps consisting of PBMC-peptide stimulation; staining of stimulated cells with 
selected monoclonal antibodies; flow cytometry acquisition and analysis.  
5.2.4.1  Cell stimulation 
Cryopreserved PBMC were thawed and resuspended in RPMI + 10% FCS at 1 x106/ml in 
5ml falcon FACS tubes. PBMC suspension (1ml) was stimulated with 1µg each of anti -
CD28/CD49d (Becton Dickinson-Pharmingen, San Jose, California) as costimulatory 
antibodies and 2µg/ml of the peptide superpool to be confirmed.  Cells containing 
CD28/CD49d only were used as a negative control and cells stimulated with positive 
control (SEB- staphylococcus enterotoxin B which is a superantigen obtained from 
1 2 4 125 76 98 1110
B
3
A
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Sigma Aldrich) were included in each experiment. The cultures were incubated at 37oC in 
the presence of 5% CO2 for 1 hour with addition of the cytokine secretion inhibitor 
Brefeldin A used at a final concentration of 10µg/ml (Sigma Aldrich, SA) followed by an 
additional incubation for 5 hours. The cells were then stored at 4oC (for a maximum of 
16-18 hours) until ready for permeabilization and staining.  
 5.2.4.2 Flow cytometry analysis 
 
 
EDTA (100µl of 20mM, Sigma Aldrich) was added to peptide stimulated and control 
tubes and incubated at room temperature for 15 minutes. The cells were then suspended 
in FACS wash solution (PBS + 1% BSA + 0.1% sodium azide) and centrifuged at 
1200rpm for 10 minutes. The cells were fixed and lysed in 2ml of 1x FACS lysing 
solution (BD Immunocytometry systems, San Jose, California) for 10 minutes at room 
temperature in the dark, and permeabilised with 0.5ml of 1x FACSPerm II (BD) for 15 
minutes at RT. Wash solution (1ml) was added and the tubes were centrifuged at 
1800rpm for 10 minutes. Permeabilized cells were then stained with directly conjugated 
CD3-APC, CD8-PerCP, CD69-PE or IL-2 PE and IFN-γ-FITC (all BD) for 30 minutes at 
room temperature in the dark. After an additional wash the cells were then resuspended in 
the fixing solution (1% paraformaldehyde, 0.05% sodium azide: in -house). Stained cells 
were stored at 4oC for a maximum of 24 hours for flow cytometry acquisition and 
analysis. Four colour flow cytometry was performed on the Becton Dickinson 
FACSCalibur using CellQuest software (BD, San Jose, California). Live events (100,000-
130,000) were acquired, gating small viable lymphocytes and saving 50,000 CD3+ T 
lymphocytes. List mode data files were analyzed using FlowJo (Tree Star, Inc. Ashland, 
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Oregon, and USA). The gating strategy is shown on Figure 5.2. Plot A is showing the 
lymphocyte gate with 21.8% of total cells, plot B is showing gated CD3+ T cells with 
43.3% of total lymphocytes which were collected from the lymphocyte gate. Frequencies 
of CD8+IFNγ+ and CD4+IFNγ+ T cell for unstimulated cells (0.035 and 0.013%) and 
SEB (3.57% and 0.6%) are shown as percentages of total T cells. HIV-1-specific 
responses were rated as positive when the frequency of CD8+IFNγ+ or CD4+IFNγ+ was 
>0.05% above the percentage of unstimulated cells.      
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Figure 5.2: Flow cytometry plots showing analysis of IFN-γ producing T cells as analyzed by FlowJo. Plot 
A is showing the lymphocyte gate with 21.8% of total cells, plot B is showing gated CD3+ T cells with 
43.3% of total lymphocytes which were collected from the lymphocyte gate. Frequencies of CD8+IFNγ+ 
and CD4+IFNγ+ T cell for unstimulated cells (0.035, plot C and 0.013%, plot D) and SEB (3.57%, plot E 
and 0.6%, plot F) are shown as percentages of either CD3+CD4+ or CD3+CD8+ T cells. 
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5.3  RESULTS 
5.3.1    The frequency of response to each region (i.e how many individuals are  
responding to each protein region)  
 
It has been shown in this dissertation that CD8+ T cells are activated by HIV-1, and more 
enhanced by the presence of TB co-infection. It was further noted that clonal dominance 
of the CD8+ T cell population occurs following activation, indicating usage of selected T 
cell receptors. Measurement of HIV-1 specific T cells was made to identify which 
recognised regions were immunodominant. To identify HIV-specific CD8+ T cells, 
PBMC were expanded for 5 days with bispecific antibody (CD3+CD4+) and stimulated 
with 2µg/ml each of 9 HIV-1 subtype C peptide superpools in the IFN-γ ELISPOT assay. 
CD8+ T cells from both HIV-1 and HIV/TB co-infected patients responded to one or 
more of the nine HIV-1 subtype C peptides.Of the 14 HIV-1 singly infected individuals, 
85% recognised Gag; 78% recognized Pol, 64% recognized Nef, 43% recognized Vif, 
36% recognized Env, Rev and Vpr; and 21% recognized Tat (Figure 5.3A and Appendix 
12). Of the 11 HIV/TB co-infected patients, 73 % targeted Pol, Vif and Nef, 45% 
recognized Env; 27% recognized Vpr and Gag, 18% recognized Tat and Vpu; and 9 % 
recognized Rev (and Figure 5.3B and Appendix 13). These data shows that the most 
frequently targeted HIV-1 genome regions in HIV-1 infected individuals differed from 
those individuals with TB and HIV co-infection. 
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Figure 5.3: Targeting of HIV-1 subtype C-peptide superpools by HIV-1 (A) and HIV/TB (B) co-infected 
patients. Frequencies of individuals targetting various HIV-1 subtype C superpools within both cohort 
groups are shown at the bottom of the graph. 
 
These data suggest that recognition of epitopic regions differ between individuals singly 
or dually infected with HIV and TB. 
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5.3.2 Confirmation of HIV-1–specific responses by intracellular cytokine 
staining (ICS) 
IFN-γ ELISPOT responses from selected peptide pools were confirmed using the ICS 
assay, which enabled simultaneous analysis of both CD8+ and CD4+ T cells. PBMC 
samples from 5 HIV/TB patients were stimulated and stained with CD3 Pacific Blue, 
CD8 APC-Cy7, CD4 PerCP Cy5.5 and IFN-γ FITC and IL-2 PE. The cells were acquired 
on the LSR II (Becton Dickinson) using FACSDiva software. List mode data was 
analysed using FlowJo (Tree Star Inc.) software.  
 
A representative example of ELISPOT results for patient JNM 55 (Figure 5.4), showing 
responses to Gag, Nef and Vif was confirmed using ICS. The ICS results confirming a 
Gag response are shown on Figure 5.5, as analysed by FlowJo software. Plot A and B are 
showing CD8+ T cells (y-axis) and CD4+ T cells (y-axis)–expressing IFN-γ (x-axis) for 
unstimulated (negative control), SEB-stimulated (C and D) and Gag-stimulated (E and F) 
PBMC. The frequency of CD8+ T cells expressing IFN-γ for this patient is 2.5% after 
subtracting the background of 0.013%, and the number of CD4+ T cells expressing IFN-γ 
is 0.12%. Other T cell responses to Gag and Nef, which were confirmed, are shown in 
Table 5.3, presented as scores of the ELISPOT (SFU x 106) and the ICS (% IFN-γ 
positive cells). HIV-1 –specific responses obtained by the ELISPOT were readily 
confirmed by the ICS and were predominantly mediated by CD8+ T cells, although there 
were at least 3 CD4+ responses to Gag and Nef (patients 1, 2 and 5).  
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Figure 5.5: The ELISPOT results showing Gag, Nef and Vif responses, for patient JNM 55. 
 
Figure 5.4: The ELISPOT and ICS results showing Gag, Nef and Vif responses for 
patient JNM 55. 
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Figure 5.5:  The ICS results confirming Gag-specific T cell response from patient JNM 055 identified by 
ELISPOT. The dot plots show frequencies of CD8+/IFN-γ+ and CD4+/IFN-γ+ for unstimulated  (A and B) 
, SEB (C and D) and Gag (E and F) were gated from the CD3+ T cells.   
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Table 5.3: ELISPOT and ICS results  
PID HIV-1 superpool ELISPOT ICS- CD8 ICS-CD4 
1 Gag ++ - + 
2 Nef + + + 
3 Gag ++ ++ - 
4 Nef +++ + - 
5 Gag ++ +++ + 
6 Gag ++ ++ - 
7 Gag + + - 
 
  ELISPOT:     ICS 
+ > 400 SFU     + > 0.05-0.5 % 
  ++ = 401-4000 SFU    ++= 0.5-2.0 % 
  +++ > 4000     +++ >2.0% 
  
5.3.3 Comparison between freshly thawed PBMC and in-vitro expanded 
CD8+ T cells in the ELISPOT assay.  
The use of bispecific monoclonal antibodies for in vitro enrichment of T cells has been 
shown to allow expansion of CD8+ T cell populations without loss of specificity (Jones 
et al., 2003). The bispecific enriched cells in this study demonstrated comparable 
repertoire to the original, unexpanded PBMC. In this dissertation, freshly thawed PBMC 
from 10 HIV/TB individuals were analysed in the ELISPOT assay and compared with in 
vitro expanded PBMC. PBMC from these individuals were expanded as discussed on 
section 5.2.3. Low frequencies of CD8+ T cells were readily expanded, and yielded 
higher levels of responses (p= 0.019) as shown on Figure 5.6. These data supports the in 
vitro expansion of specific cell populations from low frequencies when multiple 
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functional studies are required. These findings suggest that there was probably 
enrichment of memory T cell responses leading to expanded CD8+ T cell specificities. 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 5.6: HIV-specific T cell responses from freshly thawed and in vitro expanded PBMC. The p-value 
was calculated by the Mann-Whitney U test.  
 
 
5.3.4 The relationship between HIV-1 RNA load and HIV-1-specific responses 
from HIV/TB co-infected individuals  
Effective cytotoxic T cell responses have been shown to cause a drop in plasma viral load 
in acute HIV-1 infection (Klein et al., 1995; Walker et al., 1996, Jin  et al., 1999) and a 
reduction of viral replication (Koup et al., 1994) has been demonstrated. Gag p24-
specific immune responses have also been reported in the control of viraemia (Novisky et 
al., 2003) whereas a significant positive association was observed between Nef and viral 
load (Masemola et al., 2004) from HIV-1 subtype C infected individuals. This 
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dissertation examined the association between HIV-1 subtype C specific responses and 
viral load in 10 HIV-1 infected patients with mycobacterium tuberculosis co-infection. 
Freshly thawed PBMC samples were stimulated in a 6 hour ELISPOT assay with nine 
HIV-1 subtype C proteins (whole genome), as described in section 5.2.3. There was no  
significant relationship between the viral load and HIV-1-specific T cell responses 
(cumulative SFU/106 cells) for any of the HIV-1 proteins (Figure 5.7). Even though these 
were not statistically significant, Env, Tat and Vpu showed a trend towards a positive 
correlation  and Gag showed a trend towards negative correlation with viraemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: The relationship between HIV-1 RNA load and HIV-1-specific responses to the nine HIV-1 
subtype C peptide superpools from HIV/TB co-infected individuals. The correlation coefficient and the p 
values were obtained using GraphPad Prism version 4. 
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HIV-1 subtype C responses to individual gene regions did not have any significant 
impact on viraemia in HIV/TB co-infected individuals. In addition, correlation of 
response to complete protein regions (cumulative SFU/106 PBMC) with viral load was 
investigated to determine whether total responses would have an impact on viraemia. 
There was no statistically significant association between viraemia and the total SFU/106 
PBMC in these patients (Figure 5.8A). Similar results were observed when viraemia was 
correlated with breadth of responses in these individuals (Figure 5.8B), which was 
defined as the number of peptide pools targeted by each individual.   
 
 
 
 
 
 
 
 
 
Figure 5.8: Correlation between (A) Cumulative responses and viral load and (B) Number of targeted HIV-
1 subtype C regions (breadth) and viral loads.     
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the cumulative SFU/106 PBMC (Figure 5.9A) and the number of targeted gene regions by 
HIV/TB co-infected patients (Figure. 5.9B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Correlation between (A) Cumulative responses and CD4 count and (B) Number of targeted 
HIV-1 subtype C regions and CD4 count.     
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months). The One-way ANOVA, Prism 4 Bonferroni Test established that there were no 
significant differences in the magnitude of responses at different time points (Figure 
5.10) during TB therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: HIV-1-specific T cell responses to nine HIV-1 subtype C peptides at 4 different time points 
during TB therapy. The magnitude of responses were compared, and the statistical P values for each 
peptide superpool are shown in the table. 
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5.4 DISCUSSION 
HIV-1 subtype C-specific T cell responses were readily detected in both HIV-1 infected 
and HIV/TB co-infected individuals in this dissertation. Previous studies have 
demonstrated HIV-1–specific responses in HIV-1 subtype C infected individuals 
(Novitsky et al., 2003, Masemola et al., 2004). The effect of TB on T cell responses has 
not been extensively studied. It has been reported previously that Gag-specific CTL 
contribute to maintenance of the asymptomatic state by effectively controlling HIV-1 
replication (Klein et al., 1995). It was further suggested that the more immune pressure 
the host’s immune system can mount against HIV Gag, and in particular Gag p24, the 
more the virus can be controlled (Zuniga et al., 2006). The fact that recognition of Gag 
was dominant in HIV-1 singly infected individuals in this dissertation, and this was not 
the case in HIV-1 infected patients that were co-infected with TB, may have an impact on 
the control of HIV-1. However, the magnitude of response to Gag was not significantly 
affected by TB co-infection. These data provide an understanding of factors that may 
possibly skew the dominance of an effective HIV-1 specific immune response, and co-
infection with other pathogens should therefore be considered when peptide based 
vaccines are designed. The intracellular cytokine staining (ICS) method proved to be 
effective for confirmation of T cell responses observed from the ELISPOT, and it had an 
advantage of identifying CD4+ and CD8+ lymphocytes that respond to specific HIV-1 
peptides. HIV-1–specific responses were largely mediated by CD8+ cytotoxic T 
lymphocytes. Even though this method was only used to measure HIV-1 –specific cells in 
this dissertation, the use of ICS can be extended  to analyse the lineage of HIV-1-specific 
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T cells which provides valuable information on the functionality of various T cell subsets 
as well as  differentiated cells and their quality in  HIV-1 control.    
 
Some previously reported studies demonstrated no correlation between HIV-1-specific 
CTL responses and viraemia (Addo et al., 2003, Peretz et al 2005), whereas some have 
shown that patients who mounted strong gp160-specific responses, as measured by the 
ELISPOT assay showed rapid reduction of acute plasma viraemia (Borrow et al., 1994) 
and others have reported an important role of HIV-1 Gag p24-immune responses in the 
control of viraemia and no restraint of viral load from responses to Nef (Novinsky et al., 
2003, Edwards et al., 2002). Preferential targeting of Gag has been previously shown to 
be associated with low viraemia in HIV-1 subtype C infected individuals (Masemola et 
al., 2004). However, it should be noted that the protective role of HIV-1-specific CTL 
responses predominantly occurs in primary infection (Koup et al., 1994). A progressive 
loss of HIV-1 specific cytolytic activity in the advanced stages of the disease in the 
presence of substantial CTL responses has been reported (Klein et al., 1995, Pantaleo et 
al., 1990). The results from this dissertation supports the former findings, where all the 
markers of HIV-1 disease progression (CD4+ T cell counts and viral load) showed no 
association with measurements of T cell response in HIV-1 infected individuals co-
infected with TB, although there were trends and lack of significance, which may be due 
to small numbers of individuals. Findings from this dissertation showed no effect of HIV-
1 –specific T cell response on the control of viraemia and HIV-1 disease progression in 
the presence of TB. A previously reported longitudinal study revealed that rapid 
progressors were able to mount substantial transient Gag-specific CTL response which 
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disappeared with disease progression (Klein et al., 1995). In this dissertation, HIV-
positive individuals with TB co-infection did not appear to preferentially target Gag. 
Whether this may influence or be an effect of TB disease (infection) would need to be 
further studied. Does the lack of Gag targeting in these individuals relate to more rapid 
disease progression?   
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CONCLUDING REMARKS 
 
 
Various aspects of cellular immunity to HIV-1 were examined in this dissertation, using 
four different cohorts which demonstrated phenotypic changes, including CD8+ T cell 
activation, restricted T cell receptor usage and altered HIV-1 specific responses due to 
co-infection with TB. The data have implications for understanding pathogenesis in HIV 
infected patients co-infected with TB. An array of techniques was applied to measure 
these properties: a) Flow cytometry, b) ICS, c) Immunoscope, d) ELISPOT. Using these 
assays, various aspects examining the characteristics and functionality of T cells were 
explored. 
 
The loss of CD4+ T cells observed in both HIV-1 infected and HIV/TB co-infected 
patients was shown to be caused by HIV-1, and not by TB. There was a remarkable loss 
of naïve CD4+ T cells due to HIV infection, which was driven by viral load. Maintenance 
of high viraemia and low CD4 counts was demonstrated, despite TB co-infection. The 
level of activation in HIV-1 infected individuals was high, regardless of TB co-infection, 
which was also probably driven by HIV plasma RNA load (viral load). The activated T 
cells were sustained, despite TB treatment in HIV/TB co-infected patients, providing 
evidence for advaced stage HIV-1 infection. 
  
In addition to these changes selected expansions of CD8+ T cells expressing Vβ T cell 
receptor were demonstrated. Polyclonal and oligoclonal expansions were noted in both 
HIV-1 and HIV/TB co-infected individuals. Minor polyclonal expansions were also 
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observed in individuals with TB infection only. However, there was no common pattern 
of expanded T cell families observed within HIV-1 single infection or in the presence of 
TB co-infection. Expansion of totally different Vβ families within the same cohort group 
may suggest usage of unique T cell receptors by each individual in response to HIV-1. 
Oligoclonal expansions of T cells observed in some of the patients in this dissertation 
indicate limited and restricted usage of the T cell repertoire, which may impose limited 
recognition of viral variants, leading to immune escape and enhanced viral replication 
and disease progression. Further studies are necessary to determine whether these 
expanded T cell populations can elicit a protective immune response to HIV-1 infection. 
It may also be necessary to examine the diversity of HIV-1 specific clones in the 
presence of opportunistic infection such as mycobacterium tuberculosis.  
 
The TCR repertoire in another cohort of HIV-1 exposed uninfected neonates was 
investigated to assess TCR usage without infection. Oligoclonal and polyclonal 
expansions observed in HIV uninfected babies born to HIV-infected mothers suggested 
that these babies were exposed to HIV-1 antigens in-utero, and that they possess a mature 
T cell repertoire at birth. Future studies are necessary to determine whether T cell 
expansions noted in these neonates are associated with protective immunity to HIV-1 or 
they may merely be a symbol of exposure to antigen.   
 
Analysis of HIV-1 –specific responses in both HIV-1 and HIV/TB co-infected patients 
revealed that CD8+ T cells from both cohorts were able to recognize and respond to one 
or more of the nine HIV-1 Subtype C proteins. Different patterns of recognition observed 
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between the two cohort groups suggest that co-infection with TB may possibly change 
the pattern of recognition across the HIV-1 genome. Shifting of immunodominance was 
observed in the presence of dual infection with HIV and TB. These data may lead to the 
hypothesis that TB co-infection alters patterns of T cell targeting and recognition.  
 
Overall, this study demonstrated high activation of T cells driven by high HIV-1 plasma 
RNA load in response to HIV-1 infection, restricted TCR usage and shifting of 
immunodominant CD8+ T cell responses as a result of co-infection with TB. TB 
treatment had no impact on the loss of naïve T cells or reduction of immune activation. 
This may imply that TB had no role to play in the significant phenotypic alterations 
observed in HIV-1 infected individuals. Thus, combination of TB treatment with 
HAART may be considered a better option in patients with dual infection This 
dissertation further demonstrated that it is possible to detect perturbations in the TCR 
repertoire in likely exposed and HIV uninfected babies, as a result of exposure to 
antigens in utero. It remains to be seen whether these perturbed T cell populations 
provide immune competence upon encounter with antigens at some point after birth. 
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APPENDICES 
APPENDIX 1 
Recipe for Haematology diluent 
 
dH2O 482.2 g  
NaCl  16.8 g 
Kcl  15.6 g 
KH2PO4  141.0 g 
LiCl  25.8 g 
EDTA  21.6 g 
N HCl   75 ml 
 
Recipe for Cell Fixer 
 
PBS + 2% BSA +1.5% Formalin 
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APPENDIX 2 
RNA Verification 
The RNA was extracted from the PBMC samples but no product was seen from cDNA 
amplification in some of the samples. To investigate whether the RNA has not degraded, 
an RNA gel was run following the procedure outlined  below: 
 
RNA Loading Buffer 
• 0.5 M EDTA 4 µl  
• 1% Bromothemol blue 500µl 
• 1% Xylene Cyanol 500µl 
• 100% glycerol 1000µl 
 
10X RNA running buffer  
• 200mM MOPS 20.95g/500ml 
• 50mM NaAc 3M 2.051g/500ml 
• 10mM EDTA 0.35M(PH7.00) 1.861g/500ml 
 
1% Gel mix 
• Agarose 0.4g 
• H2O 27ml 
• 10 X RNA running buffer  4ml 
• Add 8.5ml formaldehyde 
The gel is poured into the gel casting tray and allowed to set at room temperature 
Appendices 
 
183 
RNA mix (use 10-20µg RNA) 
• DEPC water 3.3µl 
• 10X RNA running buffer 1.5µl 
• Formamide 7.5µl 
• Formaldehyde 2.7µl 
• RNA loading buffer 1.5µl 
• RNA 10µl 
Final volume = 26µl 
• Heat the mixture at 55oC for 10  minutes 
• Place on ice 
• RNA was then loaded on a gel and run at 30mA. 
• The gel was then stained with Ethidium bromide, rinsed with five changes of water and 
         then photographed (figure 27). The gel showed clearly separated two bands of RNA. 
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APPENDIX 3  
 
A list of TCR primers used and their sequences.  
Primer Sequence 
HuVβ1 ccg cac aac agt tcc ctg act tcg 
HuVβ2 cac aac tat gtt ttg gta tcg tc 
HuVβ3 cgc ttc tcc ctg  att ctg gag tcc 
HuVβ4 ttc cca tca gcc gcc caa acc taa 
HuVβ5 gat caa aac gag agg aca gc 
HuVβ6a gat cca att tca ggt cat act g 
HuVβ6b cag gg(g/c) cca gag ttt ctg ac 
HuVβ7 cct gaa tgc ccc aac agt tct 
HuVβ8 Ggt aca gac aga cca tga tgc 
HuVβ9 ttc cct gga gct tgg tga ctc tgc 
HuVβ11 gtc aac agt ctc cag aat aag g 
HuVβ12 tcc (c/t) cc tca ctc tgg agt c 
HuVβ13a ggt atc gac aag acc cag gca 
HuVβ13b agg ctc atc cat tat tca aat ac 
HuVβ14 ggg ctg ggc tta agg cag atc ctg 
HuVβ15 cag gca cag gct aaa ttc tcc ctg 
HuVβ16 gcc tgc aga act gga gga ttc tgg 
HuVβ17 tcc tct cac tgt gac atc tct cag cct cca 
HuVβ18 ctg ctg aat ttc cca aag agg gcc 
HuVβ20 tgc ccc aga atc tct cag cct cca 
HuVβ21 gga gta gac tcc act ctc aag 
HuVβ22 gat ccg gtc cac aaa gct gg 
HuVβ23 att ctg aac tga aca tga gct cct 
HuCβ1 ggg tgt ggg aga tct ctg c 
HuCβ2 Fam-aca cag cga cct cgg gtg gg 
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APPENDIX  4 
PCR mixture for immunoscope assay 
DEPC-H2O     315µl 
25mM Mg+ (Invitrogen Life Tech)  50µl 
10X Taq buffer (Invitrogen Life Tech)  62µl 
2mM DNTP (Roche Diagnostics)  62µl 
BC Primer (Inqaba Biotechnical Industries) 3µl 
Taq DNA polymerase (Invitrogen Life Tech) 3µl 
CDNA (or DEPC H2O) for control  5µl 
Total mixture     500µl  
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APPENDIX 5 
Preparation of 0.9 M Tris Borate, 20 mM EDTA [10 X TBE] buffer (in-house) 
Tris mw 121.1   1080gm 
Boric acid               550gm    
0.5M EDTA PH 8.0  400ml 
Preparation method: 
Dissolve the TRIS in + 6 litres of water 
Add the Boric acid directly to the solute 
Add water up to 9.5 litres (leave space for EDTA) and shake until dissolved  
Add the EDTA and make up to ten litres 
Filter sterilize with positive pressure - Store at 4oC   
Note:  Use a 293 filter for 3 x 10 litres  
Preparation  of 2% agarose gel and loading of samples: 
• 2g of agarose poured onto- 
• 100ml of TBE in a sterile  glass bottle 
• The gel was heated in a microwave until the mixture was clear 
• The mixture was allowed to cool and poured onto a gel tank with wells created using a  
   gel comb and allowed to set. 
• 5µl  of the product was mixed with 3µl of DNA loading buffer: 
Preparation of DNA  loading buffer: 
To make 1ml: v/v 50% glycerol  500µl 
10 x TBE      100µl 
200µl  0.5% Bromothemol blue and 200µl 0.5% Xylene Cyanol. (Store at -20oC).                                          
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APPENDIX 6 
 
PCR mixture for 24 runoff reactions: 
27.5µl             10X AmpliTaq buffer (Applied Biosystems) 
27.5µl            2mM each DNTPs (Roche)  
33µl 25mM MgCl2  (3mM final- Applied Biosystems)  
3µl         Human 6 FAM labeled cβ-2 primer (Inqaba Biotech)  
128µl                                Sterile water 
1µl                                    AmpliTaq enzyme (Applied Biosystems) 
220 µl                               Total volume of mixture 
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APPENDIX 7 
Running Module for acquisition of samples on a sequencer for immunoscope 
analysis 
• Select dye set D 
• Run temp  50oC 
• Capillary Fill volume 184 
• Pre-run Voltage 12.2 
• Injection voltage 20 
• Run voltage 15 
• Data Delay Time 900 
• Run Time 3250 
• Analysis module is GS400Analysis.gsp 
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APPENDIX 8 
 
The TCR profile of healthy control babies 
 
Sample 
ID 
Oligoclonal Skewed 
(%) 
Polyclonal Skewed 
(%) 
Polyclonal Gaussian 
(%) 
4863 0 70 30 
4867 0 84 16 
4857 0 7 93 
4835 0 68 32 
4829 0 53 47 
4923 0 83 17 
4855 0 75 25 
4925 0 0 100 
4861 0 45 55 
4827 0 64 36 
4791 0 50 50 
4795 0 63 37 
4831 0 50 50 
4859 0 77 23 
4908 0 0 100 
4797 0 10 90 
2163 0 67 33 
4817 0 31 69 
4833 0 94 6 
4893 0 75 25 
4837 0 100 0 
4897 0 14 86 
4935 0 70 30 
4789 0 74 26 
4933 0 26 74 
mean 0 54 46 
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APPENDIX 9 
 
The TCR profile of HIV uninfected babies born to HIV-1 infected mothers 
Sample 
ID 
Oligoclonal Skewed 
(%) 
Polyclonal Skewed 
(%) 
Polyclonal Gaussian 
(%) 
B1 0 95 5 
B2 0 100 0 
B3 24 76 0 
B4 94 6 0 
B5 0 95 5 
B6 0 100 0 
B7 80 20 0 
B8 86 14 0 
B9 10 90 0 
B10 10 90 0 
B11 0 100 0 
B12 4 91 4 
B13 0 100 0 
B14 75 25 0 
B15 0 100 0 
B16 0 100 0 
B17 83 17 0 
B18 14 86 0 
B19 0 100 0 
B20 67 33 0 
mean 27 72 1 
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APPENDIX 10 
The TCR profile of HIV-1 infected mothers 
Sample 
ID 
Oligoclonal Skewed 
(%) 
Polyclonal Skewed 
(%) 
Polyclonal Gaussian 
(%) 
4000 88 12 0 
4003 75 25 0 
4038 36 64 0 
4139 79 21 0 
4152 33 67 0 
4204 62 38 0 
4211 30 70 0 
4216 5 95 0 
4218 71 29 0 
4222 94 6 0 
4226 100 0 0 
4231 86 14 0 
Mean 63 37 0 
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APPENDIX  11  
 
Cohort groups 
HIV/TB ( freshly thawed)   
SAMPLE ID NUMBER CD4 VL 
JLD 20 136 132001 
LMM 072 446 70764 
BRG 113 1517 500000 
BBS 077 588 164 
NTM 119 374 1008 
ZKC 084 506 17878 
JNM 55 199 33569 
NYJ 060 335 3773 
TMZ 123 385 5547 
MPM 135 216 178465 
   
HIV/TB+ (in vitro expanded) 
SAMPLE ID NUMBER CD4 VL 
IM018    
IM021 177 35413 
IM029 945 6378 
IM030 66 49172 
IM060 939 67166 
IM062 536 5217 
IM066 324 3645 
PMM071 117 545898 
VSG049 990 9010 
NPM100 736 338 
SBK121 691 482 
HIV+ (in-vitro expanded)* 
Dur10 
Dur24 
Dur27 
JHB30 
JHB31 
JHB32 
JHB39 
JHB41 
IM077 
IM080 
IM086 
IM087 
IM089 
IM092 
*Clinical data was not available for the HIV+ in-vitro expanded cohort. 
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APPENDIX 12  
ELISPOT results of HIV-1 singly infected individuals presented as SFU/106 PBMC  
Gag Pol Vif Vpr Tat Rev Vpu Env Nef
Dur10 1364 498 20 0 0 50 0 0 2930
Dur24 206 280 10 0 170 20 40 12 7
Dur27 730 125 240 300 400 0 140 180 24
JHB30 200 197 0 70 0 0 10 10 40
JHB31 522 105 230 0 10 3270 0 76 1526
JHB32 4216 1670 230 360 60 100 120 140 192
JHB39 176 390 380 450 200 1560 590 1196 18
JHB41 116 245 75 110 20 130 10 48 408
IM077 9 33 50 0 77 242 33 128 253
IM080 364 335 1690 0 60 460 0 0 218
IM086 250 130 45 40 10 40 20 10 15
IM087 0 0 74 4 0 4 0 0 349
IM089 116 15 20 530 0 210 0 0 112
IM092 80 305 1150 80 0 0 0 128 908  
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APPENDIX 13 
ELISPOT results of HIV/TB co-infected individuals presented as SFU/106 PBMC  
Gag Pol Vif Vpr Tat Rev Vpu Env Nef
IM018 0 0 0 0 0 300 0 0 0
IM021 14 328 169 0 100 10 20 185 161
IM029 75 103 66.25 40 480 20 50 48 383
IM030 75 422 469 1725 38 62.5 388 729 50
IM060 60 47 120 200 0 0 0 0 113
IM062 60 253 600 0 0 20 0 217 283
IM066 720 1543 2303 0 0 40 0 45 2053
PMM071 50 213 460 1580 0 0 0 260 2555
VSG049 0 1035 5260 0 20 0 160 860 148
NPM100 680 50 0 60 40 0 50 2 0
SBK121 1232 427.5 240 0 20 50 40 80 240  
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APPENDIX 14: ETHICAL CLEARANCE 
 
This study was approved by the University of the Witwatersrand Ethical Committee, 
protocol number M080114. Patients were recruited after informed consent was 
obtained and confidentially of all records ensured. 
 
